CUMULATIVE SUPPLEMENT 11
JAN'98-NOV'98



APPROVED DRUG PRODUCTS

WITH THERAPEUTIC EQUIVALENCE EVALUATIONS

18TH EDITION

U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES
PUBLIC HEALTH SERVICE
FOOD AND DRUG ADMINISTRATION
CENTER FOR DRUG EVALUATION AND RESEARCH
OFFICE OF INFORMATION TECHNOLOGY
DIVISION OF DATA MANAGEMENT AND SERVICES

1998

Prepared By
Division of Data Management and Services
Office of Information Technology
Center for Drug Evaluation and Research, FDA

I

SUBSCRIBE NOW!

Available in March 1999

New 19th Edition



APPROVED DRUG PRODUCTS

WITH
THERAPEUTIC EQUIVALENCE EVALUATIONS

19TH EDITION
1999

CONTENTS

- Prescription Drug Product List
- OTC Drug Product List
- Drug Products with Approval under Section 505 of the Act Administered by the Center for Biologics Evaluation and Research List
- Discontinued Drug Product List
- Orphan Drug Product Designations
- Drug Products Which Must Demonstrate in vivo Bioavailability Only if Product Fails to Achieve Adequate Dissolution
- Patent and Exclusivity Information

See Subscription Form Inside Back Cover

APPROVED DRUG PRODUCTS
with
THERAPEUTIC EQUIVALENCE EVALUATIONS

18TH EDITION

Cumulative Supplement 11

NOVEMBER 1998

CONTENTS

		PAGE
1.0	INTRODUCTION	iii
1.1	How to Use the Cumulative Supplement	iii
1.2	Applicant Name Changes	iv
1.3	Acyclovir 200 mg Tablet-Reference Listed Drug	vi
1.4	Diclofenac Sodium Ophthalmic Solution	vi
1.5	Ribavirin 200 mg Oral Capsule	vi
1.6	Follitropin Alfa and Beta	vi
1.7	Availability of the Publication and Updating Procedures	vii
1.8	Report of Counts for the Prescription Drug Product List	viii
2.0	DRUG PRODUCT LISTS	
2.1	Prescription Drug Product List	1
2.2	OTC Drug Product List	73
2.3	Drug Products with Approval under Section 505 of the Act Administered by the Center for Biologics Evaluation and Research List	76
2.4	Orphan Product Designations and Approvals List	77
2.5	Drug Products Which Must Demonstrate in vivo Bioavailability Only if Product Fails to Achieve Adequate Dissolution	90
PATENT AND EXCLUSIVITY INFORMATION ADDENDUM		
A.	Patent and Exclusivity Terms	91
B.	Patent and Exclusivity Lists	95

APPROVED DRUG PRODUCTS
with
THERAPEUTIC EQUIVALENCE EVALUATIONS

18TH EDITION

CUMULATIVE SUPPLEMENT 11
NOVEMBER 1998

1.0 INTRODUCTION

1.1 HOW TO USE THE CUMULATIVE SUPPLEMENT

This Cumulative Supplement is one of a series of monthly updates to the Approved Drug Products with Therapeutic Equivalence Evaluations, 18th Edition (the List). The List is composed of four parts: approved prescription drug products with therapeutic equivalence evaluations, over-the-counter (OTC) drug products that require approved applications as a condition of marketing, drug products with approval under Section 505 of the Act administered by the Center for Biologics Evaluation and Research and products that have never been marketed, have been discontinued from marketing or that have had their approvals withdrawn for other than safety or efficacy reasons.

The Cumulative Supplement provides, among other things, information on newly approved drugs and, if necessary, revised therapeutic equivalence evaluations and updated patent and exclusivity data. The Addendum contains appropriate drug patent and exclusivity information required of the Agency by the "Drug Price Competition and Patent Term Restoration Act of 1984" for the Prescription, OTC, and Drug Products with Approval under Section 505 of the Act Administered by the Center for Biologics Evaluation and Research Lists.

The Patent and Exclusivity Lists are arranged in alphabetical order by active ingredient name. For those products with multiple active ingredients, only the first active ingredient (in alphabetical sort) will appear. In addition, the trade name will be displayed to the right of the active ingredient name for each product. Also shown is the application number and product number (FDA's internal file number) for reference purposes. All patents with their expiration dates are displayed for each application number. Use patents are indicated with the symbol "U" followed by a number representing a specific use. Patent and Exclusivity information for a specific drug is indicated by an abbreviation followed by the date upon which the patent and/or exclusivity expires. Refer to the Patent and Exclusivity Terms section in the Patent and Exclusivity Information Addendum for an explanation of all codes and abbreviations. Information regarding drug patents and exclusivity for an approved product will appear in this addendum as it is received and may not correspond with the month the drug product is approved and published in the Rx/OTC sections of the Cumulative Supplement.

IV

Because all parts of the publication are subject to changes, additions, or deletions, the List must be used in conjunction with the most current Cumulative Supplement. Users may wish to place an asterisk (*) to the left of the ingredient(s) in the List to indicate that changes to that entry appear in the Cumulative Supplement.

Drug product information is provided in each Cumulative Supplement for completeness to assist in locating the proper place in the List for the revision. [Strength(s) which already exist in the List will not be repeated for context.]

The presence of any therapeutic equivalence code indicates that the drug product is multisource; the deletion of a therapeutic equivalence code indicates that the drug product has become single source. (An infrequent exception exists when a therapeutic equivalence code is revised. In that case the deletion of the therapeutic equivalence code is followed immediately by the addition of the revised one.)

New additions to the Prescription Drug Product List, OTC Drug Product List, and the Patent and Exclusivity Data are indicated by the symbol **>ADD>** to the left of the line on which new information exists. The **>ADD>** symbol is then dropped in subsequent Cumulative Supplements for that item.

New deletions to the Prescription Drug Product List, OTC Drug Product List, and the Patent and Exclusivity Data are indicated by the symbol **>DLT>** (DELETE) to the left of the line. The **>DLT>** symbol is dropped in subsequent Cumulative Supplements for that item. The shaded print remains in the Prescription Drug Product List and OTC Drug Product Lists in all Cumulative Supplements (hard copy only) for this edition. However, the overstruck data in the Patent and Exclusivity Data is dropped in subsequent Cumulative Supplements (hard copy).

Products that have never been marketed, have been discontinued from marketing or that have had their approvals withdrawn for other than safety or efficacy reasons, will be flagged in this Cumulative Supplement with the "@" symbol to designate their non-marketed status. All products having a "@" symbol in the 12th Cumulative Supplement of the 18th Edition List will then be added to the "Discontinued Drug Product List" appearing in the 19th Edition.

1.2 APPLICANT NAME CHANGES

It is not practical to identify in the Cumulative Supplement each and every product involved when an applicant transfers its entire line of approved drug products to another applicant, or when an applicant changes its name. Therefore, the cumulation of these transfers and name changes will be identified in this section only. Where only partial lines of approved products are transferred between applicants, each approved product involved will appear as an applicant name change entry in the Cumulative Supplement.

It is also not practical to identify each and every product involved when an applicant name is changed to meet internal publication standards (e.g., MSD or Zenith [Former Abbreviated Names] are changed, respectively, to Merck Sharp Dohme or Zenith Labs [New Abbreviated Names]). When this occurs, each product involved (either currently in the Cumulative Supplement or in the following year's edition) will automatically reflect the new abbreviated name. Consequently, it will not appear as an applicant name change entry in the Cumulative Supplement nor will the cumulation of these name changes appear in this section. However, when the applicant name change is one which may not be easily recognized or located in the listing (e.g., White Towne Paulsen [Former Abbreviated Name] is changed to Whiteworth Towne PLSN [New Abbreviated Name], the name change will appear in this section and will be identified with an asterisk.

APPLICANT NAME CHANGES

FORMER APPLICANT NAME (FORMER ABBREVIATED NAME)	NEW APPLICANT NAME (NEW ABBREVIATED NAME)
ASTRA MERCK INC (ASTRA MERCK)	ASTRA PHARMACEUTICALS LP (ASTRA PHARMS)
ASTRA USA INC (ASTRA)	ASTRA PHARMACEUTICALS LP (ASTP . PHARMS)
DUPONT RADIOPHARMACEUTICALS DIV (DUPONT)	DUPONT PHARMACEUTICALS COMPANY (DUPONT PHARMS)
FUJISAWA USA INC (FUJISAWA)	AMERICAN PHARMACEUTICAL PARTNERS INC (AM PHARM PARTNERS)
GENSIA INC (GENSIA)	GENSIA SICOR PHARMACEUTICALS INC (GENSIA SICOR PHARMS)
GENSIA LABORATORIES LTD (GENSIA)	GENSIA SICOR PHARMACEUTICALS INC (GENSIA SICOR PHARMS)
JONES MEDICAL INDUSTRIES INC (JONES MEDCL INDS)	JONES PHARMA INC (JONES PHARMA)
MERCK RESEARCH LABORATORIES DIV MERCK AND CO INC (MERCK)	MERCK AND CO INC (MERCK)
MERCK SHARP AND DOHME DIV MERCK AND CO INC (MERCK)	MERCK AND CO INC (MERCK)
ZENITH LABORATORIES (ZENITH LABS)	ZENITH GOLDLINE PHARMACEUTICALS (ZENITH GOLDLINE)

1.3 ACYCLOVIR 200MG TABLET-REFERENCE LISTED DRUG

Novopharm's single source acyclovir tablets have been declared to be a reference listed drug for the 200 mg tablet in addition to the acylcovir (Zovirax) 800 mg tablet of the innovator. A generic firm wishing to submit an ANDA for a duplicate of the 200 mg acyclovir tablet will be eligible for a waiver of the *in vivo* determination of bioequivalence (1) if their product is proportionally similar in its active and inactive ingredients to their own 800 mg acyclovir tablet and (2) by doing an acceptable comparative dissolution test (dissolution profile) against Novopharm's 200 mg acyclovir reference listed drug.

Before a waiver of the *in vivo* determination of bioequivalence can be granted for the 200 mg acyclovir tablet, the generic firm must have completed an acceptable fasting and fed study comparing their acyclovir 800 mg tablet against the Zovirax 800 mg tablet.

For further information on the study designs, you should contact the Division of Bioequivalence, Office of Generic Drugs.

1.4 DICLOFENAC SODIUM OPHTHALMIC SOLUTION 0.1%

Two NDAs have been approved for diclofenac sodium ophthalmic solution 0.1% (DSOS), (1) Ciba's NDA 20-037 for Voltaren and (2) Alcon's NDA 20-809 for DSOS. Alcon was required to do a study comparing their DSOS to Voltaren and to a placebo control in post cataract surgical inflammation. This study was necessary to demonstrate that the different formulation of the Alcon drug product did not affect the safety and/or effectiveness of the proposed drug product for this indication. Prior to the approval of Alcon's DSOS Ciba did clinical studies and was approved for two additional indications for the temporary relief of pain and photophobia in patients undergoing corneal refractive surgery. Three years of Waxman-Hatch marketing exclusivity was granted to Ciba for these two new uses.

Since the treatment of pain has a different site of action than the anti-inflammatory or photophobia indications the Agency did not have information to support a recommendation that the Alcon and Ciba DSOS are therapeutically equivalent for the treatment of pain. The designation of therapeutic equivalence at this time applies only to the anti-inflammatory indication. The therapeutic equivalence designation will apply to the photophobia indication upon expiration of Ciba's marketing exclusivity.

1.5 RIBAVIRIN 200MG ORAL CAPSULE

Indicated for use and comarketed with interferon alfa-2b, recombinant (Intron A), as Rebetron Combination Therapy.

1.6 FOLLITROPIN ALFA AND BETA

Based on available data derived from physico-chemical tests and bioassay, follitropin alfa and follitropin beta are indistinguishable.

V11

I.7 AVAILABILITY OF THE PUBLICATION AND UPDATING PROCEDURES

The *Approved Drug Products with Therapeutic Equivalence Evaluations* files are available on Internet. There is more than one media users may select to access these files.

Preface and ASCII Text Files:
The Preface may be accessed using this URL: http://www.fda.gov/cder/orange/adp.htm. Users who wish to download the Prescription Drug Product List: OTC Drug Products and Discontinued Drug Products lists may access the ASCII text files using this URL: htttp://www.fda.gov/cder/orange/obreadme.htm. The drug product lists and the zipobtxt.exe files are updated concurrently with the publication of the annual edition or monthly cumulative supplements. Appendix A and B are updated twice a year.

Preface and Searchable Query Database:
The Preface may be accessed using this URL: http://www.fda.gov/cder/ob/docs/preface/ectablec18.htm. Users who wish to query on a specific drug product may access the database using this URL: http://www.fda.gov/cder/ob. The Query enables searching of the database by active ingredient, proprietary name, applicant holder or applicant number. The data is updated concurrently with the publication of the annual edition or monthly cumulative supplements.

1.8 REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST

DESCRIPTION OF REPORT

This report provides summary counts derived from the product information in the Prescription Drug Product List and the current Cumulative Supplement. Products included in the counts are domestically marketed drug products approved for both safety and effectiveness under section 505 of the Federal Food, Drug, and Cosmetic Act. Excluded are approved drug products marketed by distributors; those marketed solely abroad; and those now regarded as medical devices, biologics or foods.

The baseline column (Dec 1997) refers to the products in the Prescription Drug Product List. For each three-month period, a column of quarterly data is added which incorporates counts of product activity from the previous quarter(s) with those in the baseline count.

DEFINITIONS

Drug Product

For this report, a drug product is the representation in the Prescription Drug Product List of an active moiety (molecular entity and its salts, esters and derivatives) either as a single ingredient or as a combination product provided in a specific dosage form and strength for a given route of administration with approval for marketing by a firm under a particular generic or trade name.

New Molecular Entity

A new molecular entity is considered an active moiety that has not previously been approved (either as the parent compound or as a salt, ester or derivative of the parent compound) in the United States for use in a drug product either as a single ingredient or as part of a combination.

REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST

COUNTS CUMULATIVE BY QUARTER

CATEGORIES COUNTED	DEC 1997	MAR 1998	JUN 1998	SEP 1998
DRUG PRODUCTS LISTED	9624	9711	9768	9798
SINGLE SOURCE	2462 (25.6%)	2484 (25.6%)	2494 (25.6%)	2479 (25.3%)
MULTISOURCE	7052 (73.3%)	7117 (73.3%)	7164 (73.3%)	7208 (73.6%)
THERAPEUTICALLY EQUIVALENT	6673 (69.3%)	6746 (69.5%)	6790 (69.5%)	6829 (69.7%)
NOT THERAPEUTICALLY EQUIVALENT	379 (4.0%)	371 (3.8%)	374 (3.8%)	379 (3.9%)
EXCEPTIONS[1]	110 (1.1%)	110 (1.1%)	110 (1.1%)	111 (1.1%)
NEW MOLECULAR ENTITIES APPROVED	--	8	9	4
NUMBER OF APPLICANTS	551	529	538	551

[1]Amino acid-containing products of varying composition (see Introduction, page xx of the List).

ACARBOSE

TABLET; ORAL

	PRECOSE			
	@ BAYER	25MG	N20482 004	
			MAY 29, 1997	
		25MG	N20482 004	
			MAY 29, 1997	

ACETAMINOPHEN; BUTALBITAL

TABLET; ORAL

	BUTALBITAL AND ACETAMINOPHEN			
AB	DANBURY PHARMA	325MG;50MG	N87550 001	
			OCT 19, 1984	
	@	325MG;50MG	N87550 001	
			OCT 19, 1984	

ACETAMINOPHEN; BUTALBITAL; CAFFEINE

CAPSULE; ORAL

	BUTALBITAL, ACETAMINOPHEN AND CAFFEINE			
AB	WEST WARD	500MG;50MG;40MG	N40261 001	
			OCT 28, 1998	
	ESGIC-PLUS			
AB	+ MIKART	500MG;50MG;40MG	N40085 001	
			MAR 28, 1996	

TABLET; ORAL

	ACETAMINOPHEN, BUTALBITAL AND CAFFEINE			
AB	GILBERT LABS	325MG;50MG;40MG	N87629 001	
			NOV 13, 1984	
	@	325MG;50MG;40MG	N87629 001	
			NOV 13, 1984	
	BUTALBITAL, ACETAMINOPHEN AND CAFFEINE			
AB	MALLINCKRODT	325MG;50MG;40MG	N87804 001	
			JAN 24, 1985	
AB	+ MIKART	500MG;50MG;40MG	N89451 001	
			MAY 23, 1988	
AB	WATSON LABS	500MG;50MG;40MG	N40267 001	
			JUL 30, 1998	
	REPAN			
AB	MALLINCKRODT	325MG;50MG;40MG	N87804 001	> ADD <
			JAN 24, 1985	> ADD <
				> ADD <
				> ADD <

ACETAMINOPHEN; CODEINE PHOSPHATE

TABLET; ORAL

	ACETAMINOPHEN AND CODEINE PHOSPHATE			
AA	ROXCH LABS	300MG;15MG	N89997 001	
			DEC 28, 1994	
AA		300MG;30MG	N89998 001	
			DEC 28, 1994	
AA		300MG;60MG	N89999 001	
			DEC 28, 1994	
AA	WATSON LABS	300MG;15MG	N89997 001	
			DEC 28, 1994	
AA		300MG;30MG	N89998 001	
			DEC 28, 1994	
AA		300MG;60MG	N89999 001	
			DEC 28, 1994	
	ACETAMINOPHEN AND CODEINE PHOSPHATE #3			
AA	PUREPAC PHARM	300MG;30MG	N89080 001	
			JUL 17, 1986	
	@	300MG;30MG	N89080 001	
			JUL 17, 1986	

ACETAMINOPHEN; HYDROCODONE BITARTRATE

ELIXIR; ORAL

	HYDROCODONE BITARTRATE AND ACETAMINOPHEN			
AA	+ MIKART	500MG/15ML;7.5MG/15ML	N81051 001	
			AUG 28, 1992	
AA	PHARM ASSOC	500MG/15ML;7.5MG/15ML	N40182 001	
			MAR 13, 1998	

TABLET; ORAL

	HYDROCODONE BITARTRATE AND ACETAMINOPHEN			
AA	ENDO PHARMS	500MG;5MG	N40281 001	
			SEP 30, 1998	
AA		500MG;7.5MG	N40280 001	
			SEP 30, 1998	
AA		650MG;7.5MG	N40280 002	
			SEP 30, 1998	
AA		650MG;10MG	N40280 003	
			SEP 30, 1998	
AA		750MG;7.5MG	N40281 002	
			SEP 30, 1998	
		400MG;5MG	N40288 001	
			NOV 27, 1998	
		400MG;7.5MG	N40288 002	
			NOV 27, 1998	

ACETAMINOPHEN; HYDROCODONE BITARTRATE

TABLET; ORAL
HYDROCODONE BITARTRATE AND ACETAMINOPHEN

> ADD >		ENDO PHARMS	400MG;10MG	N40288 003 NOV 27, 1998
> ADD >	AA	MALLINCKRODT	500MG;7.5MG	N40201 001 FEB 27, 1998
	AA		500MG;10MG	N40201 002 FEB 27, 1998
	AA	ROYCE LABS	500MG;2.5MG	N40123 003 MAR 04, 1996
	AA		500MG;5MG	N40122 001 MAR 04, 1996
	AA		500MG;7.5MG	N40123 004 MAR 04, 1996
	AA		650MG;7.5MG	N40123 001 MAR 04, 1996
	AA		650MG;10MG	N40123 002 MAR 04, 1996
	AA		750MG;7.5MG	N40122 002 MAR 04, 1996
	AA	WATSON LABS	500MG;2.5MG	N40123 003 MAR 04, 1996
	AA		500MG;5MG	N40122 001 MAR 04, 1996
	AA		500MG;7.5MG	N40123 004 MAR 04, 1996
	AA		650MG;7.5MG	N40123 001 MAR 04, 1996
	AA		650MG;10MG	N40123 002 MAR 04, 1996
	AA		750MG;7.5MG	N40122 002 MAR 04, 1996

ACETAMINOPHEN; OXYCODONE

CAPSULE; ORAL
OXYCODONE AND ACETAMINOPHEN

	AA	HALSEY	500MG;5MG	N40219 001 JAN 22, 1998

ACETAMINOPHEN; OXYCODONE HYDROCHLORIDE

CAPSULE; ORAL
OXYCODONE AND ACETAMINOPHEN

	AA	MALLINCKRODT	500MG;5MG	N40257 001 AUG 04, 1998

ACETAMINOPHEN; OXYCODONE HYDROCHLORIDE

CAPSULE; ORAL
OXYCODONE AND ACETAMINOPHEN

	AA	ROYCE LABS	500MG;5MG	N40234 001 OCT 30, 1997
	AA	WATSON LABS	500MG;5MG	N40234 001 OCT 30, 1997

TABLET; ORAL
OXYCODONE AND ACETAMINOPHEN

	AA	DURAMED	325MG;5MG	N40272 001 JUN 30, 1998
	AA	ROYCE LABS	325MG;5MG	N40171 001 OCT 30, 1997
	AA	WATSON LABS	325MG;5MG	N40171 001 OCT 30, 1997

ACETAMINOPHEN; PROPOXYPHENE HYDROCHLORIDE

TABLET; ORAL
PROPOXYPHENE HCL AND ACETAMINOPHEN

	AA	ROYCE LABS	650MG;65MG	N40139 001 DEC 16, 1996
	AA	WATSON LABS	650MG;65MG	N40139 001 DEC 16, 1996

ACETIC ACID, GLACIAL

SOLUTION; IRRIGATION, URETHRAL
ACETIC ACID 0.25% IN PLASTIC CONTAINER

AT	B BRAUN	250MG/100ML	N18161 001
AT	MCGAW	250MG/100ML	N18161 001

ACETIC ACID, GLACIAL; HYDROCORTISONE

SOLUTION/DROPS; OTIC
HYDROCORTISONE AND ACETIC ACID

	AT	BAUSCH AND LOMB	2%;1%	N40097 001 OCT 31, 1994
		④	2%;1%	N40097 001 OCT 31, 1994

ACYCLOVIR

CAPSULE; ORAL
ACYCLOVIR

AB	CHELSEA LABS	200MG	N75101 001	APR 15, 1998
AB	GENPHARM	200MG	N74977 001	APR 13, 1998
AB	RANBAXY	200MG	N74975 001	SEP 30, 1998

TABLET; ORAL
ACYCLOVIR

AB	COPLEY PHARM	400MG	N75021 001	MAR 18, 1998
AB		800MG	N75021 002	MAR 18, 1998
AB	GENPHARM	400MG	N74976 001	APR 13, 1998
AB		800MG	N74976 002	APR 13, 1998
AB	MYLAN	400MG	N75211 001	SEP 28, 1998
AB		800MG	N75211 002	SEP 28, 1998
	※ NOVOPHARM	200MG	N74556 001	APR 22, 1997
	@	200MG	N74556 001	APR 22, 1997
AB	RANBAXY	400MG	N74980 001	SEP 30, 1998
AB		800MG	N74980 002	SEP 30, 1998

ACYCLOVIR SODIUM

INJECTABLE; INJECTION
ACYCLOVIR SODIUM

AP	AESGEN	EQ 500MG BASE/VIAL	N75015 001	APR 30, 1998	> DLT >
+	AM PHARM PARTNERS	EQ 50MG BASE/ML	N74930 001	MAY 13, 1998	> DLT >
AP	APOTHECON	EQ 500MG BASE/VIAL	N74897 001	FEB 27, 1998	> DLT >
AP		EQ 1GM BASE/VIAL	N74897 002	FEB 27, 1998	> DLT >
AP	FUJISAWA	EQ 500MG BASE/VIAL	N74930 001	MAY 13, 1998	> ADD >
					> ADD >
					> ADD >
					> ADD >

ADENOSINE

INJECTABLE; INJECTION
ADENOCARD

+	FUJISAWA HLTHCARE	3MG/ML	N19937 002	OCT 30, 1989
※	NEDCO RES	3MG/ML	N19937 002	OCT 30, 1989

ADENOSCAN

+	FUJISAWA HLTHCARE	3MG/ML	N20059 001	MAY 18, 1995
※	NEDCO RES	3MG/ML	N20059 001	MAY 18, 1995

ALBUTEROL SULFATE

SOLUTION; INHALATION
ALBUTEROL SULFATE

AN	BAUSCH AND LOMB	EQ 0.5% BASE	N75050 001	JUN 18, 1998
AN	HI TECH PHARMA	EQ 0.5% BASE	N74543 001	JAN 15, 1998

SYRUP; ORAL
ALBUTEROL SULFATE

AA	HI TECH PHARMA	EQ 2MG BASE/5ML	N74749 001	JAN 30, 1998
AA	NOVA	EQ 2MG BASE/5ML	N74302 001	SEP 30, 1994
	@	EQ 2MG BASE/5ML	N74302 001	SEP 30, 1994

TABLET; ORAL
ALBUTEROL SULFATE

AB	COPLEY PHARM	EQ 2MG BASE	N72966 001	NOV 22, 1991
AB		EQ 4MG BASE	N72967 001	NOV 22, 1991
	@	EQ 2MG BASE	N72966 001	NOV 22, 1991
	@	EQ 4MG BASE	N72967 001	NOV 22, 1991

ALFENTANIL HYDROCHLORIDE

INJECTABLE; INJECTION

	ALFENTA			
+	AKORN	EQ 0.5MG BASE/ML	N19353 001	DEC 29, 1986
+	JANSSEN	EQ 0.5MG BASE/ML	N19353 001	DEC 29, 1986

ALLOPURINOL SODIUM

INJECTABLE; INJECTION

	ZYLOPRIM			
+	CATALYTICA PHARMS	EQ 500MG BASE/VIAL	N20298 001	MAY 17, 1996
+	GLAXO WELLCOME	EQ 500MG BASE/VIAL	N20298 001	MAY 17, 1996

ALPRAZOLAM

TABLET; ORAL

	ALPRAZOLAM			
AB	GENEVA PHARMS	2MG	N74909 001	MAR 25, 1998
AB	ROYCE LABS	0.25MG	N74479 001	JAN 21, 1997
AB		0.5MG	N74479 002	JAN 21, 1997
AB		1MG	N74479 003	JAN 21, 1997
AB	WATSON LABS	0.25MG	N74479 001	JAN 21, 1997
AB		0.5MG	N74479 002	JAN 21, 1997
AB		1MG	N74479 003	JAN 21, 1997

ALPROSTADIL

INJECTABLE; INJECTION

	ALPROSTADIL			
AP	BEDFORD	0.5MG/ML	N74815 001	JAN 20, 1998
	PROSTIN VR PEDIATRIC			
AP	+ PHARMACIA AND UPJOHN	0.5MG/ML	N18484 001	
	+	0.5MG/ML	N18484 001	

AMANTADINE HYDROCHLORIDE

CAPSULE; ORAL

	AMANTADINE HCL			
AB	ROSEMONT	100MG	N70589 001	AUG 05, 1986
AB	+	100MG	N70589 001	AUG 05, 1986
	SYMMETREL			
	+ ENDO PHARMS	100MG	N16020 001	
	@	100MG	N16020 001	

SYRUP; ORAL

	SYMMETREL			
AA	+ DUPONT MERCK	50MG/5ML	N16023 002	
AA	+ ENDO PHARMS	50MG/5ML	N16023 002	

TABLET; ORAL

SYMMETREL			
@ ENDO PHARMS	100MG	N18101 001	
+	100MG	N18101 001	

AMCINONIDE

OINTMENT; TOPICAL

CYCLOCORT			
+ LEDERLE	0.1%	N18498 001	
+ WYETH AYERST	0.1%	N18498 001	

AMILORIDE HYDROCHLORIDE

TABLET; ORAL

	MIDAMOR			
AB	+ MERCK	5MG	N18200 001	
AB	+ MERCK SHARP DOHME	5MG	N18200 001	

AMILORIDE HYDROCHLORIDE; HYDROCHLOROTHIAZIDE

TABLET; ORAL

	AMILORIDE HCL AND HYDROCHLOROTHIAZIDE			
AB	RUGBY LABS	EQ 5MG ANHYDROUS;50MG	N73334 001	JUL 19, 1991
AB	WATSON LABS	EQ 5MG ANHYDROUS;50MG	N73334 001	JUL 19, 1991
	MODURETIC 5-50			
AB	+ MERCK	EQ 5MG ANHYDROUS;50MG	N18201 001	

AMILORIDE HYDROCHLORIDE; HYDROCHLOROTHIAZIDE

TABLET; ORAL

MODURETIC 5-50

AB	+ MERCK SHARP DOHME	EQ 5MG ANHYDROUS;50MG	N18201 001	

AMINO ACIDS

INJECTABLE; INJECTION

PROSOL 20% SULFITE FREE IN PLASTIC CONTAINER

	+ BAXTER HLTHCARE	20%	N20849 001	AUG 26, 1998

AMINOCAPROIC ACID

SYRUP; ORAL

AMICAR

AA	+ IMMUNEX	1.25GM/5ML	N15230 002	
	+	1.25GM/5ML	N15230 002	

AMINOCAPROIC ACID

AA	MIKART	1.25GM/5ML	N74759 001	SEP 02, 1998

AMIODARONE HYDROCHLORIDE

TABLET; ORAL

AMIODARONE HCL

> ADD > AB	COPLEY PHARM	200MG	N74739 001	NOV 30, 1998

CORDARONE

AB	+ WYETH AYERST	200MG	N13972 001	DEC 24, 1985

PACERONE

AB	UPSHER SMITH	200MG	N75135 001	APR 30, 1998

AMITRIPTYLINE HYDROCHLORIDE

TABLET; ORAL

AMITRIPTYLINE HCL

AB	DANBURY PHARMA	10MG	N88620 001	MAR 02, 1984
AB		25MG	N88621 001	MAR 02, 1984
AB		50MG	N88622 001	MAR 02, 1984
AB		75MG	N88633 001	MAR 02, 1984
AB		100MG	N88634 001	MAR 02, 1984
AB		150MG	N88635 001	MAR 02, 1984
@		10MG	N88620 001	MAR 02, 1984
@		25MG	N88621 001	MAR 02, 1984
@		50MG	N88622 001	MAR 02, 1984
@		75MG	N88633 001	MAR 02, 1984
@		100MG	N88634 001	MAR 02, 1984
@		150MG	N88635 001	MAR 02, 1984

AMITRIPTYLINE HYDROCHLORIDE; PERPHENAZINE

TABLET; ORAL

PERPHENAZINE AND AMITRIPTYLINE HCL

AB	DANBURY PHARMA	10MG;2MG	N72539 001	FEB 15, 1989
AB		10MG;4MG	N72540 001	FEB 15, 1989
AB		25MG;2MG	N72541 001	FEB 15, 1989
AB		25MG;4MG	N72134 001	FEB 15, 1989
AB		50MG;4MG	N72135 001	FEB 15, 1989
@		10MG;2MG	N72539 001	FEB 15, 1989
@		10MG;4MG	N72540 001	FEB 15, 1989
@		25MG;2MG	N72541 001	FEB 15, 1989
@		25MG;4MG	N72134 001	FEB 15, 1989

AMITRIPTYLINE HYDROCHLORIDE; PERPHENAZINE

TABLET; ORAL
PERPHENAZINE AND AMITRIPTYLINE HCL

	@ DANBURY PHARMA	50MG;4MG	N72135 001	FEB 15, 1989
AB	ROYCE LABS	10MG;2MG	N73007 001	OCT 17, 1991
AB		10MG;4MG	N73009 001	OCT 17, 1991
AB		25MG;2MG	N73008 001	OCT 17, 1991
AB		25MG;4MG	N73010 001	OCT 17, 1991
AB	WATSON LABS	10MG;2MG	N73007 001	OCT 17, 1991
AB		10MG;4MG	N73009 001	OCT 17, 1991
AB		25MG;2MG	N73008 001	OCT 17, 1991
AB		25MG;4MG	N73010 001	OCT 17, 1991

AMMONIUM CHLORIDE

INJECTABLE; INJECTION
AMMONIUM CHLORIDE 2.14%

	@ B BRAUN	40MEQ/100ML	N85734 001
	@ MCGAW	40MEQ/100ML	N85734 001

AMMONIUM LACTATE

CREAM; TOPICAL
LAC-HYDRIN

	WESTWOOD SQUIBB	EQ 12% BASE	N20508 001 AUG 29, 1996
	+	EQ 12% BASE	N20508 001 AUG 29, 1996

AMOXICILLIN

TABLET; ORAL
AMOXIL

	+ SMITHKLINE BEECHAM	500MG	N50754 002 JUL 10, 1998

AMOXICILLIN

TABLET; ORAL
AMOXIL

	+ SMITHKLINE BEECHAM	875MG	N50754 001 JUL 10, 1998

AMRINONE LACTATE

INJECTABLE; INJECTION
AMRINONE

AP	ABBOTT	EQ 5MG BASE/ML	N74616 001 AUG 03, 1998

INOCOR

AP	+ SANOFI	EQ 5MG BASE/ML	N18700 001 JUL 31, 1984

ARBUTAMINE HYDROCHLORIDE

INJECTABLE; INJECTION
GENESA

	+ GENSIA	0.05MG/ML	N20420 001 SEP 12, 1997
	+ GENSIA AUTOMEDICS	0.05MG/ML	N20420 001 SEP 12, 1997

ASPIRIN; BUTALBITAL; CAFFEINE; CODEINE PHOSPHATE

CAPSULE; ORAL
BUTALBITAL,ASPIRIN,CAFFEINE AND CODEINE PHOSPHATE

AB	STEVENS J	325MG;50MG;40MG;30MG	N74951 001 AUG 31, 1998

ASPIRIN; CAFFEINE; ORPHENADRINE CITRATE

TABLET; ORAL
ORPHENGESIC

AB	PAR PHARM	385MG;30MG;25MG	N75141 001 MAY 29, 1998

ORPHENGESIC FORTE

AB	PAR PHARM	770MG;60MG;50MG	N75141 002 MAY 29, 1998

ASPIRIN; OXYCODONE HYDROCHLORIDE; OXYCODONE TEREPHTHALATE

TABLET; ORAL
OXYCODONE AND ASPIRIN

AA	HALSEY	325MG;4.5MG;0.38MG	N40260 001	JUL 17, 1998
AA	WATSON LABS	325MG;4.5MG;0.38MG	N40255 001	FEB 27, 1998

ATENOLOL

TABLET; ORAL
ATENOLOL

AB	GENPHARM	25MG	N74126 003	AUG 26, 1998

ATENOLOL; CHLORTHALIDONE

TABLET; ORAL
ATENOLOL AND CHLORTHALIDONE

AB	MARTEC	50MG;25MG	N74404 001	MAY 14, 1998
AB		100MG;25MG	N74404 002	MAY 14, 1998

ATORVASTATIN CALCIUM

TABLET; ORAL
LIPITOR

	PARKE DAVIS	EQ 10MG BASE	N20702 001	DEC 17, 1996
		EQ 20MG BASE	N20702 002	DEC 17, 1996
+		EQ 40MG BASE	N20702 003	DEC 17, 1996
	WARNER LAMBERT EXPOR	EQ 10MG BASE	N20702 001	DEC 17, 1996
		EQ 20MG BASE	N20702 002	DEC 17, 1996
+		EQ 40MG BASE	N20702 003	DEC 17, 1996

ATRACURIUM BESYLATE

INJECTABLE; INJECTION
ATRACURIUM BESYLATE

AP	MARSAM	10MG/ML	N74945 001	JUL 28, 1998

ATRACURIUM BESYLATE PRESERVATIVE FREE

AP	MARSAM	10MG/ML	N74944 001	JUL 28, 1998

BACITRACIN

POWDER; FOR RX COMPOUNDING
BACITRACIN

	PADDOCK	5,000,000 UNITS/BOT	N62456 001	JUL 27, 1983
	@	5,000,000 UNITS/BOT	N62456 001	JUL 27, 1983

BACITRACIN ZINC; HYDROCORTISONE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

OINTMENT; OPHTHALMIC
CORTISPORIN

AT	* GLAXO WELLCOME	400 UNITS/GM;1%;EQ 3.5MG BASE/GM; 10,000 UNITS/GM	N50418 002	
AT	+ MONARCH PHARMS	400 UNITS/GM;1%;EQ 3.5MG BASE/GM; 10,000 UNITS/GM	N50416 002	

BACITRACIN ZINC; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

OINTMENT; OPHTHALMIC
NEOSPORIN

AT	* GLAXO WELLCOME	400 UNITS/GM;EQ 3.5MG BASE/GM; 10,000 UNITS/GM	N50417 001	
AT	+ MONARCH PHARMS	400 UNITS/GM;EQ 3.5MG BASE/GM; 10,000 UNITS/GM	N50417 001	

BACITRACIN ZINC; POLYMYXIN B SULFATE

OINTMENT; OPHTHALMIC
BACITRACIN ZINC AND POLYMYXIN B SULFATE

AT	ADV RESEARCH	500 UNITS/GM; 10,000 UNITS/GM	N64078 001	JAN 30, 1995

BACITRACIN ZINC; POLYMYXIN B SULFATE

OINTMENT; OPHTHALMIC

BACITRACIN ZINC AND POLYMYXIN B SULFATE

AT		AKORN	500 UNITS/GM; 10,000 UNITS/GM	N64028 001 JAN 30, 1995

POLYSPORIN

AT	*	GLAXO WELLCOME	500 UNITS/GM; 10,000 UNITS/GM	N61229 001
AT	+	MONARCH PHARMS	500 UNITS/GM; 10,000 UNITS/GM	N61229 001

BACLOFEN

TABLET; ORAL

BACLOFEN

AB		ROXANE LABS	10MG	N73082 001 JAN 28, 1994
AB			20MG	N73083 001 JAN 28, 1994
AB		WATSON LABS	10MG	N73092 001 JAN 28, 1994
AB			20MG	N73093 001 JAN 28, 1994

BENZYL PENICILLOYL-POLYLYSINE

INJECTABLE; INJECTION

PRE-PEN

	+	BAYER	60 UMOLAR	N50114 001
	*	SCHWARZ PHARMA	60 UMOLAR	N50114 001

BEPRIDIL HYDROCHLORIDE

TABLET; ORAL

VASCOR

		JOHNSON RW	300MG	N19002 002 DEC 28, 1990
	*		400MG	N19002 003 DEC 28, 1990
	+		300MG	N19002 002 DEC 28, 1990
	●		400MG	N19002 003 DEC 28, 1990

BETAMETHASONE VALERATE

CREAM; TOPICAL

BETAMETHASONE VALERATE

AA		GLAY PARK	EQ 0.1% BASE	N70053 001 JUN 10, 1986
	●		EQ 0.1% BASE	N70053 001 JUN 10, 1986

BETHANECHOL CHLORIDE

TABLET; ORAL

BETHANECHOL CHLORIDE

AA		DANBURY PHARMA	5MG	N84402 001
	●		5MG	N84402 001

BRETYLIUM TOSYLATE

INJECTABLE; INJECTION

BRETYLOL

AP	*	FAULDING	50MG/ML	N17954 001
	●		50MG/ML	N17954 001

BRINZOLAMIDE

SUSPENSION/DROPS; OPHTHALMIC

AZOPT

	+	ALCON	1%	N20816 001 APR 01, 1998

BROMOCRIPTINE MESYLATE

TABLET; ORAL

BROMOCRIPTINE MESYLATE

AB		LEK PHARM	EQ 2.5MG BASE	N74631 001 JAN 13, 1998

PARLODEL

AB	+	NOVARTIS	EQ 2.5MG BASE	N17962 001

BROMPHENIRAMINE MALEATE

TABLET; ORAL

BROMPHENIRAMINE MALEATE

AA		DANBURY PHARMA	4MG	N83123 001

BROMPHENIRAMINE MALEATE

TABLET; ORAL
BROMPHENIRAMINE MALEATE

	• DANBURY PHARMA	4MG		N83123 001

BUPROPION HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL
ZYBAN

	[redacted]	100MG		[redacted]
	•	100MG		N20711 002 MAY 14, 1997

BUTORPHANOL TARTRATE

INJECTABLE; INJECTION
BUTORPHANOL TARTRATE

AP	BEDFORD	2MG/ML		N75046 001 AUG 12, 1998

BUTORPHANOL TARTRATE PRESERVATIVE FREE

AP	BEDFORD	1MG/ML		N75045 001 AUG 12, 1998
AP		2MG/ML		N75045 002 AUG 12, 1998
AP	FAULDING	1MG/ML		N75170 001 SEP 28, 1998
AP		2MG/ML		N75170 002 SEP 28, 1998

CALCITRIOL

SOLUTION; ORAL
ROCALTROL

>ADD>	+ ROCHE	1 UGM/ML		N21068 001 NOV 20, 1998

CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE

INJECTABLE; INJECTION
ISOLYTE R IN DEXTROSE 5% IN PLASTIC CONTAINER

	B BRAUN	37MG/100ML;5GM/100ML;31MG/100ML; 120MG/100ML;330MG/100ML; 88MG/100ML	N19864 001 JUN 10, 1993
	[redacted]	[redacted]	[redacted]

CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM CITRATE

INJECTABLE; INJECTION
ISOLYTE E IN DEXTROSE 5% IN PLASTIC CONTAINER

	B BRAUN	35MG/100ML;5GM/100ML;30MG/100ML; 74MG/100ML;640MG/100ML;500MG/100ML; 74MG/100ML	N19867 001 DEC 20, 1993
	[redacted]	[redacted]	[redacted]

CALCIUM CHLORIDE; DEXTROSE; POTASSIUM CHLORIDE; SODIUM CHLORIDE

INJECTABLE; INJECTION
DEXTROSE 5% IN RINGER'S IN PLASTIC CONTAINER

AP	B BRAUN	33MG/100ML;5GM/100ML;30MG/100ML; 860MG/100ML	N18256 001
AP		33MG/100ML;5GM/100ML;30MG/100ML; 860MG/100ML	N20000 001 APR 17, 1992
AP	[redacted]	[redacted]	[redacted]
AP		[redacted]	[redacted]

CALCIUM CHLORIDE; DEXTROSE; POTASSIUM CHLORIDE; SODIUN CHLORIDE; SODIUM LACTATE

INJECTABLE; INJECTION
DEXTROSE 5% IN LACTATED RINGER'S IN PLASTIC CONTAINER

	● B BRAUN	20MG/100ML;5GM/100ML;30MG/100ML; 600MG/100ML;310MG/100ML	N17510 001
	● MCGAW	20MG/100ML;5GM/100ML;30MG/100ML; 600MG/100ML;310MG/100ML	N17510 001

CALCIUM CHLORIDE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM CITRATE

INJECTABLE; INJECTION
ISOLYTE E IN PLASTIC CONTAINER

	B BRAUN	35MG/100ML;30MG/100ML;74MG/100ML; 640MG/100ML;500MG/100ML; 74MG/100ML	N19718 001 SEP 29, 1989
	MCGAW	35MG/100ML;30MG/100ML;74MG/100ML; 640MG/100ML;500MG/100ML; 74MG/100ML	N19718 001 SEP 29, 1989

CALCIUN CHLORIDE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM CHLORIDE

SOLUTION; PERFUSION, CARDIAC
PLEGISOL IN PLASTIC CONTAINER

	ABBOTT	17.6MG/100ML;325.3MG/100ML; 119.3MG/100ML;643MG/100ML	N18608 001 FEB 26, 1982
	+	17.6MG/100ML;325.3MG/100ML; 119.3MG/100ML;643MG/100ML	N18608 001 FEB 26, 1982

CALCIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM CHLORIDE

INJECTABLE; INJECTION
RINGER'S IN PLASTIC CONTAINER

AP	B BRAUN	33MG/100ML;30MG/100ML; 860MG/100ML	N18721 001 NOV 09, 1982
AP		33MG/100ML;30MG/100ML; 860MG/100ML	N20002 001 APR 17, 1992

CALCIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM CHLORIDE

INJECTABLE; INJECTION
RINGER'S IN PLASTIC CONTAINER

AP	MCGAW	33MG/100ML;30MG/100ML; 860MG/100ML	N18721 001 NOV 09, 1982
AP		33MG/100ML;30MG/100ML; 860MG/100ML	N20002 001 APR 17, 1992

SOLUTION; IRRIGATION
RINGER'S IN PLASTIC CONTAINER

AT	B BRAUN	33MG/100ML;30MG/100ML; 860MG/100ML	N18156 001
AT	MCGAW	33MG/100ML;30MG/100ML; 860MG/100ML	N18156 001

CALCIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM CHLORIDE; SODIUM LACTATE

INJECTABLE; INJECTION
LACTATED RINGER'S IN PLASTIC CONTAINER

AP	B BRAUN	20MG/100ML;30MG/100ML;600MG/100ML; 310MG/100ML	N19632 001 FEB 29, 1988
	●	20MG/100ML;30MG/100ML;600MG/100ML; 310MG/100ML	N18023 001
AP	MCGAW	20MG/100ML;30MG/100ML;600MG/100ML; 310MG/100ML	N19632 001 FEB 29, 1988
	●	20MG/100ML;30MG/100ML;600MG/100ML; 310MG/100ML	N18023 001

SOLUTION; IRRIGATION
LACTATED RINGER'S IN PLASTIC CONTAINER

AT	B BRAUN	20MG/100ML;30MG/100ML;600MG/100ML; 310MG/100ML	N18681 001 DEC 27, 1982
AT	MCGAW	20MG/100ML;30MG/100ML;600MG/100ML; 310MG/100ML	N18681 001 DEC 27, 1982

CALFACTANT

INJECTABLE; INJECTION
INFASURF PRESERVATIVE FREE
+ ONY 35MG/ML N20521 001 JUL 01, 1998

CANDESARTAN CILEXETIL

TABLET; ORAL
ATACAND
ASTRA MERCK 4MG N20838 001 JUN 04, 1998
8MG N20838 002 JUN 04, 1998
16MG N20838 003 JUN 04, 1998
32MG N20838 004 JUN 04, 1998
ASTRA PHARMS 4MG N20838 001 JUN 04, 1998
8MG N20838 002 JUN 04, 1998
16MG N20838 003 JUN 04, 1998
+ 32MG N20838 004 JUN 04, 1998

CAPECITABINE

TABLET; ORAL
XELODA
ROCHE 150MG N20896 001 APR 30, 1998
+ 500MG N20896 002 APR 30, 1998

CAPTOPRIL

TABLET; ORAL
CAPTOPRIL
AB KUNERAC PHARM 12.5MG N74640 001 MAR 31, 1997
AB 25MG N74640 002 MAR 31, 1997
● 12.5MG N74640 001 MAR 31, 1997
● 25MG N74640 002 MAR 31, 1997
● 50MG N74640 003 MAR 31, 1997
● 100MG N74640 004 MAR 31, 1997
AB ROXCK LABS 12.5MG N74451 001 FEB 13, 1996
AB 25MG N74451 002 FEB 13, 1996
AB 50MG N74451 003 FEB 13, 1996
AB 100MG N74451 004 FEB 13, 1996
AB TORPHARM 12.5MG N74737 001 OCT 28, 1998
AB 25MG N74737 002 OCT 28, 1998
AB 50MG N74737 003 OCT 28, 1998
AB 100MG N74737 004 OCT 28, 1998
AB WATSON LABS 12.5MG N74451 001 FEB 13, 1996
AB 25MG N74451 002 FEB 13, 1996
AB 50MG N74451 003 FEB 13, 1996
AB 100MG N74451 004 FEB 13, 1996

CAPTOPRIL; HYDROCHLOROTHIAZIDE

TABLET; ORAL
CAPOZIDE 25/15
AB BRISTOL MYERS SQUIBB 25MG;15MG N18709 001 OCT 12, 1984

CAPTOPRIL; HYDROCHLOROTHIAZIDE

TABLET; ORAL

CAPOZIDE 25/15

AB		SQUIBB	25MG;15MG	N18709 001 OCT 12, 1984

CAPOZIDE 25/25

AB	+	BRISTOL MYERS SQUIBB	25MG;25MG	N18709 002 OCT 12, 1984
AB	*	SQUIBB	25MG;25MG	N18709 002 OCT 12, 1984

CAPOZIDE 50/15

AB	+	BRISTOL MYERS SQUIBB	50MG;15MG	N18709 004 OCT 12, 1984
AB	*	SQUIBB	50MG;15MG	N18709 004 OCT 12, 1984

CAPOZIDE 50/25

AB		BRISTOL MYERS SQUIBB	50MG;25MG	N18709 003 OCT 12, 1984
AB		SQUIBB	50MG;25MG	N18709 003 OCT 12, 1984

CAPTOPRIL AND HYDROCHLOROTHIAZIDE

AB		ZENITH GOLDLINE	25MG;15MG	N75055 001 JUN 18, 1998
AB			25MG;25MG	N75055 002 JUN 18, 1998
AB			50MG;15MG	N75055 004 JUN 18, 1998
AB			50MG;25MG	N75055 003 JUN 18, 1998

CARBAMAZEPINE

CAPSULE, EXTENDED RELEASE; ORAL

CARBATROL

	*	ATHENA	200MG	N20712 001 SEP 30, 1997
	*		300MG	N20712 002 SEP 30, 1997
	+	SHIRE	200MG	N20712 001 SEP 30, 1997
	+		300MG	N20712 002 SEP 30, 1997

CARBIDOPA

TABLET; ORAL

LODOSYN

	*	DUPONT MERCK	25MG	N17830 001
	+	DUPONT PHARMS	25MG	N17830 001

CARBIDOPA; LEVODOPA

TABLET; ORAL

SINEMET

AB		DUPONT MERCK	10MG;100MG	N17555 001
AB			25MG;100MG	N17555 003
AB	*		25MG;250MG	N17555 002
AB		DUPONT PHARMS	10MG;100MG	N17555 001
AB			25MG;100MG	N17555 003
AB	+		25MG;250MG	N17555 002

TABLET, EXTENDED RELEASE; ORAL

SINEMET CR

		DUPONT MERCK	25MG;100MG	N19856 002 DEC 24, 1992
	*		50MG;200MG	N19856 001 MAY 30, 1991
		DUPONT PHARMS	25MG;100MG	N19856 002 DEC 24, 1992
	+		50MG;200MG	N19856 001 MAY 30, 1991

CARISOPRODOL

TABLET; ORAL

CARISOPRODOL

AA		ROYCE LABS	350MG	N40152 001 DEC 03, 1996
AA		WATSON LABS	350MG	N40152 001 DEC 03, 1996

CEFACLOR

POWDER FOR RECONSTITUTION; ORAL

CEFACLOR

AB		MARSAM	EQ 125MG BASE/5ML	N64204 001 FEB 18, 1998
AB			EQ 187MG BASE/5ML	N64205 001 FEB 18, 1998

CEFACLOR

POWDER FOR RECONSTITUTION; ORAL

CEFACLOR

AB	NARSAN	EQ 250MG BASE/5ML	N64206 001 FEB 18, 1998
AB		EQ 375MG BASE/5ML	N64207 001 FEB 18, 1998

CEFAZOLIN SODIUM

INJECTABLE; INJECTION

CEFAZOLIN SODIUM

AP	AM PHARM PARTNERS	EQ 1MG BASE/VIAL	N64169 002 AUG 14, 1998
AP		EQ 500MG BASE/VIAL	N64169 001 AUG 14, 1998
AP		EQ 10GM BASE/VIAL	N64170 001 MAR 18, 1998
AP		EQ 20GM BASE/VIAL	N64170 002 MAR 18, 1998

CEFTIZOXIME SODIUM

INJECTABLE; INJECTION

CEFIZOX

*	FUJISAWA	EQ 500MG BASE/VIAL	N50560 001 SEP 15, 1983
*		EQ 1GM BASE/VIAL	N50560 002 SEP 15, 1983
*		EQ 2GM BASE/VIAL	N50560 003 SEP 15, 1983
		EQ 10GM BASE/VIAL	N50560 005 MAR 19, 1993
+	FUJISAWA HLTHCARE	EQ 500MG BASE/VIAL	N50560 001 SEP 15, 1983
+		EQ 1GM BASE/VIAL	N50560 002 SEP 15, 1983
+		EQ 2GM BASE/VIAL	N50560 003 SEP 15, 1983
		EQ 10GM BASE/VIAL	N50560 005 MAR 19, 1993

CEFIZOX IN DEXTROSE 5% IN PLASTIC CONTAINER

@	FUJISAWA	EQ 40MG BASE/ML	N50589 002 OCT 03, 1984
@	FUJISAWA HLTHCARE	EQ 40MG BASE/ML	N50589 002 OCT 03, 1984

CEFTIZOXIME SODIUM

INJECTABLE; INJECTION

CEFIZOX IN PLASTIC CONTAINER

*	FUJISAWA	EQ 20MG BASE/ML	N50589 003 APR 13, 1995
*		EQ 40MG BASE/ML	N50589 004 APR 13, 1995
+	FUJISAWA HLTHCARE	EQ 20MG BASE/ML	N50589 003 APR 13, 1995
+		EQ 40MG BASE/ML	N50589 004 APR 13, 1995

CEFUROXIME SODIUM

INJECTABLE; INJECTION

CEFUROXIME

AB	ASTRA PHARMS	EQ 750MG BASE/VIAL	N64192 002 APR 16, 1998
AP		EQ 1.5GM BASE/VIAL	N64192 001 APR 16, 1998
AP		EQ 7.5GM BASE/VIAL	N64191 001 APR 16, 1998

CEFUROXIME SODIUM

AP	AM PHARM PARTNERS	EQ 7.5GM BASE/VIAL	N65002 001 SEP 28, 1998

CEPHALEXIN

CAPSULE; ORAL

CEPHALEXIN

AB	ZENITH GOLDLINE	EQ 250MG BASE	N61969 001
AB		EQ 500MG BASE	N61969 002
AB	ZENITH LABS	EQ 250MG BASE	N61969 001
AB		EQ 500MG BASE	N61969 002

POWDER FOR RECONSTITUTION; ORAL

KEFLEX

*	LILLY	EQ 100MG BASE/ML	N50406 003
		EQ 100MG BASE/ML	N62117 001
@		EQ 100MG BASE/ML	N50406 003
+		EQ 100MG BASE/ML	N62117 001

CHLORAMPHENICOL

CAPSULE; ORAL

		CHLOROMYCETIN		
[redacted]	#	[redacted]	[redacted]	[redacted]
	#		[redacted]	[redacted]
	#		[redacted]	[redacted]
AB	+	PARKEDALE	250MG	N60591 002
			50MG	N60591 001
	+		100MG	N60591 003

OINTMENT; OPHTHALMIC

		CHLOROMYCETIN		
[redacted]	#	[redacted]	[redacted]	[redacted]
AT	+	PARKEDALE	1%	N50156 001

POWDER FOR RECONSTITUTION; OPHTHALMIC

		CHLOROMYCETIN		
	#	[redacted]	[redacted]	[redacted]
	+	PARKEDALE	25MG/VIAL	N50143 001

SOLUTION/DROPS; OPHTHALMIC

		OPHTHOCHLOR		
[redacted]	#	[redacted]	[redacted]	[redacted]
AT		PARKEDALE	0.5%	N61220 001

SOLUTION/DROPS; OTIC

		CHLOROMYCETIN		
	#	[redacted]	[redacted]	[redacted]
	+	PARKEDALE	0.5%	N50205 001

CHLORAMPHENICOL; HYDROCORTISONE ACETATE

POWDER FOR RECONSTITUTION; OPHTHALMIC

		CHLOROMYCETIN HYDROCORTISONE		
	#	[redacted]	[redacted]	[redacted]
	+	PARKEDALE	12.5MG/VIAL;25MG/VIAL	N50202 001

CHLORAMPHENICOL; HYDROCORTISONE ACETATE; POLYMYXIN B SULFATE

OINTMENT; OPHTHALMIC

		OPHTHOCORT		
	#	[redacted]	[redacted]	[redacted]
	@	PARKEDALE	10MG/GM;5MG/GM; 10,000 UNITS/GM	N50201 002

CHLORAMPHENICOL SODIUM SUCCINATE

INJECTABLE; INJECTION

		CHLOROMYCETIN		
[redacted]	#	[redacted]	[redacted]	[redacted]
AP	+	PARKEDALE	EQ 1GM BASE/VIAL	N50155 001

CHLORDIAZEPOXIDE

TABLET; ORAL

		LIBRITABS		
	+	ICN	5MG	N85482 001
	@		10MG	N85481 001
	@		25MG	N85488 001
	#	ROCHE	[redacted]	[redacted]
	@		[redacted]	[redacted]
	@		[redacted]	[redacted]

CHLORDIAZEPOXIDE HYDROCHLORIDE

CAPSULE; ORAL

		LIBRIUM		
AB		ICN	5MG	N85461 001
AB			10MG	N85472 001
AB	+		25MG	N85475 001
[redacted]		ROCHE	[redacted]	[redacted]
[redacted]			[redacted]	[redacted]
[redacted]	#		[redacted]	[redacted]

CHLORHEXIDINE GLUCONATE

SOLUTION; DENTAL

		PERIDEX		
[redacted]	+	PROCTER AND GAMBLE	[redacted]	[redacted] AUG 13, 1986
AT	+	ZILA	0.12%	N19028 001 AUG 13, 1986

TABLET; DENTAL

		PERIOCHIP		
	+	PERIO PRODS	2.5MG	N20774 001 MAY 15, 1998

CHLOROPROCAINE HYDROCHLORIDE

INJECTABLE; INJECTION
CHLOROPROCAINE HCL

AP		BEDFORD	2%	N40273 001 SEP 09, 1998
AP			3%	N40273 002 SEP 09, 1998

CHLOROQUINE PHOSPHATE

TABLET; ORAL
CHLOROQUINE PHOSPHATE

AA		WEST WARD	EQ 150MG BASE	N83082 001
	@		EQ 150MG BASE	N83082 001

CHLOROTHIAZIDE

SUSPENSION; ORAL
DIURIL

	+	MERCK	250MG/5ML	N11870 001
	#	MERCK SHARP DOHME	250MG/5ML	N11870 001

TABLET; ORAL
DIURIL

AB		MERCK	250MG	N11145 004
AB	+		500MG	N11145 002
AB		MERCK SHARP DOHME	250MG	N11145 004
AB	#		500MG	N11145 002

CHLOROTHIAZIDE; RESERPINE

TABLET; ORAL
DIUPRES-250

BP		MERCK	250MG;0.125MG	N11635 003 AUG 26, 1987
BP		MERCK SHARP DOHME	250MG;0.125MG	N11635 003 AUG 26, 1987

DIUPRES-500

BP	+	MERCK	500MG;0.125MG	N11635 006 AUG 26, 1987
BP	#	MERCK SHARP DOHME	500MG;0.125MG	N11635 006 AUG 26, 1987

CHLOROTHIAZIDE SODIUM

INJECTABLE; INJECTION
DIURIL

	+	MERCK	EQ 500MG BASE/VIAL	N11145 005
	#	MERCK SHARP DOHME	EQ 500MG BASE/VIAL	N11145 005

CHLORPHENIRAMINE MALEATE

TABLET; ORAL
CHLORPHENIRAMINE MALEATE

AA	DANBURY PHARMA	4MG	N80696 001
	@	4MG	N80696 001

CHLORPROMAZINE HYDROCHLORIDE

INJECTABLE; INJECTION
CHLORPROMAZINE HCL

AP	MARSAM	25MG/ML	N89563 001 APR 15, 1988
	@	25MG/ML	N89563 001 APR 15, 1988

CHLORZOXAZONE

TABLET; ORAL
CHLORZOXAZONE

AA	DANBURY PHARMA	250MG	N86901 001
	@	250MG	N86901 001
AA	ROYCE LABS	500MG	N81040 001 AUG 22, 1989
AA	WATSON LABS	500MG	N81040 001 AUG 22, 1989

CHOLESTYRAMINE

POWDER; ORAL
CHOLESTYRAMINE

AB	NOVOPHARM	EQ 4GM RESIN/PACKET	N74347 001 MAY 28, 1998
AB		EQ 4GM RESIN/SCOOPFUL	N74347 002 MAY 28, 1998

CHOLESTYRAMINE LIGHT

AB	COPLEY PHARM	EQ 4GM RESIN/PACKET	N74555 001 SEP 30, 1998

CHOLESTYRAMINE

POWDER; ORAL

	CHOLESTYRAMINE LIGHT			
AB	NOVOPHARM	EQ 4GM RESIN/PACKET	N74348 001	MAY 28, 1998
AB		EQ 4GM RESIN/SCOOPFUL	N74348 002	MAY 28, 1998
	LOCHOLEST			
AB	EON	EQ 4GM RESIN/PACKET	N74561 001	AUG 15, 1996
AB		EQ 4GM RESIN/SCOOPFUL	N74561 002	AUG 15, 1996
#		[redacted]	[redacted]	[redacted]
#		[redacted]	[redacted]	[redacted]
	LOCHOLEST LIGHT			
AB	EON	EQ 4GM RESIN/PACKET	N74562 001	AUG 15, 1996
AB		EQ 4GM RESIN/SCOOPFUL	N74562 002	AUG 15, 1996
#		[redacted]	[redacted]	[redacted]
#		[redacted]	[redacted]	[redacted]

CIMETIDINE

SOLUTION; ORAL

	CIMETIDINE HCL			
AA	DURAMED	300MG/5ML	N75110 001	JUN 18, 1998

TABLET; ORAL

	CIMETIDINE			
[redacted]	[redacted]	[redacted]	[redacted]	[redacted]
[redacted]		[redacted]	[redacted]	[redacted]
[redacted]		[redacted]	[redacted]	[redacted]
[redacted]		[redacted]	[redacted]	[redacted]
AB	ZENITH LABS	200MG	N74424 001	JUL 28, 1995
AB		300MG	N74424 002	JUL 28, 1995

CIMETIDINE

TABLET; ORAL

	CIMETIDINE			
AB	ZENITH LABS	400MG	N74424 003	JUL 28, 1995
AB		800MG	N74424 004	JUL 28, 1995

CIMETIDINE HYDROCHLORIDE

SOLUTION; ORAL

	CIMETIDINE HCL			
AA	COPLEY PHARM	EQ 300MG BASE/5ML	N74859 001	JUL 09, 1998

CIPROFLOXACIN HYDROCHLORIDE

OINTMENT; OPHTHALMIC

	CILOXAN			
+	ALCON	EQ 0.3% BASE	N20369 001	MAR 30, 1998

CIPROFLOXACIN HYDROCHLORIDE; HYDROCORTISONE

SUSPENSION/DROPS; OTIC

	CIPRO HC			
+	BAYER	EQ 0.2% BASE;1%	N20805 001	FEB 10, 1998

CISAPRIDE MONOHYDRATE

TABLET; ORAL

	PROPULSID QUICKSOLV			
#	JANSSEN	EQ 20MG BASE	[redacted]	[redacted]

TABLET, ORALLY DISINTEGRATING; ORAL

	PROPULSID QUICKSOLV			
+	JANSSEN	EQ 20MG BASE	N20767 001	NOV 07, 1997

CITALOPRAM HYDROBROMIDE

TABLET; ORAL
CELEXA
FOREST LABS

	EQ 20MG BASE	N20822 002	JUL 17, 1998
	EQ 40MG BASE	N20822 003	JUL 17, 1998
+	EQ 60MG BASE	N20822 004	JUL 17, 1998

CLEMASTINE FUMARATE

SYRUP; ORAL
CLEMASTINE FUMARATE

AA NORTON GROVE	EQ 0.5MG BASE/5ML	N74863 001	MAR 13, 1998

CLIDINIUM BROMIDE

CAPSULE; ORAL
CHARESE
ROCHE

	2.5MG	N10355 001	
	5MG	N10355 002	

CLINDAMYCIN HYDROCHLORIDE

CAPSULE; ORAL
CLINDAMYCIN HCL
BARRY'S PHARMA

AB	EQ 75MG BASE	N63082 001	JUL 31, 1991
	EQ 75MG BASE	N63082 001	JUL 31, 1991

CLINDAMYCIN PHOSPHATE

CREAM; VAGINAL
CLEOCIN
* PHARMACIA AND UPJOHN EQ 2% BASE N50680 001 AUG 11, 1992

	EQ 2% BASE	N50680 001	AUG 11, 1992

CLINDAMYCIN PHOSPHATE

CREAM; VAGINAL
CLEOCIN
\+ PHARMACIA AND UPJOHN EQ 2% BASE N50680 002 MAR 02, 1998

INJECTABLE; INJECTION
CLINDAMYCIN PHOSPHATE

AP HANDAN	EQ 150MG BASE/ML	N62913 001	OCT 20, 1988
	EQ 150MG BASE/ML	N62913 001	OCT 20, 1988

SOLUTION; TOPICAL
CLEOCIN T
AT PHARMACIA AND UPJOHN EQ 1% BASE N62363 001 FEB 08, 1982

	EQ 1% BASE	N62363 001	FEB 08, 1982

CLOBETASOL PROPIONATE

OINTMENT; TOPICAL
CLOBETASOL PROPIONATE

AB	STIEFEL	0.05%		N75057 001 AUG 12, 1998
	EMBELINE			
AB	DRX	0.05%		N74221 001 MAR 31, 1995
AB	HEALTHPOINT	0.05%	> ADD >	N74221 001 MAR 31, 1995

SOLUTION; TOPICAL
CLOBETASOL PROPIONATE

AT	MORTON GROVE	0.05%	> ADD >	N75205 001 NOV 13, 1998
AT	TARO	0.05%	> ADD >	N75224 001 NOV 16, 1998

CLOMIPRAMINE HYDROCHLORIDE

CAPSULE; ORAL
CLOMIPRAMINE HCL

AB	CHELSEA LABS	25MG	N74751 001 SEP 30, 1998

CLOMIPRAMINE HYDROCHLORIDE

CAPSULE; ORAL
CLOMIPRAMINE HCL

AB	CHELSEA LABS	50MG	N74751 002 SEP 30, 1998	> DLT >	
AB		75MG	N74751 003 SEP 30, 1998	> DLT >	
AB	MYLAN	25MG	N74947 001 APR 30, 1998		
AB		50MG	N74947 002 APR 30, 1998		
AB		75MG	N74947 003 APR 30, 1998	> ADD >	

CLONAZEPAM

TABLET; ORAL
CLONAZEPAM

AB	MYLAN	0.5MG	N75150 001 OCT 05, 1998		
AB		1MG	N75150 002 OCT 05, 1998		
AB		2MG	N75150 003 OCT 05, 1998		
AB	NOVOPHARM	0.5MG	N74920 001 AUG 04, 1998		
AB		1MG	N74920 002 AUG 04, 1998		
AB		2MG	N74920 003 AUG 04, 1998		

KLONOPIN

> DLT > AB	ROCHE	1MG	N17533 002		
> ADD > AB	+	1MG	N17533 002		
> DLT > AB	*	2MG	N17533 003		
> ADD > AB		2MG	N17533 003		

KLONOPIN RAPIDLY DISINTEGRATING

	* ROCHE	0.125MG	N20813 001 DEC 23, 1997		
		0.25MG	N20813 002 DEC 23, 1997		
		0.5MG	N20813 003 DEC 23, 1997		

TABLET, ORALLY DISINTEGRATING; ORAL
KLONOPIN RAPIDLY DISINTEGRATING

> DLT >	ROCHE	1MG	N20813 004 DEC 23, 1997		
> DLT >					

CLONAZEPAM

TABLET, ORALLY DISINTEGRATING; ORAL
KLONOPIN RAPIDLY DISINTEGRATING

	* ROCHE	2MG	N20813 005 DEC 23, 1997		
	+	0.125MG	N20813 001 DEC 23, 1997		
		0.25MG	N20813 002 DEC 23, 1997		
		0.5MG	N20813 003 DEC 23, 1997		
	+	1MG	N20813 004 DEC 23, 1997	> ADD >	
		2MG	N20813 005 DEC 23, 1997	> ADD >	

CLONIDINE HYDROCHLORIDE

INJECTABLE; INJECTION
DURACLON

	* FUJISAWA	0.1MG/ML	N20615 001 OCT 02, 1996		
	+ ROXANE	0.1MG/ML	N20615 001 OCT 02, 1996		

CODEINE PHOSPHATE; PSEUDOEPHEDRINE HYDROCHLORIDE; TRIPROLIDINE HYDROCHLORIDE

SYRUP; ORAL
ACTIFED W/ CODEINE

AA	* GLAXO WELLCOME	10MG/5ML;10MG/5ML; 1.25MG/5ML	N12575 003 APR 04, 1984		
	@	10MG/5ML;30MG/5ML; 1.25MG/5ML	N12575 003 APR 04, 1984		

TRIPROLIDINE HCL, PSEUDOEPHEDRINE HCL AND CODEINE PHOSPHATE

AA	MORTON GROVE	10MG/5ML;10MG/5ML; 1.25MG/5ML	N88833 001 NOV 16, 1984		
AA	+	10MG/5ML;30MG/5ML; 1.25MG/5ML	N88833 001 NOV 16, 1984		

COLISTIMETHATE SODIUM

INJECTABLE; INJECTION
COLY-MYCIN M
[redacted] PARKE DAVIS EQ 150MG BASE/VIAL N50108 003
\+ PARKEDALE EQ 150MG BASE/VIAL N50108 002

COLISTIN SULFATE; HYDROCORTISONE ACETATE; NEOMYCIN SULFATE; THONZONIUM BROMIDE

SUSPENSION/DROPS; OTIC
COLY-MYCIN S
[redacted] PARKE DAVIS EQ 3MG BASE/ML;10MG/ML; EQ 3.3MG BASE/ML;0.5MG/ML N50356 001
\+ PARKEDALE EQ 3MG BASE/ML;10MG/ML; EQ 3.3MG BASE/ML;0.5MG/ML N50356 001

CORTICOTROPIN

INJECTABLE; INJECTION
ACTH
[redacted] PARKE DAVIS 25 UNITS/VIAL N08317 003
[redacted] 40 UNITS/VIAL N08317 004
PARKEDALE 25 UNITS/VIAL N08317 002
40 UNITS/VIAL N08317 004

CROMOLYN SODIUM

[redacted]
INTAL
[redacted] FISONS PHARMS DIV 20MG N16990 001
20MG N16990 001

SOLUTION/DROPS; OPHTHALMIC
CROLOM
AT BAUSCH AND LOMB 4% N74443 001 JAN 30, 1995
[redacted] 4% [redacted] JAN 30, 1995

CROMOLYN SODIUM
AT [redacted] 4% [redacted] APR 29, 1998
AT AKORN 4% N74706 001 APR 29, 1998

OPTICROM
AT \+ ALLERGAN 4% N18155 001 OCT 03, 1984

CROMOLYN SODIUM

SOLUTION/DROPS; OPHTHALMIC
OPTICROM
[redacted] FISONS PHARMS DIV 4% [redacted] N18155 001 OCT 03, 1984

CYCLOBENZAPRINE HYDROCHLORIDE

TABLET; ORAL
CYCLOBENZAPRINE HCL
AB ROXIE LABS 10MG [redacted] N74436 001 NOV 30, 1994
AB WATSON LABS 10MG N74436 001 NOV 30, 1994

CYCLOSPORINE

CAPSULE; ORAL
NEORAL
BX NOVARTIS 25MG N50715 001 JUL 14, 1995
BX 50MG N50715 003 JUL 14, 1995
BX \+ 100MG N50715 002 JUL 14, 1995

SANDIMMUNE
BX NOVARTIS 25MG N50625 001 MAR 02, 1990
BX 50MG N50625 003 NOV 23, 1992
BX \+ 100MG N50625 002
25MG [redacted]
50MG
[redacted] 100MG

CAPSULE, MICROEMULSION; ORAL
NEORAL
NOVARTIS 25MG N50715 001 JUL 14, 1995
50MG N50715 003 JUL 14, 1995

CYCLOSPORINE

CAPSULE; MICROEMULSION; ORAL
NEORAL
* NOVARTIS 100MG N50716 002 JUL 14, 1995

SOLUTION; ORAL
NEORAL
AB + NOVARTIS 100MG/ML N50716 001 JUL 14, 1995
* 100MG/ML N50716 001 JUL 14, 1995

SANDIMMUNE
BX + NOVARTIS 100MG/ML N50574 001 NOV 14, 1983
* 100MG/ML N50574 001 NOV 14, 1983

SANGCYA
AB SANGSTAT 100MG/ML N64195 001 OCT 31, 1998

CYPROHEPTADINE HYDROCHLORIDE

TABLET; ORAL
CYPROHEPTADINE HCL
AA [redacted] 4MG A86580 001
● 4MG N86580 001

DACARBAZINE

INJECTABLE; INJECTION
DACARBAZINE
AP GENSIA SICOR PHARMS 200MG/VIAL N75259 002 AUG 27, 1998

DTIC-DOME
AP + BAYER 200MG/VIAL N17575 002

DACTINOMYCIN

INJECTABLE; INJECTION
COSMEGEN
+ MERCK 0.5MG/VIAL N50682 001
* MERCK SHARP DOHME 0.5MG/VIAL N50682 001

DALTEPARIN SODIUM

INJECTABLE; INJECTION
FRAGMIN
* PHARMACIA AND UPJOHN 10,000 IU/3.5ML N20287 004 JAN 30, 1998
+ 10,000 IU/ML N20287 004 JAN 30, 1998

DANAZOL

CAPSULE; ORAL
DANAZOL
AB BARR 50MG N74582 003 MAY 29, 1998
AB 100MG N74582 002 MAY 29, 1998

DANOCRINE
AB SANOFI 50MG N17557 003
AB 100MG N17557 004

DAUNORUBICIN HYDROCHLORIDE

INJECTABLE; INJECTION
CERUBIDINE
+ BEDFORD EQ 20MG BASE/VIAL N64103 001 FEB 03, 1995

DAUNORUBICIN HCL
* BEDFORD EQ 20MG BASE/VIAL N64103 001 FEB 03, 1995

DAUNORUBICIN HCL PRESERVATIVE FREE
AP + BEDFORD EQ 20MG BASE/VIAL N50731 001 JAN 30, 1998
AP GENSIA SICOR PHARMS EQ 20MG BASE/VIAL N64212 001 JUN 23, 1998

DESOGESTREL; ETHINYL ESTRADIOL

TABLET; ORAL-28
MIRCETTE
+ ORGANON 0.15MG;0.02MG N20713 001 APR 22, 1998

DESOXIMETASONE

GEL; TOPICAL

DESOXIMETASONE

AB	TARO	0.05%	N74904 001	JUL 14, 1998

TOPICORT

AB	+ HOECHST MARION RSSL	0.05%	N18586 001	MAR 29, 1982

OINTMENT; TOPICAL

DESOXIMETASONE

AB	ALTANA	0.25%	N73440 001	APR 01, 1998

DEXAMETHASONE SODIUM PHOSPHATE

[redacted]

[redacted]		[redacted]	[redacted]
	EQ 0.1MG PHOSPHATE/INH	N13413 001	

[redacted]

[redacted]		[redacted]	[redacted]
	EQ 0.1MG PHOSPHATE/INH	N14242 001	

DEXTROAMPHETAMINE SULFATE

TABLET; ORAL

DEXEDRINE

[redacted]	[redacted]	[redacted]	[redacted]	
AA		5MG	N84935 001	

DEXTROSTAT

[redacted]	[redacted]	[redacted]	[redacted]	
AA	+	5MG	N84051 001	

DEXTROSE

INJECTABLE; INJECTION

DEXTROSE 10% IN PLASTIC CONTAINER

AP	B BRAUN	10GM/100ML	N18046 001	
[redacted]	[redacted]	[redacted]	[redacted]	

DEXTROSE 5% IN PLASTIC CONTAINER

AP	B BRAUN	5GM/100ML	N16730 001	
AP		50MG/ML	N16730 002	

DEXTROSE

INJECTABLE; INJECTION

DEXTROSE 5% IN PLASTIC CONTAINER

[redacted]	[redacted]	[redacted]	[redacted]	
[redacted]		[redacted]	[redacted]	

DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM ACETATE

INJECTABLE; INJECTION

ISOLYTE P IN DEXTROSE 5% IN PLASTIC CONTAINER

	B BRAUN	5GM/100ML;31MG/100ML;130MG/100ML; 26MG/100ML;320MG/100ML	N19873 001	JUN 10, 1993
[redacted]	[redacted]	[redacted]	[redacted]	[redacted]

DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE

INJECTABLE; INJECTION

ISOLYTE H IN DEXTROSE 5% IN PLASTIC CONTAINER

	B BRAUN	5GM/100ML;30MG/100ML;97MG/100ML; 220MG/100ML;140MG/100ML	N19844 001	JUN 10, 1993
[redacted]	[redacted]	[redacted]	[redacted]	[redacted]

DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM GLUCONATE

INJECTABLE; INJECTION

ISOLYTE S IN DEXTROSE 5% IN PLASTIC CONTAINER

AP	B BRAUN	5GM/100ML;30MG/100ML;37MG/100ML; 370MG/100ML;530MG/100ML; 500MG/100ML	N19843 001	AUG 09, 1993
[redacted]	[redacted]	[redacted]	[redacted]	[redacted]

DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM GLUCONATE

INJECTABLE; INJECTION
ISOLYTE S W/ DEXTROSE 5% IN PLASTIC CONTAINER

AP	B BRAUN	5GM/100ML;30MG/100ML;37MG/100ML; 370MG/100ML;530MG/100ML; 500MG/100ML	N18274 001	
AP	MCGAW	[illegible]	N18274 001	

DEXTROSE; POTASSIUM CHLORIDE

INJECTABLE; INJECTION
POTASSIUM CHLORIDE 0.075% IN DEXTROSE 5% IN PLASTIC CONTAINER

AP	B BRAUN	5GM/100ML;75MG/100ML	N18744 001 NOV 09, 1982	
AP	MCGAW	5GM/100ML;75MG/100ML	N18744 001 NOV 09, 1982	

DEXTROSE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM ACETATE; SODIUM CHLORIDE

INJECTABLE; INJECTION
ISOLYTE M IN DEXTROSE 5% IN PLASTIC CONTAINER

	B BRAUN	5GM/100ML;150MG/100ML;130MG/100ML; 280MG/100ML;91MG/100ML	N19870 001 JUN 10, 1993	
	MCGAW	5GM/100ML;150MG/100ML;130MG/100ML; 280MG/100ML;91MG/100ML	N19870 001 JUN 10, 1993	

DEXTROSE; SODIUM CHLORIDE

INJECTABLE; INJECTION
DEXTROSE 10% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

	● B BRAUN	10GM/100ML;900MG/100ML	N18047 001	
	● MCGAW	10GM/100ML;900MG/100ML	N18047 001	

DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

	● B BRAUN	5GM/100ML;900MG/100ML	N18026 001	
	● MCGAW	5GM/100ML;900MG/100ML	N18026 001	

DIAZEPAM

CAPSULE, EXTENDED RELEASE; ORAL
VALRELEASE

	● ROCHE	10MG	N18179 001	
	●	15MG	N18179 001	

INJECTABLE; INJECTION
DIAZEPAM

AP	WARNER	5MG/ML	N72371 001 JAN 29, 1993	
	●	5MG/ML	N72371 001 JAN 29, 1993	

DICLOFENAC POTASSIUM

TABLET; ORAL
CATAFLAM

AB	◆ CIBA	50MG	N20142 002 NOV 24, 1993	

DICLOFENAC POTASSIUM

> ADD > AB	INVAMED	50MG	N75229 001 NOV 20, 1998	
> ADD > AB	TEVA	50MG	N75219 001 AUG 06, 1998	
> ADD > AB	WATSON LABS	50MG	N75152 001 NOV 27, 1998	

DICLOFENAC SODIUM

SOLUTION/DROPS; OPHTHALMIC
DICLOFENAC SODIUM

AB	ALCON	0.1%	N20809 001 MAY 04, 1998	†

VOLTAREN

AB	◆ CIBA	0.1%	N20037 001 MAR 28, 1991	

TABLET, DELAYED RELEASE; ORAL
DICLOFENAC SODIUM

> ADD > AB	CARLSBAD	25MG	N75185 002 NOV 13, 1998	
> ADD > AB		50MG	N75185 003 NOV 13, 1998	
> ADD > AB		75MG	N75185 001 NOV 13, 1998	

† SEE SECTION 1.4 OF INTRODUCTION

DICYCLOMINE HYDROCHLORIDE

TABLET; ORAL
DICYCLOMINE HCL

[redacted]	[redacted]	[redacted]	[redacted]
	@	20MG	N84600 001 JUL 29, 1985

> DLT > **DIETHYLSTILBESTROL; METHYLTESTOSTERONE**

> DLT > [redacted]
> DLT > TYLOSTERONE
> DLT > @ [redacted] [redacted] [redacted]

DIFLORASONE DIACETATE

CREAM; TOPICAL
DIFLORASONE DIACETATE

AB	ALTANA	0.05%	N75187 001 MAR 30, 1998
	PSORCON		
AB	+ DERMIK LABS	0.05%	N20205 001 NOV 20, 1992
[redacted]	#	[redacted]	[redacted] [redacted]

DIGOXIN

INJECTABLE; INJECTION
DIGOXIN

AP	ABBOTT	0.25MG/ML	N40206 001 AUG 28, 1998

DILTIAZEM HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL
CARTIA XT

	@ ANDRX PHARMS	120MG	N74752 002 JUL 09, 1998
	@	180MG	N74752 001 JUL 09, 1998
	@	240MG	N74752 003 JUL 09, 1998

DILTIAZEM HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL
CARTIA XT

	@ ANDRX PHARMS	300MG	N74752 004 JUL 09, 1998

DILTIAZEM HCL

AB2	MYLAN	120MG	N75124 002 MAR 18, 1998
AB2		180MG	N75124 003 MAR 18, 1998
AB2		240MG	N75124 001 MAR 18, 1998

DILTIAZEM XR

AB2	TORPHARM	240MG	N74943 001 AUG 06, 1998

TIAZAC

[redacted]	[redacted]	[redacted]	[redacted] [redacted]
BC	+	120MG	N20401 001 SEP 11, 1995
[redacted]		[redacted]	[redacted] [redacted]
BC	+	180MG	N20401 002 SEP 11, 1995
[redacted]		[redacted]	[redacted] [redacted]
BC	+	240MG	N20401 003 SEP 11, 1995
[redacted]		[redacted]	[redacted] [redacted]
BC	+	300MG	N20401 004 SEP 11, 1995
		[redacted]	[redacted] [redacted]
	+	360MG	N20401 005 SEP 11, 1995
	+	420MG	N20401 006 OCT 16, 1998

INJECTABLE; INJECTION
DILTIAZEM HCL

AP	ABBOTT	5MG/ML	N74941 001 APR 15, 1998
AP	TAYLOR PHARMA	5MG/ML	N75086 001 APR 09, 1998

TABLET; ORAL
DILTIAZEM HCL

AB	[redacted]	[redacted]	[redacted] [redacted]

DILTIAZEM HYDROCHLORIDE

TABLET; ORAL
DILTIAZEM HCL

[redacted]	[redacted]	[redacted]	[redacted]	[redacted]
	●	30MG	N74084 001 FEB 25, 1994	
	●	60MG	N74084 002 FEB 25, 1994	

DILTIAZEM MALATE

TABLET, EXTENDED RELEASE; ORAL
TIAMATE

	+	HOECHST MARION RSSL	EQ 120MG HCL	N20506 001 OCT 04, 1996
	+		EQ 180MG HCL	N20506 002 OCT 04, 1996
	+		EQ 240MG HCL	N20506 003 OCT 04, 1996
[redacted]	[redacted]	[redacted]	[redacted]	[redacted]
[redacted]	[redacted]	[redacted]	[redacted]	[redacted]
[redacted]	[redacted]	[redacted]	[redacted]	[redacted]

DINOPROSTONE

INSERT, EXTENDED RELEASE; VAGINAL
CERVIDIL

	+	CONTROLLED THERAP	10MG	N20411 001 MAR 30, 1995
[redacted]	[redacted]	[redacted]	[redacted]	[redacted]

DIPHENHYDRAMINE HYDROCHLORIDE

ELIXIR; ORAL
DIPHENHYDRAMINE HCL

[redacted]	[redacted]	[redacted]	[redacted]	[redacted]
	●	12.5MG/5ML	N83237 001 JAN 25, 1982	

DIPHENHYDRAMINE HYDROCHLORIDE

INJECTABLE; INJECTION
DIPHENHYDRAMINE HCL

	AP	ABBOTT	50MG/ML	N40140 001 NOV 20, 1998

DIPYRIDAMOLE

INJECTABLE; INJECTION
DIPYRIDAMOLE

	AP	AN PHARM PARTNERS	5MG/ML	N74956 001 SEP 30, 1998
	AP	BEDFORD	5MG/ML	N74939 001 APR 13, 1998

TABLET; ORAL
DIPYRIDAMOLE

[redacted]	[redacted]	[redacted]	[redacted]	[redacted]
	●	25MG	N89425 001 JUL 12, 1990	

DISOPYRAMIDE PHOSPHATE

[redacted]
DISOPYRAMIDE PHOSPHATE

	@	[redacted]	MG 100MG BASE	[redacted]

DOBUTAMINE HYDROCHLORIDE

INJECTABLE; INJECTION
DOBUTAMINE HCL

	AP	LUITPOLD	EQ 12.5MG BASE/ML	N74545 001 JUN 25, 1998
	AP	MARSAM	EQ 12.5MG BASE/ML	N74279 001 FEB 18, 1998
	AP		EQ 12.5MG BASE/ML	N74995 001 MAR 31, 1998

DORZOLAMIDE HYDROCHLORIDE; TIMOLOL MALEATE

SOLUTION/DROPS; OPHTHALMIC
COSOPT

	+ MERCK	EQ 2% BASE;EQ 0.5% BASE	N20869 001 APR 07, 1998

DOXEPIN HYDROCHLORIDE

CAPSULE; ORAL
DOXEPIN HCL

[redacted]			
AB	WATSON LABS	EQ 10MG BASE	[redacted] MAR 29, 1991
AB		EQ 25MG BASE	N72986 001 MAR 29, 1991
AB		EQ 50MG BASE	N72987 001 MAR 29, 1991

DOXORUBICIN HYDROCHLORIDE

INJECTABLE; INJECTION
RUBEX

[redacted]			
AP	BRISTOL MYERS SQUIBB	10MG/VIAL	[redacted] APR 13, 1989
AP		50MG/VIAL	N62926 002 APR 13, 1989
		100MG/VIAL	N62926 003 APR 13, 1989

DOXYCYCLINE HYCLATE

CAPSULE; ORAL
PERIOSTAT

	+ COLLAGENEX	EQ 20MG BASE	N50744 001 SEP 30, 1998

DOXYCYCLINE HYCLATE

LIQUID, EXTENDED RELEASE; PERIODONTAL
ATRIDOX

	+ ATRIX	EQ 10% W/W	N50751 001 SEP 03, 1998

DROPERIDOL

INJECTABLE; INJECTION
INAPSINE

AP	+ AKORN MFG	2.5MG/ML	N16796 001
[redacted]			

DYPHYLLINE

[redacted]

	@	250MG/ML	N09088 001

ECHOTHIOPHATE IODIDE

POWDER FOR RECONSTITUTION; OPHTHALMIC
PHOSPHOLINE IODIDE

	+ AYERST	0.03%	N11963 002
	+	0.06%	N11963 004
	+	0.125%	N11963 001
	+	0.25%	N11963 003
[redacted]			

EDROPHONIUM CHLORIDE

INJECTABLE; INJECTION
[redacted]

AP	ABBOTT	10MG/ML	N40131 001 FEB 24, 1998
[redacted]			
	@	10MG/ML	N40044 001 MAR 20, 1996

EDROPHONIUM CHLORIDE

INJECTABLE; INJECTION
EDROPHONIUM CHLORIDE PRESERVATIVE FREE

AP	[redacted]	[redacted]	[redacted]	> ADD >
	●	10MG/ML	N40043 001 MAR 20, 1996	> ADD >

EFAVIRENZ

CAPSULE; ORAL
SUSTIVA

	DUPONT PHARMS	50MG	N20972 001 SEP 17, 1998
		100MG	N20972 002 SEP 17, 1998
	+	200MG	N20972 003 SEP 17, 1998

ENCAINIDE HYDROCHLORIDE

CAPSULE; ORAL
ENCAID

	[redacted]	25MG	[redacted]
		35MG	[redacted]
	●	25MG	N18981 002 DEC 24, 1986
	●	35MG	N18981 003 DEC 24, 1986

ENOXAPARIN SODIUM

INJECTABLE; INJECTION
LOVENOX

	+ RHONE POULENC RORER	40MG/0.4ML	N20164 002 JAN 30, 1998
	+	60MG/0.6ML	N20164 003 MAR 27, 1998
	+	80MG/0.8ML	N20164 004 MAR 27, 1998
	+	100MG/ML	N20164 005 MAR 27, 1998

EPINEPHRINE

INJECTABLE; INTRAMUSCULAR
EPI E Z PEN JR

	+ MERIDIAN MEDCL TECHN	0.15MG/DELIVERY	N19430 004 AUG 03, 1995

EPIPEN E Z PEN

	+ MERIDIAN MEDCL TECHN	0.3MG/DELIVERY	N19430 003 AUG 03, 1995

EPTIFIBATIDE

INJECTABLE; INJECTION
INTEGRILIN

	+ COR	75MG/100ML	N20718 002 MAY 18, 1998
	+	2MG/ML	N20718 001 MAY 18, 1998

ERYTHROMYCIN

OINTMENT; OPHTHALMIC
ERYTHROMYCIN

AP	[redacted]	[redacted]	[redacted]
AT	AKORN	0.5%	N64030 001 JUL 18, 1996

OINTMENT; TOPICAL
AKNE-MYCIN

	[redacted]	2%	[redacted]
	+ HEALTHPOINT	2%	N50584 001 JAN 10, 1985

TABLET, DELAYED RELEASE; ORAL
E-MYCIN

AB	[redacted]	[redacted]	[redacted]
AB		333MG	N60272 002

ERY-TAB

AB	[redacted]	[redacted]	[redacted]
AB	+	250MG	N62298 001
AB	[redacted]	[redacted]	[redacted]
AB	+	333MG	N62298 003 MAR 29, 1982
AB		500MG	[redacted]

ERYTHROMYCIN

TABLET, DELAYED RELEASE; ORAL
ERY-TAB

AB	+ ABBOTT	500MG	N62298 002	

ERYTHROMYCIN ETHYLSUCCINATE

SUSPENSION; ORAL
ERYTHROMYCIN ETHYLSUCCINATE

	[redacted]			

ESMOLOL HYDROCHLORIDE

INJECTABLE; INJECTION
BREVIBLOC

	+ BAXTER PHARM PROD	10MG/ML	N19386 001 AUG 15, 1988	
		100MG/ML	N19386 003 DEC 31, 1986	
	+	250MG/ML	N19386 002	
	[redacted]			

ESTAZOLAM

TABLET; ORAL
ESTAZOLAM

[redacted]				
AB	WATSON LABS	1MG	N74818 001 AUG 19, 1997	
AB		2MG	N74818 002 AUG 19, 1997	

ESTRADIOL

FILM, EXTENDED RELEASE; TRANSDERMAL
ALORA

BX	PROCTER AND GAMBLE	0.05MG/24HR	N20655 001 DEC 20, 1996	
BX		0.075MG/24HR	N20655 002 DEC 20, 1996	
BX		0.1MG/24HR	N20655 003	
[redacted]				

CLIMARA

BX	+ BERLEX	0.075MG/24HR	N20375 003 MAR 23, 1998	

ESCLIM

BX	FOURNIER	0.025MG/24HR	N20847 001 AUG 04, 1998	
BX		0.0375MG/24HR	N20847 002 AUG 04, 1998	
BX		0.05MG/24HR	N20847 003 AUG 04, 1998	
BX		0.075MG/24HR	N20847 004 AUG 04, 1998	
BX		0.1MG/24HR	N20847 005 AUG 04, 1998	

FEMPATCH

BX	+ PARKE DAVIS	0.025MG/24HR	N20417 001 DEC 03, 1996	

TABLET; ORAL
ESTRADIOL

AB	ENDEAVOR	0.5MG	N40138 001 JAN 30, 1998	
AB		1MG	N40138 002 JAN 30, 1998	
AB		2MG	N40138 003 JAN 30, 1998	

ESTRADIOL; NORETHINDRONE ACETATE

FILM, EXTENDED RELEASE; TRANSDERMAL
COMBIPATCH

	RHONE POULENC RORER	0.05MG/24HR;0.14MG/24HR	N20870 001 AUG 07, 1998	

ESTRADIOL; NORETHINDRONE ACETATE

FILM, EXTENDED RELEASE; TRANSDERMAL
CombiPatch
+ RHONE POULENC RORER 0.05MG/24HR;0.25MG/24HR N20870 002
AUG 07, 1998

> ADD > TABLET; ORAL
> ADD > Activella
> ADD > + NOVO NORDISK 1MG;0.5MG N20907 001
> ADD > NOV 18, 1998

ESTRADIOL CYPIONATE

INJECTABLE; INJECTION
Depo-Estradiol
[redacted] [redacted] [redacted]
[redacted] [redacted] [redacted]
● 1MG/ML N85470 001
● 3MG/ML N85470 002

ESTRADIOL VALERATE

INJECTABLE; INJECTION
Delestrogen
AQ + BRISTOL MYERS SQUIBB 20MG/ML N09402 004
AQ + 40MG/ML N09402 003
+ 10MG/ML N09402 002
[redacted] # [redacted] [redacted] [redacted]
[redacted] # [redacted] [redacted] [redacted]
[redacted] [redacted] [redacted]

ESTRADIOL VALERATE; TESTOSTERONE ENANTHATE

INJECTABLE; INJECTION
Deladumone
> ADD > ● BRISTOL MYERS SQUIBB 4MG/ML;90MG/ML N09545 001
> DLT > # [redacted] [redacted] [redacted]
Deladumone OB
> ADD > ● BRISTOL MYERS SQUIBB 8MG/ML;180MG/ML N09545 002
> DLT > # [redacted] [redacted] [redacted]

ESTROGENS, CONJUGATED; MEDROXYPROGESTERONE ACETATE

TABLET; ORAL-28
PremPro 14/14
+ WYETH AYERST 0.625MG,0.625MG;5MG,5MG N20527 003
JAN 09, 1998

ESTROGENS, ESTERIFIED

TABLET; ORAL
Menest
BS MONARCH PHARMS 0.3MG N84951 001
BS 0.625MG N84948 001
BS 2.5MG N84949 001
1.25MG N84950 001
[redacted] [redacted] [redacted] [redacted]
[redacted] [redacted] [redacted] [redacted]
[redacted] [redacted] [redacted] [redacted]
[redacted] [redacted] [redacted] [redacted]

ESTRONE

INJECTABLE; INJECTION
Theelin
[redacted] [redacted] [redacted]
[redacted] [redacted] [redacted]
[redacted] [redacted] [redacted]
● PARKEDALE 1MG/ML N03977 001
● 2MG/ML N03977 002
● 5MG/ML N03977 003

ETHACRYNATE SODIUM

INJECTABLE; INJECTION
Edecrin
+ MERCK EQ 50MG BASE/VIAL N16093 001
# [redacted] [redacted] [redacted]

ETHACRYNIC ACID

TABLET; ORAL
Edecrin
MERCK 25MG N16092 001
+ 50MG N16092 002
[redacted] [redacted] [redacted]

ETHACRYNIC ACID

TABLET; ORAL
EDECRIN
[redacted] 50MG [redacted]

ETHINYL ESTRADIOL; FLUOXYMESTERONE

> DLT > TABLET; ORAL
> DLT > HALOSTEN
> DLT > # PHARMACIA AND UPJOHN 0.02MG;1MG N11267 001

ETHINYL ESTRADIOL; LEVONORGESTREL

TABLET; ORAL
PREVEN EMERGENCY CONTRACEPTIVE KIT
\+ GYNETICS 0.05MG;0.25MG N20946 001 SEP 01, 1998

TABLET; ORAL-21
ALESSE
BX + WYETH AYERST 0.02MG;0.1MG N20683 001 MAR 27, 1997
[redacted] [redacted]

LEVLITE
BX BERLEX LABS 0.02MG;0.1MG N20860 001 JUL 13, 1998
[redacted] [redacted]

LEVORA 0.15/30-21
AB [redacted] [redacted] [redacted]
AB WATSON LABS 0.03MG;0.15MG N73592 001 DEC 13, 1993

TABLET; ORAL-28
ALESSE
BX WYETH AYERST 0.02MG;0.1MG N20683 002 MAR 27, 1997
[redacted] [redacted]

LEVLITE
BX BERLEX LABS 0.02MG;0.1MG N20860 002 JUL 13, 1998
[redacted] [redacted]

ETHINYL ESTRADIOL; LEVONORGESTREL

TABLET; ORAL-28
LEVORA 0.15/30-28
AB [redacted] [redacted] [redacted]
AB WATSON LABS 0.03MG;0.15MG N73594 001 DEC 13, 1993

ETHINYL ESTRADIOL; NORETHINDRONE

TABLET; ORAL-21
NORETHIN 1/35E-21
AB [redacted] [redacted] [redacted]
AB WATSON LABS 0.035MG;1MG N71480 001 APR 12, 1988

TABLET; ORAL-28
NORETHIN 1/35E-28
AB [redacted] [redacted] [redacted]
AB WATSON LABS 0.035MG;1MG N71481 001 APR 12, 1988

ETODOLAC

CAPSULE; ORAL
ETODOLAC
AB AESGEN 300MG N74929 001 JAN 30, 1998
AB GENPHARM 200MG N75071 001 SEP 30, 1998
AB 300MG N75071 002 SEP 30, 1998
AB TARO 200MG N75078 001 APR 30, 1998
AB 300MG N75078 002 APR 30, 1998

TABLET; ORAL
ETODOLAC
AB CHELSEA LABS 400MG N75069 001 APR 16, 1998
AB GENPHARM 400MG N75012 001 SEP 30, 1998

ETODOLAC

TABLET; ORAL
ETODOLAC

	AB	GENPHARM	500MG	N75012 002 SEP 30, 1998
	AB	MYLAN	400MG	N75104 001 FEB 06, 1998
> ADD >	AB		500MG	N75104 002 NOV 20, 1998
> ADD >	AB	RANBAXY	400MG	N75226 001 NOV 24, 1998
> ADD >	AB		500MG	N75226 002 NOV 24, 1998
> ADD >	AB	ROXANE LABS	400MG	N74892 001 APR 16, 1997
	AB	TARO	400MG	N75074 001 MAR 11, 1998
	AB	WATSON LABS	400MG	N74892 001 APR 16, 1997
> ADD >	AB		500MG	N74892 002 OCT 29, 1998
> ADD >	AB	ZENITH GOLDLINE	500MG	N74883 002 NOV 20, 1998

LODINE

	AB	+ WYETH AYERST	500MG	N18922 005 JUN 28, 1996

TABLET, EXTENDED RELEASE; ORAL
LODINE XL

	+	WYETH AYERST	500MG	N20584 003 JAN 20, 1998

ETOPOSIDE

INJECTABLE; INJECTION
ETOPOSIDE

	AP	APPLIED ANAL	20MG/ML	N74983 001 SEP 30, 1998
	AP	MARSAM	20MG/ML	N74968 001 JAN 09, 1998

ETOPOSIDE PHOSPHATE

INJECTABLE; INJECTION
ETOPOPHOS

	*	BRISTOL MYERS SQUIBB	EQ 100MG BASE/VIAL	N20457 001 MAY 17, 1996

ETOPOSIDE PHOSPHATE

INJECTABLE; INJECTION
ETOPOPHOS PRESERVATIVE FREE

+	BRISTOL MYERS SQUIBB	EQ 100MG BASE/VIAL	N20457 001 MAY 17, 1996
+		EQ 500MG BASE/VIAL	N20906 001 FEB 27, 1998

FAMOTIDINE

TABLET, ORALLY DISINTEGRATING; ORAL
PEPCID RPD

	MERCK	20MG	N20752 001 MAY 28, 1998
+		40MG	N20752 002 MAY 28, 1998

FENFLURAMINE HYDROCHLORIDE

TABLET; ORAL
PONDIMIN

*	ROBINS AH	20MG	N16618 001
@		20MG	N16618 001

FENOFIBRATE

CAPSULE; ORAL
LIPIDIL

@	ABBOTT	100MG	N19304 001 DEC 31, 1993
@	LABS FOURNIER	100MG	N19304 001 DEC 31, 1993

TRICOR (MICRONIZED)

+	ABBOTT	67MG	N19304 002 FEB 09, 1998

FENOPROFEN CALCIUM

CAPSULE; ORAL
FENOPROFEN CALCIUM

AB	DANBURY PHARMA	EQ 200MG BASE	N72981 001 AUG 19, 1991
AB		EQ 300MG BASE	N72982 001 AUG 19, 1991

FENOPROFEN CALCIUM

CAPSULE; ORAL
FENOPROFEN CALCIUM

	@	DANBURY PHARMA	EQ 200MG BASE	N72981 001 AUG 19, 1991
	@		EQ 300MG BASE	N72982 001 AUG 19, 1991

FENTANYL CITRATE

INJECTABLE; INJECTION
[redacted]

AP		ABBOTT	[redacted]	N72786 001 SEP 24, 1991
AP	*	ELKINS SINN	[redacted]	N19101 001 JUL 11, 1984

FENTANYL CITRATE PRESERVATIVE FREE

AP		ABBOTT	EQ 0.05MG BASE/ML	N72786 001 SEP 24, 1991
AP	+	ELKINS SINN	EQ 0.05MG BASE/ML	N19101 001 JUL 11, 1984
AP		MARSAM	EQ 0.05MG BASE/ML	N74917 001 FEB 03, 1998

[redacted]

AP	*	[redacted]	[redacted]	[redacted]

SUBLIMAZE PRESERVATIVE FREE

AP	+	JANSSEN	EQ 0.05MG BASE/ML	N16619 001

TROCHE/LOZENGE; ORAL
ACTIQ

>_ADD_>		ANESTA	EQ 0.2MG BASE	N20747 001 NOV 04, 1998
>_ADD_>			EQ 0.4MG BASE	N20747 002 NOV 04, 1998
>_ADD_>			EQ 0.6MG BASE	N20747 003 NOV 04, 1998
>_ADD_>			EQ 0.8MG BASE	N20747 004 NOV 04, 1998
>_ADD_>			EQ 1.2MG BASE	N20747 005 NOV 04, 1998
>_ADD_>	+		EQ 1.6MG BASE	N20747 006 NOV 04, 1998

FERRIC AMMONIUM CITRATE

POWDER FOR RECONSTITUTION; ORAL
FERRISELTZ

	+	NYCOMED AMERSHAM	600MG/PACKET	N20292 001 OCT 14, 1997
	*	[redacted]	[redacted]	[redacted]

FLOSEQUINAN

[redacted]
MANOPLAX

		KNOLL PHARM	50MG	[redacted]
			75MG	[redacted]
	*		100MG	[redacted]
	@		50MG	N19960 001 DEC 30, 1992
	@		75MG	N19960 002 DEC 30, 1992
	@		100MG	N19960 003 DEC 30, 1992

FLUOCINOLONE ACETONIDE

CREAM; TOPICAL
FLUOCINOLONE ACETONIDE

AT	TARO	0.01%	N40035 001 OCT 31, 1994
AT		0.1%	[redacted]

FLUOCINONIDE

CREAM; TOPICAL
FLUOCINONIDE

AB	DRAXIS HLTH	0.05%	N72494 001 JAN 19, 1989
AB	TARO	0.05%	[redacted]

FLUOROURACIL

INJECTABLE; INJECTION

ADRUCIL

AP		PHARMACIA AND UPJOHN	50MG/ML	N81225 001 AUG 28, 1991
AP	+		50MG/ML	N81225 001 AUG 28, 1991

FLUOROURACIL

AP		AM PHARM PARTNERS	50MG/ML	N40278 001 SEP 30, 1998
AP			50MG/ML	N40279 001 SEP 30, 1998
> ADD > AP	+	ICN PUERTO RICO	50MG/ML	N12209 001
> DLT > AP	#	ROCHE	50MG/ML	N12209 001

FLUPHENAZINE DECANOATE

INJECTABLE; INJECTION

FLUPHENAZINE DECANOATE

AO		KING PHARMS	25MG/ML	N74966 001 APR 16, 1998

FLURANDRENOLIDE; NEOMYCIN SULFATE

CREAM; TOPICAL

CORDRAN-N

#	LILLY	0.05%;EQ 3.5MG BASE/GM	N50346 001
@		0.05%;EQ 3.5MG BASE/GM	N50346 001

OINTMENT; TOPICAL

CORDRAN-N

#	LILLY	0.05%;EQ 3.5MG BASE/GM	N50345 001
@		0.05%;EQ 3.5MG BASE/GM	N50345 001

FLURAZEPAM HYDROCHLORIDE

CAPSULE; ORAL

DALMANE

> ADD > AB		ICN PUERTO RICO	15MG	N16721 001
> ADD > AB	+		30MG	N16721 002
> DLT > AB		ROCHE	15MG	N16721 001
> DLT > AB	#		30MG	N16721 002

FLUVOXAMINE MALEATE

TABLET; ORAL

LUVOX

#	SOLVAY	25MG	N19843 001 DEC 05, 1994
		25MG	N20243 001 DEC 05, 1994

FOMIVIRSEN SODIUM

INJECTABLE; INJECTION

VITRAVENE PRESERVATIVE FREE

+	CIBA VISION OPHTHLMC	6.6MG/ML	N20961 001 AUG 26, 1998

GABAPENTIN

CAPSULE; ORAL

NEURONTIN

	PARKE DAVIS PHARMS	100MG	N20235 001 DEC 30, 1993
#		400MG	N20235 003 DEC 30, 1993
+		100MG	N20235 001 DEC 30, 1993
		400MG	N20235 003 DEC 30, 1993

TABLET; ORAL

NEURONTIN

	PARKE DAVIS	600MG	N20882 001 OCT 09, 1998
+		800MG	N20882 002 OCT 09, 1998

GANCICLOVIR

IMPLANT; IMPLANTATION

VITRASERT

+	BAUSCH AND LOMB	4.5MG	N20569 001 MAR 04, 1996
#	CHIRON VISION	4.5MG	N20569 001 MAR 04, 1996

GEMFIBROZIL

CAPSULE; ORAL

LOPID

	[redacted]	[redacted]	[redacted]
	[redacted]	[redacted]	[redacted]
	● PARKE DAVIS PHARMS	200MG	N18422 001
	●	300MG	N18422 002

TABLET; ORAL

GEMFIBROZIL

AB	TORPHARM	600MG	N75034 001 JUL 20, 1998

LOPID

[redacted]	[redacted]	[redacted]	[redacted]
AB	✦ PARKE DAVIS PHARMS	600MG	N18422 003 NOV 20, 1986

GENTAMICIN SULFATE

INJECTABLE; INJECTION

GENTAMICIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

AP	B BRAUN	EQ 40MG BASE/100ML	N62814 008 AUG 28, 1987
AP		EQ 60MG BASE/100ML	N62814 009 AUG 28, 1987
AP		EQ 70MG BASE/100ML	N62814 010 AUG 28, 1987
AP		EQ 0.8MG BASE/ML	N62814 001 AUG 28, 1987
AP		EQ 80MG BASE/100ML	N62814 011 AUG 28, 1987
AP		EQ 90MG BASE/100ML	N62814 012 AUG 28, 1987
AP		EQ 100MG BASE/100ML	N62814 013 AUG 28, 1987
AP		EQ 1.2MG BASE/ML	N62814 002 AUG 28, 1987
AP		EQ 120MG BASE/100ML	N62814 014 AUG 28, 1987
AP		EQ 1.4MG BASE/ML	N62814 003 AUG 28, 1987
AP		EQ 1.6MG BASE/ML	N62814 004 AUG 28, 1987
AP		EQ 1.8MG BASE/ML	N62814 005 AUG 28, 1987

GENTAMICIN SULFATE

INJECTABLE; INJECTION

GENTAMICIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

AP	B BRAUN	EQ 2MG BASE/ML	N62814 006 AUG 28, 1987
AP		EQ 2.4MG BASE/ML	N62814 007 AUG 28, 1987
[redacted]	[redacted]	[redacted]	[redacted]
[redacted]	[redacted]	[redacted]	[redacted]
[redacted]	[redacted]	[redacted]	[redacted]
[redacted]	[redacted]	[redacted]	[redacted]
[redacted]	[redacted]	[redacted]	[redacted]
[redacted]	[redacted]	[redacted]	[redacted]
[redacted]	[redacted]	[redacted]	[redacted]
[redacted]	[redacted]	[redacted]	[redacted]
[redacted]	[redacted]	[redacted]	[redacted]
[redacted]	[redacted]	[redacted]	[redacted]
[redacted]	[redacted]	[redacted]	[redacted]
[redacted]	[redacted]	[redacted]	[redacted]
[redacted]	[redacted]	[redacted]	[redacted]
[redacted]	[redacted]	[redacted]	[redacted]

OINTMENT; OPHTHALMIC

GENTAMICIN SULFATE

[redacted]	[redacted]	[redacted]	[redacted]
AT	AKORN	EQ 0.3% BASE	N64093 001 AUG 31, 1995

GLUCAGON HYDROCHLORIDE RECOMBINANT

INJECTABLE; INJECTION
GLUCAGEN

	+	NOVO NORDISK	EQ 1MG BASE/VIAL	N20918 001 JUN 22, 1998

GLUCAGON, BIOSYNTHETIC

INJECTABLE; INJECTION
GLUCAGON

	+	LILLY	1MG/VIAL	N20928 001 SEP 11, 1998

GLYBURIDE

TABLET; ORAL
GLYBURIDE (MICRONIZED)

AB		INVAMED	1.5MG	N75174 001 JUN 22, 1998
AB			3MG	N75174 002 JUN 22, 1998
AB		MYLAN	1.5MG	N74792 001 JUN 26, 1998
AB			3MG	N74792 002 JUN 26, 1998

GLYCOPYRROLATE

TABLET; ORAL
GLYCOPYRROLATE

[redacted]		[redacted]	[redacted]	[redacted]
[redacted]		[redacted]	[redacted]	[redacted]
	@		1MG	N86902 001
	@		2MG	N86900 001

ROBINUL

[redacted]	*	[redacted]	[redacted]	[redacted]
	+		1MG	N12827 001

ROBINUL FORTE

[redacted]	*	[redacted]	[redacted]	[redacted]
	+		2MG	N12827 002

GRAMICIDIN; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

SOLUTION/DROPS; OPHTHALMIC
NEOSPORIN

[redacted]	*	[redacted]	[redacted]	[redacted]
AT	+	MONARCH PHARMS	0.025MG/ML;EQ 1.75MG BASE/ML; 10,000 UNITS/ML	N60582 001

GRANISETRON HYDROCHLORIDE

TABLET; ORAL
KYTRIL

	@	SMITHKLINE BEECHAM	EQ 2MG BASE	N20305 002 JUN 15, 1998

GREPAFLOXACIN HYDROCHLORIDE

TABLET; ORAL
RAXAR

	*	[redacted]	[redacted]	[redacted]
			EQ 200MG BASE	N20695 001 NOV 06, 1997
			EQ 400MG BASE	N20695 002 MAY 14, 1998
	+		EQ 600MG BASE	N20695 003 MAY 14, 1998

GUANABENZ ACETATE

TABLET; ORAL
GUANABENZ ACETATE

AB		EON	EQ 4MG BASE	N74517 001 SEP 30, 1998
AB			EQ 8MG BASE	N74517 002 SEP 30, 1998

GUANETHIDINE MONOSULFATE; HYDROCHLOROTHIAZIDE

TABLET; ORAL
[redacted]

	*	NOVARTIS	[redacted]	[redacted]
	@		10MG;25MG	N13553 001

GUANFACINE HYDROCHLORIDE

TABLET; ORAL
GUANFACINE HCL

> ADD >	AB	GENPHARM	EQ 1MG BASE	N75109 001 NOV 25, 1998
> ADD >				
> ADD >	AB		EQ 2MG BASE	N75109 002 NOV 25, 1998
> ADD >				
	AB	[redacted]	[redacted]	[redacted]
	AB		[redacted]	[redacted]
	AB	WATSON LABS	EQ 1MG BASE	N74762 001 JUN 25, 1997
	AB		EQ 2MG BASE	N74762 002 JUN 25, 1997

HALOPERIDOL

TABLET; ORAL
HALOPERIDOL

AB	[redacted]	[redacted]	[redacted]
AB		[redacted]	[redacted]
	●	10MG	N72113 001 AUG 27, 1991
	●	20MG	N72353 001 AUG 27, 1991
AB	[redacted]	[redacted]	[redacted]
AB		[redacted]	[redacted]
AB		[redacted]	[redacted]
AB		[redacted]	[redacted]
AB		[redacted]	[redacted]
AB		[redacted]	[redacted]
	●	0.5MG	N71071 001 NOV 03, 1986
	●	1MG	N71072 001 NOV 03, 1986
	●	2MG	N71073 001 NOV 03, 1986

HALOPERIDOL

TABLET; ORAL
HALOPERIDOL

	● PUREPAC PHARM	5MG	N71074 001 NOV 03, 1986
	●	10MG	N71075 001 AUG 04, 1987
	●	20MG	N71076 001 AUG 04, 1987

HALOPERIDOL DECANOATE

INJECTABLE; INJECTION
HALOPERIDOL DECANOATE

AO	BEDFORD	EQ 50MG BASE/ML	N74811 001 JAN 30, 1998
AO		EQ 100MG BASE/ML	N75305 001 SEP 28, 1998

HALOPERIDOL LACTATE

INJECTABLE; INJECTION
HALOPERIDOL

AB	[redacted]	[redacted]	[redacted]
AB		[redacted]	[redacted]
	●	EQ 5MG BASE/ML	N72516 001 FEB 25, 1993
	●	EQ 5MG BASE/ML	N72517 001 FEB 25, 1993

HEPARIN SODIUM

INJECTABLE; INJECTION
HEP FLUSH KIT IN PLASTIC CONTAINER

	● AM PHARM PARTNERS	10 UNITS/ML	N17029 017 DEC 05, 1985
	●	100 UNITS/ML	N17029 018 DEC 05, 1985
	# [redacted]	[redacted]	[redacted]
	#	[redacted]	[redacted]

HEPARIN SODIUM

INJECTABLE; INJECTION

HEPARIN LOCK FLUSH

AP	AM PHARM PARTNERS	10 UNITS/ML	N17029 007	MAY 06, 1982
AP		100 UNITS/ML	N17029 006	
@		100 UNITS/ML		
AP	FUJISAWA	10 UNITS/ML	[illegible]	
AP		100 UNITS/ML	[illegible]	
@		100 UNITS/ML	[illegible]	
> DLT > AP	SOLOPAK	10 UNITS/ML	[illegible]	
> DLT >				
> ADD > @		10 UNITS/ML	N88457 001	OCT 25, 1984
> ADD >				

HEPARIN LOCK FLUSH PRESERVATIVE FREE

@	AM PHARM PARTNERS	10 UNITS/ML	N17029 011	SEP 22, 1987
@		100 UNITS/ML	N17029 012	SEP 22, 1987
@	FUJISAWA	10 UNITS/ML	[illegible]	
@		100 UNITS/ML	[illegible]	

HEPARIN LOCK FLUSH PRESERVATIVE FREE IN PLASTIC CONTAINER

@	AM PHARM PARTNERS	10 UNITS/ML	N17029 008	SEP 22, 1987
@		100 UNITS/ML	N17029 009	SEP 22, 1987
@	FUJISAWA	10 UNITS/ML	[illegible]	
@		100 UNITS/ML	[illegible]	

HEPARIN SODIUM

AP	AM PHARM PARTNERS	1,000 UNITS/ML	N17029 001	
AP		1,000 UNITS/ML	N17979 001	
AP		5,000 UNITS/ML	N17651 006	
AP		10,000 UNITS/ML	N17029 003	
AP		10,000 UNITS/ML	N17979 002	
AP		20,000 UNITS/ML	N17029 004	
@		1,000 UNITS/ML	N17651 005	
@		5,000 UNITS/ML	N17029 002	
@		5,000 UNITS/ML	N17979 003	
@		10,000 UNITS/ML	N17651 00[illegible]	
@		20,000 UNITS/ML	N17651 008	
AP	FUJISAWA	1,000 UNITS/ML	[illegible]	
AP		1,000 UNITS/ML	[illegible]	
AP		5,000 UNITS/ML	[illegible]	

HEPARIN SODIUM

INJECTABLE; INJECTION

HEPARIN SODIUM

AP	FUJISAWA	10,000 UNITS/ML	[illegible]	
AP		10,000 UNITS/ML	[illegible]	
AP		20,000 UNITS/ML	[illegible]	
@		1,000 UNITS/ML	[illegible]	
@		5,000 UNITS/ML	[illegible]	
@		5,000 UNITS/ML	[illegible]	
@		10,000 UNITS/ML	[illegible]	
@		20,000 UNITS/ML	[illegible]	

HEPARIN SODIUM 1,000 UNITS IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

AP	B BRAUN	200 UNITS/100ML	N19953 001	JUL 20, 1992
@		200 UNITS/100ML	N19042 001	MAR 29, 1985
AP	NCGAN	200 UNITS/100ML	[illegible]	
@		200 UNITS/100ML	[illegible]	

HEPARIN SODIUM 10,000 UNITS IN DEXTROSE 5%

AP	ABBOTT	10,000 UNITS/100ML	[illegible]	
@		10,000 UNITS/100ML	N18911 006	JAN 30, 1985

HEPARIN SODIUM 12,500 UNITS IN DEXTROSE 5%

AP	ABBOTT	5,000 UNITS/100ML	[illegible]	
@		5,000 UNITS/100ML	N18911 007	JAN 30, 1985

HEPARIN SODIUM 12,500 UNITS IN DEXTROSE 5% IN PLASTIC CONTAINER

AP	ABBOTT	5,000 UNITS/100ML	[illegible]	
		5,000 UNITS/100ML	N19339 001	MAR 27, 1985

HEPARIN SODIUM 12,500 UNITS IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER

@	B BRAUN	5,000 UNITS/100ML	N19802 001	JUL 20, 1992
@	NCGAN	5,000 UNITS/100ML	[illegible]	

HEPARIN SODIUM 2,000 UNITS IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

@	B BRAUN	200 UNITS/100ML	N19042 002	MAR 29, 1985

HEPARIN SODIUM

INJECTABLE; INJECTION

HEPARIN SODIUM 2,000 UNITS IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

@	MCGAW	200 UNITS/100ML	N19042 002 MAR 29, 1985

HEPARIN SODIUM 20,000 UNITS IN DEXTROSE 5% IN PLASTIC CONTAINER

AP	B BRAUN	4,000 UNITS/100ML	N19952 001 JUL 20, 1992
AP	MCGAW	4,000 UNITS/100ML	N19952 001 JUL 20, 1992

HEPARIN SODIUM 45,000 UNITS IN DEXTROSE 5%

AP	ABBOTT	5,000 UNITS/100ML	N18911 009 JAN 30, 1985
AP		10,000 UNITS/100ML	N18911 008 JAN 30, 1985
@		5,000 UNITS/100ML	N18911 009 JAN 30, 1985
@		10,000 UNITS/100ML	N18911 008 JAN 30, 1985

HEPARIN SODIUM 25,000 UNITS IN DEXTROSE 5% IN PLASTIC CONTAINER

AP	B BRAUN	5,000 UNITS/100ML	N19952 004 JUL 20, 1992
AP		10,000 UNITS/100ML	N19952 005 JUL 20, 1992
@		5,000 UNITS/100ML	N19134 001 MAR 29, 1985
AP	MCGAW	5,000 UNITS/100ML	N19952 004 JUL 20, 1992
AP		10,000 UNITS/100ML	N19952 005 JUL 20, 1992
@		5,000 UNITS/100ML	N19134 001 MAR 29, 1985

HEPARIN SODIUM 25,000 UNITS IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER

@	B BRAUN	5,000 UNITS/100ML	N19802 005 JUL 20, 1992
@		10,000 UNITS/100ML	N19802 002 JUL 20, 1992
@	MCGAW	5,000 UNITS/100ML	N19802 005 JUL 20, 1992
@		10,000 UNITS/100ML	N19802 002 JUL 20, 1992

HEPARIN SODIUM 25,000 UNITS IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

@	B BRAUN	5,000 UNITS/100ML	N19135 001 MAR 29, 1985

HEPARIN SODIUM

INJECTABLE; INJECTION

HEPARIN SODIUM 25,000 UNITS IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

@	B BRAUN	5,000 UNITS/100ML	N19802 003 JUL 20, 1992
@	MCGAW	5,000 UNITS/100ML	N19135 001 MAR 29, 1985
@		5,000 UNITS/100ML	N19802 003 JUL 20, 1992

HEPARIN SODIUM 5,000 UNITS IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

@	B BRAUN	1,000 UNITS/100ML	N19042 004 MAR 29, 1985
@	MCGAW	1,000 UNITS/100ML	N19042 004 MAR 29, 1985

HEPARIN SODIUM IN PLASTIC CONTAINER

AP	AM PHARM PARTNERS	1,000 UNITS/ML	N17029 013 DEC 05, 1985
AP		5,000 UNITS/ML	N17029 014 DEC 05, 1985
AP		10,000 UNITS/ML	N17029 015 DEC 05, 1985
AP		20,000 UNITS/ML	N17029 016 DEC 05, 1985
AP	FUJISAWA	1,000 UNITS/ML	N17029 013 DEC 05, 1985
AP		5,000 UNITS/ML	N17029 014 DEC 05, 1985
AP		10,000 UNITS/ML	N17029 015 DEC 05, 1985
AP		20,000 UNITS/ML	N17029 016 DEC 05, 1985

HEPARIN SODIUM PRESERVATIVE FREE

AP	+	AM PHARM PARTNERS	1,000 UNITS/ML	N17029 010 APR 28, 1986
AP	+	FUJISAWA	1,000 UNITS/ML	N17029 010 APR 28, 1986

HEPFLUSH-10

AP	AM PHARM PARTNERS	10 UNITS/ML	N17651 009 JUN 26, 1984
AP	FUJISAWA	10 UNITS/ML	N17651 009 JUN 26, 1984

HYDRALAZINE HYDROCHLORIDE

INJECTABLE; INJECTION

	AP	*	[redacted]	20MG/ML	A08303 003
		@		20MG/ML	N08303 003
			HYDRALAZINE HCL		
	AP		[redacted]	20MG/ML	A40136 001 JUN 30, 1997
	AP	+		20MG/ML	N40136 001 JUN 30, 1997
> DLT >	AP	*	SOLOPAK	20MG/ML	A88517 001 AUG 22, 1985
> DLT >					
> ADD >	AP			20MG/ML	N88517 001 AUG 22, 1985
> ADD >					

HYDROCHLOROTHIAZIDE; IRBESARTAN

TABLET; ORAL

		AVAPRO HCT		
		@ SANOFI	12.5MG;75MG	N20758 001 SEP 30, 1997
		+	12.5MG;150MG	N20758 002 SEP 30, 1997
		IRBESARTAN-HYDROCHLOROTHIAZIDE		
		@ SANOFI	12.5MG;75MG	A20758 001 SEP 30, 1997
		*	12.5MG;150MG	A20758 002 SEP 30, 1997

HYDROCHLOROTHIAZIDE; METHYLDOPA

TABLET; ORAL

		METHYLDOPA AND HYDROCHLOROTHIAZIDE		
	AB	[redacted]	15MG;250MG	A70829 001 MAR 09, 1987
	AB		25MG;250MG	A70830 001 MAR 09, 1987
		@	15MG;250MG	N70829 001 MAR 09, 1987
		@	25MG;250MG	N70830 001 MAR 09, 1987

HYDROCHLOROTHIAZIDE; PROPRANOLOL HYDROCHLORIDE

TABLET; ORAL

	PROPRANOLOL HCL AND HYDROCHLOROTHIAZIDE		
AB	[redacted]	25MG;40MG	A71498 001 DEC 18, 1991
AB		25MG;80MG	A71501 001 DEC 18, 1991
@		25MG;40MG	N71498 001 DEC 18, 1991
@		25MG;80MG	N71501 001 DEC 18, 1991

HYDROCHLOROTHIAZIDE; RESERPINE

TABLET; ORAL

		HYDROPRES 25		
BP		MERCK	25MG;0.125MG	N11958 002
BP		[redacted]	25MG;0.125MG	N11958 002
		HYDROPRES 50		
BP	+	MERCK	50MG;0.125MG	N11958 003
BP	*	[redacted]	50MG;0.125MG	N11958 003

HYDROCHLOROTHIAZIDE; SPIRONOLACTONE

TABLET; ORAL

	SPIRONOLACTONE AND HYDROCHLOROTHIAZIDE		
AB	GENEVA PHARMS	25MG;25MG	A86881 001
	SPIRONOLACTONE W/ HYDROCHLOROTHIAZIDE		
AB	[redacted]	25MG;25MG	A86881 001

HYDROCHLOROTHIAZIDE; TIMOLOL MALEATE

TABLET; ORAL

	TIMOLIDE 10-25		
+	MERCK	25MG;10MG	N18061 001
*	[redacted]	25MG;10MG	A18061 001

HYDROCHLOROTHIAZIDE; TRIAMTERENE

CAPSULE; ORAL

	TRIAMTERENE AND HYDROCHLOROTHIAZIDE		
AB	BARR	25MG;37.5MG	A74970 001 JAN 06, 1998

HYDROCHLOROTHIAZIDE; TRIAMTERENE

TABLET; ORAL

TRIAMTERENE AND HYDROCHLOROTHIAZIDE

AB		BARR	25MG;37.5MG	N71251 002 MAY 05, 1998

HYDROCHLOROTHIAZIDE; VALSARTAN

TABLET; ORAL

DIOVAN HCT

		NOVARTIS	12.5MG;80MG	N20818 001 MAR 06, 1998
	+		12.5MG;160MG	N20818 002 MAR 06, 1998

HYDROCORTISONE

AEROSOL, TOPICAL

AEROSEB-HC

	+	ALLERGAN HERBERT	0.5%	N85805 001
	@		0.5%	N85805 001

CREAM; TOPICAL

ANUSOL HC

AT		PARKE DAVIS	2.5%	N88250 001 JUN 06, 1984
AT		PARKEDALE	2.5%	N88250 001 JUN 06, 1984

ELDECORT

	@	ELDER	1%	N80459 001
	@		2.5%	N84055 001
	@	ICN	1%	N80459 001
	@		2.5%	N84055 001

LOTION; TOPICAL

CETACORT

AT		GALDERMA	0.5%	N80426 002
AT			1%	N80426 001
AT		HEALTHPOINT	0.5%	N80426 002
AT			1%	N80426 001

SOLUTION; TOPICAL

TEXACORT

AT	+	GALDERMA	1%	N80425 001
AT	+	MEDICIS	1%	N80425 001

HYDROCORTISONE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

SUSPENSION/DROPS; OPHTHALMIC

CORTISPORIN

AT	+	GLAXO WELLCOME	1%;EQ 3.5MG BASE/ML; 10,000 UNITS/ML	N50169 001
AT	+	MONARCH PHARMS	1%;EQ 3.5MG BASE/ML; 10,000 UNITS/ML	N50169 001

SUSPENSION/DROPS; OTIC

CORTISPORIN

	@	GLAXO WELLCOME	1%;EQ 3.5MG BASE/ML; 10,000 UNITS/ML	N60613 001
AT	+	MONARCH PHARMS	1%;EQ 3.5MG BASE/ML; 10,000 UNITS/ML	N60613 001

HYDROCORTISONE VALERATE

CREAM; TOPICAL

HYDROCORTISONE VALERATE

AB		COPLEY PHARM	0.2%	N74489 001 AUG 12, 1998
AB		TARO	0.2%	N75042 001 AUG 25, 1998

WESTCORT

AB	+	WESTWOOD SQUIBB	0.2%	N17950 001

OINTMENT; TOPICAL

HYDROCORTISONE VALERATE

AB		TARO	0.2%	N75043 001 AUG 25, 1998

WESTCORT

AB	+	WESTWOOD SQUIBB	0.2%	N18726 001 AUG 08, 1983

HYDROMORPHONE HYDROCHLORIDE

SOLUTION; ORAL

DILAUDID

AA	+	KNOLL PHARM	5MG/5ML	N19891 001 DEC 07, 1992

HYDROMORPHONE HCL

AA		ROXANE	5MG/5ML	N74653 001 JUL 29, 1998

TABLET; ORAL

DILAUDID

AB	+	KNOLL PHARM	8MG	N19892 001 DEC 07, 1992

HYDROMORPHONE HYDROCHLORIDE

TABLET; ORAL
HYDROMORPHONE HCL

AB		ROXANE	8MG	N74597 001 JUL 29, 1998

HYDROXYAMPHETAMINE HYDROBROMIDE; TROPICAMIDE

SOLUTION/DROPS; OPHTHALMIC
PAREMYD

	+	AKORN	1%;0.25%	N19261 001 JAN 30, 1992
	*	ALLERGAN	1%;0.25%	N19261 001 JAN 30, 1992

HYDROXYCHLOROQUINE SULFATE

TABLET; ORAL
HYDROXYCHLOROQUINE SULFATE

AB		MYLAN	200MG	N40274 001 MAY 29, 1998

HYDROXYCHLOROQUINE SULFATE

AB		ROYCE LABS	200MG	N40133 001 NOV 30, 1995
AB		WATSON LABS	200MG	N40133 001 NOV 30, 1995

HYDROXYUREA

CAPSULE; ORAL
DROXIA

		BRISTOL MYERS SQUIBB	300MG	N16295 003 FEB 25, 1998
			200MG	N16295 002 FEB 25, 1998
			300MG	N16295 003 FEB 25, 1998
	+		400MG	N16295 004 FEB 25, 1998

HYDREA

AB	+	BRISTOL MYERS SQUIBB	500MG	N16295 001
AB	*	SQUIBB	500MG	N16295 001

HYDROXYUREA

AB		BARR	500MG	N75143 001 OCT 16, 1998

HYDROXYUREA

CAPSULE; ORAL
HYDROXYUREA

AB		DURAMED	500MG	N75020 001 JUL 30, 1998

HYDROXYZINE HYDROCHLORIDE

TABLET; ORAL
HYDROXYZINE HCL

AB		ROYCE LABS	10MG	N81149 001 MAR 18, 1994
AB			25MG	N81150 001 MAR 18, 1994
AB			50MG	N81151 001 MAR 18, 1994
AB		WATSON LABS	10MG	N81149 001 MAR 18, 1994
AB			25MG	N81150 001 MAR 18, 1994
AB			50MG	N81151 001 MAR 18, 1994

HYDROXYZINE PAMOATE

CAPSULE; ORAL
HYDROXYZINE PAMOATE

AB		DANBURY PHARMA	EQ 50MG HCL	N87767 001 AUG 16, 1982
AB			EQ 100MG HCL	N87790 001 AUG 16, 1982
	@		EQ 50MG HCL	N87767 001 AUG 16, 1982
	@		EQ 100MG HCL	N87790 001 AUG 16, 1982

IBUPROFEN

SUSPENSION; ORAL
CHILDREN'S ADVIL

BX		AM HOME PRODS	100MG/5ML	N19833 002 SEP 19, 1989
BX		WHITEHALL ROBINS	100MG/5ML	N19833 002 SEP 19, 1989

IBUPROFEN

SUSPENSION; ORAL

	IBUPROFEN			
AB	ALPHARMA	100MG/5ML	N74978 001	MAR 25, 1998
	MOTRIN			
AB	+ MCNEIL	100MG/5ML	N19842 001	SEP 19, 1989
[illegible]	#	100MG/5ML	[illegible]	[illegible]

TABLET; ORAL

	IBUPROFEN			
[illegible]	[illegible]	400MG	[illegible]	[illegible]
[illegible]		600MG	[illegible]	[illegible]
[illegible]		800MG	[illegible]	[illegible]
	@	400MG	N72064 001	JAN 14, 1988
	@	600MG	N72065 001	JAN 14, 1988
	@	800MG	N71938 001	JAN 14, 1988

INDAPAMIDE

TABLET; ORAL

	INDAPAMIDE			
AB	ALPHAPHARM	1.25MG	N75105 001	JUL 23, 1998
AB		2.5MG	N75105 002	JUL 23, 1998
AB	TEVA	1.25MG	N74498 002	FEB 12, 1998

INDOMETHACIN

CAPSULE; ORAL

	INDOMETHACIN			
AB	DANBURY PHARMA	25MG	[illegible]	[illegible]
AB		50MG	[illegible]	[illegible]

INDOMETHACIN

CAPSULE; ORAL

	INDOMETHACIN			
	@ DANBURY PHARMA	25MG	N72996 001	JUL 31, 1991
	@	50MG	N72997 001	JUL 31, 1991
AB	EON	75MG	N74464 001	MAY 28, 1998

INSULIN LISPRO

INJECTABLE; INJECTION

	HUMALOG PEN			
	+ LILLY	100 UNITS/ML	N20563 002	AUG 06, 1998

IODAMIDE MEGLUMINE

INJECTABLE; INJECTION

	RENOVUE-DIP			
	+ BRACCO	24%	N17903 001	
	@	24%	N17903 001	

IOPAMIDOL

INJECTABLE; INJECTION

	IOPAMIDOL			
AP	ELKINS SINN	51%	N74629 004	MAR 31, 1998
	IOPAMIDOL-250			
AP	ABBOTT	51%	N75005 001	FEB 24, 1998
	IOPAMIDOL-300			
AP	ABBOTT	61%	N75005 002	FEB 24, 1998
	IOPAMIDOL-370			
AP	ABBOTT	76%	N75005 003	FEB 24, 1998

IOTROLAN

INJECTABLE; INTRATHECAL

OSMOVIST 190						
BERLEX LABS	40.6%	N19580 001 DEC 07, 1989				
@	40.6%	N19580 001 DEC 07, 1989				
OSMOVIST 240						
BERLEX LABS	51.3%	N19580 002 DEC 07, 1989				
@	51.3%	N19580 002 DEC 07, 1989				

IOVERSOL

INJECTABLE; INJECTION

OPTIRAY 240						
+ MALLINCKRODT	51%	N20923 001 MAY 28, 1998				
OPTIRAY 320						
+ MALLINCKRODT	68%	N20923 002 MAY 29, 1998	> ADD >	> ADD >		
OPTIRAY 350						
+ MALLINCKRODT	74%	N20923 003 MAY 28, 1998				

IPRATROPIUM BROMIDE

AEROSOL, METERED; INHALATION

ATROVENT						
BOEHRINGER INGELHEIN	0.018MG/INH	N19085 001 DEC 29, 1986				
+	0.018MG/INH	N19085 001 DEC 29, 1986				

ISOPROTERENOL HYDROCHLORIDE

AEROSOL, METERED; INHALATION

ISUPREL						
+ SANOFI	0.131MG/INH	N11178 001				
+	0.103MG/INH	N11178 001				

ISOSORBIDE DINITRATE

TABLET; SUBLINGUAL

SORBITRATE						
ZENECA	2.5MG	N16191 002 APR 01, 1996				
	5MG	N16191 001 APR 01, 1996				
@	2.5MG	N16191 002 APR 01, 1996				
@	5MG	N16191 001 APR 01, 1996				

ISOSORBIDE MONONITRATE

TABLET; ORAL

ISOSORBIDE MONONITRATE						
			AB	PUREPAC PHARM	10MG	N75037 002 OCT 30, 1998
			AB		20MG	N75037 001 OCT 30, 1998
			AB	TEVA	20MG	N75147 001 NOV 27, 1998
MONOKET						
			AB	SCHWARZ	10MG	N20215 002 JUN 30, 1993

TABLET, EXTENDED RELEASE; ORAL

IMDUR						
			AB	+ SCHERING	60MG	N20225 002 AUG 12, 1993
ISOSORBIDE MONONITRATE						
			AB	ELAN PHARM	60MG	N75041 001 SEP 22, 1998
			AB	KREMERS URBAN	60MG	N75155 001 OCT 30, 1998

ISOSULFAN BLUE

INJECTABLE; INJECTION

LYMPHAZURIN						
+ HIRSCH INDS	1%	N18310 001				
+ US SURGCL	1%	N18310 001				

KETAMINE HYDROCHLORIDE

INJECTABLE; INJECTION
KETALAR

AP	*	PARKE DAVIS	[illegible]	N16812 002
AP	*			N16812 003
AP	*			N16812 001
	*			
AP	+	PARKEDALE		N16812 002
AP	+			N16812 003
	+			N16812 001

KETOPROFEN

CAPSULE, EXTENDED RELEASE; ORAL
ORUVAIL

	*	WYETH AYERST	100MG	N19816 003 FEB 08, 1995
	*		150MG	N19816 002 FEB 08, 1995
			100MG	N19816 003 FEB 08, 1995
			150MG	N19816 002 FEB 08, 1995

LABETALOL HYDROCHLORIDE

TABLET; ORAL
LABETALOL HCL

> ADD >	AB	APOTHECON	100MG	N75223 001 NOV 20, 1998
> ADD >	AB		200MG	N75223 002 NOV 20, 1998
> ADD >	AB		300MG	N75223 003 NOV 20, 1998
	AB	EON	100MG	N75113 001 AUG 04, 1998
	AB		200MG	N75113 002 AUG 04, 1998
	AB		300MG	N75113 003 AUG 04, 1998
	AB	TEVA	100MG	N74989 001 SEP 30, 1998
	AB		200MG	N74989 002 SEP 30, 1998
	AB		300MG	N74989 003 SEP 30, 1998

LABETALOL HYDROCHLORIDE

TABLET; ORAL
LABETALOL HCL

AB		WATSON LABS	100MG	N75133 001 AUG 03, 1998
AB			200MG	N75133 002 AUG 03, 1998
AB			300MG	N75133 003 AUG 03, 1998
AB		ZENITH GOLDLINE	100MG	N74787 001 AUG 03, 1998
AB			200MG	N74787 002 AUG 03, 1998
AB			300MG	N74787 003 AUG 03, 1998

LACTULOSE

POWDER FOR RECONSTITUTION; ORAL
LACTULOSE

	INALCO	10GM/PACKET	N74712 001 DEC 10, 1997
+		10GM/PACKET	N74712 001 DEC 10, 1997

LAMOTRIGINE

TABLET, CHEWABLE; ORAL
LAMICTAL CD

	GLAXO WELLCOME	5MG	N20764 001 AUG 24, 1998
		25MG	N20764 002 AUG 24, 1998
+		100MG	N20764 003 AUG 24, 1998

LEFLUNOMIDE

TABLET; ORAL
ARAVA

	HOECHST MARION RSSL	10MG	N20905 001 SEP 10, 1998
		20MG	N20905 002 SEP 10, 1998

LEFLUNOMIDE

TABLET; ORAL
ARAVA

+	HOECHST MARION RSSL	100MG	N20905 003 SEP 10, 1998
	QUINTILES	10MG	N20905 001 SEP 10, 1998
		20MG	N20905 002 SEP 10, 1998
*		100MG	N20905 003 SEP 10, 1998

LEPIRUDIN

INJECTABLE; INJECTION
REFLUDAN

+	HOECHST MARION RSSL	50MG/VIAL	N20807 001 MAR 06, 1998

LEUPROLIDE ACETATE

INJECTABLE; INJECTION
LEUPROLIDE ACETATE

AP	BEDFORD LABS	1MG/0.2ML	N74728 001 AUG 04, 1998

LUPRON

AP	+ TAP HOLDINGS	1MG/0.2ML	N19010 001 APR 09, 1985

LEVODOPA

CAPSULE; ORAL
DOPAR

	ROBERTS LABS	100MG	N16913 003
		250MG	N16913 001
		500MG	N16913 002
	@	100MG	N16913 003
	+ @	250MG	N16913 001
	@	500MG	N16913 002

LEVORPHANOL TARTRATE

INJECTABLE; INJECTION
LEVO-DROMORAN

	+ ICN	2MG/ML	N08719 001 DEC 19, 1991
	* ROCHE	2MG/ML	N08719 001 DEC 19, 1991

TABLET; ORAL
LEVO-DROMORAN

	+ ICN	2MG	N08720 001 DEC 19, 1991
	* ROCHE	2MG	N08720 001 DEC 19, 1991

LIDOCAINE

AEROSOL; ORAL
XYLOCAINE

	+ ASTRA PHARMS	10%	N14394 001

DISC; ORAL
XYLOCAINE

	ASTRA	10%	N14394 001

LIDOCAINE; PRILOCAINE

AEROSOL; TOPICAL
EMLA

	+ ASTRA PHARMS	2.5%;2.5%	N20962 001 FEB 04, 1998

LIDOCAINE HYDROCHLORIDE

INJECTABLE; INJECTION
LIDOCAINE HCL

AP	ABBOTT	1%	N80408 001
AP		1.5%	N80408 002
AP		4%	N88295 001 MAY 17, 1984
AP	ELKINS SINN	1%	N84625 001
AP		2%	N84625 002
AP	FUJISAWA	1%	N80404 002
AP		2%	N17584 001
AP		4%	N80404 003

LIDOCAINE HYDROCHLORIDE

INJECTABLE; INJECTION

	LIDOCAINE HCL				
AP		RUGBY LABS	4%	N17584 002	
AP		INTL MEDICATION	20%	N17702 001	
	LIDOCAINE HCL PRESERVATIVE FREE				
AP		ABBOTT	1%	N80408 001	
AP			1.5%	N80408 002	
AP			4%	N88295 001	
				MAY 17, 1984	
AP		AM PHARM PARTNERS	1%	N80404 002	
AP			2%	N17584 001	
AP			2%	N80404 003	
AP			4%	N17584 002	
AP		ELKINS SINN	1%	N84625 001	
AP			2%	N84625 002	
AP		INTL MEDICATION	20%	N17702 001	
	LIDOCAINE HCL PRESERVATIVE FREE IN PLASTIC CONTAINER				
AP		ABBOTT	1%	N40302 001	
				SEP 28, 1998	
AP			2%	N40302 002	
				SEP 28, 1998	
	XYLOCAINE				
AP		ASTRA	2%	N16801 001	
AP			4%	N16801 002	
AP	*		10%	N16801 003	
AP	*		20%	N16801 004	
	XYLOCAINE 4%				
AP	*	ASTRA	4%	N10417 001	
	XYLOCAINE 4% PRESERVATIVE FREE				
AP	*	ASTRA PHARMS	4%	N10417 001	
	XYLOCAINE PRESERVATIVE FREE				
AP		ASTRA PHARMS	2%	N16801 001	
AP			4%	N16801 002	
AP	*		10%	N16801 003	
AP	*		20%	N16801 004	

LISINOPRIL

TABLET; ORAL

	ZESTRIL				
AB	*	ZENECA	2.5MG	N19777 005	
				APR 29, 1993	
AB			2.5MG	N19777 005	
				APR 29, 1993	
AB			10MG	N19777 002	
				MAY 19, 1988	

LISINOPRIL

TABLET; ORAL

	ZESTRIL				
AB	+	ZENECA	10MG	N19777 002	
				MAY 19, 1988	

LORATADINE

TABLET; ORAL

	CLARITIN REDITABS				
		SCHERING	10MG	N20704 001	
				DEC 23, 1996	

TABLET, ORALLY DISINTEGRATING; ORAL

	CLARITIN REDITABS				
	+	SCHERING	10MG	N20704 001	
				DEC 23, 1996	

LORAZEPAM

INJECTABLE; INJECTION

	LORAZEPAM				
AP		AKORN	2MG/ML	N74974 001	
				JUL 23, 1998	
AP		ELKINS SINN	2MG/ML	N74496 001	
				SEP 28, 1998	
AP			4MG/ML	N74496 002	
				SEP 28, 1998	
AP		TAYLOR	2MG/ML	N75025 001	
				JUL 23, 1998	

TABLET; ORAL

	LORAZEPAM				
AB		ROYCE LABS	0.5MG	N72926 001	
				OCT 31, 1991	
AB			1MG	N72927 001	
				OCT 31, 1991	
AB			2MG	N72928 001	
				OCT 31, 1991	
AB		WATSON LABS	0.5MG	N72926 001	
				OCT 31, 1991	
AB			1MG	N72927 001	
				OCT 31, 1991	
AB			2MG	N72928 001	
				OCT 31, 1991	

LOTEPREDNOL ETABONATE

SUSPENSION/DROPS; OPHTHALMIC

	ALREX			
+	PHARMOS	0.2%	N20803 001	MAR 09, 1998
	LOTEMAX			
+	PHARMOS	0.5%	N20583 001	MAR 09, 1998
+		0.5%	N20841 001	MAR 09, 1998

LOXAPINE HYDROCHLORIDE

CONCENTRATE; ORAL

	LOXITANE C		
+	COCENSYS	EQ 25MG BASE/ML	N17658 001
+	WATSON LABS	EQ 25MG BASE/ML	N17658 001

INJECTABLE; INJECTION

	LOXITANE IM		
+	COCENSYS	EQ 50MG BASE/ML	N18039 001
+	WATSON LABS	EQ 50MG BASE/ML	N18039 001

LOXAPINE SUCCINATE

CAPSULE; ORAL

	LOXITANE			
AB	COCENSYS	[redacted]	N17525 001	
AB			N17525 002	
AB	*		N17525 003	
AB			N17525 004	
AB	WATSON LABS		N17525 001	
AB			N17525 002	
AB	+		N17525 003	
AB			N17525 004	

TABLET; ORAL

	LOXITANE			
@	COCENSYS	EQ 10MG BASE	N17525 006	
@		EQ 25MG BASE	N17525 007	
@		EQ 50MG BASE	N17525 008	
@	WATSON LABS	EQ 10MG BASE	N17525 006	
@		EQ 25MG BASE	N17525 007	
@		EQ 50MG BASE	N17525 008	

MAFENIDE ACETATE

CREAM; TOPICAL

	SULFAMYLON			
+	BERTEK	EQ 85MG BASE/GM	N16763 001	
+	DOW HICKAM	EQ 85MG BASE/GM	N16763 001	

POWDER FOR RECONSTITUTION; TOPICAL

	SULFAMYLON			
+	MYLAN	5%	N19832 003	JUN 05, 1998

MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, MONOBASIC; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM GLUCONATE; SODIUM PHOSPHATE, DIBASIC

INJECTABLE; INJECTION

	ISOLYTE S PH 7.4 IN PLASTIC CONTAINER			
	B BRAUN	30MG/100ML;37MG/100ML;0.82MG/100ML; 370MG/100ML;530MG/100ML;500MG/100ML; 12MG/100ML	N19696 001	SEP 29, 1989
	MCGAW	30MG/100ML;37MG/100ML;0.82MG/100ML; 370MG/100ML;530MG/100ML;500MG/100ML; 12MG/100ML	N19696 001	SEP 29, 1989

MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM GLUCONATE

INJECTABLE; INJECTION

	ISOLYTE S IN PLASTIC CONTAINER			
AP	B BRAUN	30MG/100ML;37MG/100ML;370MG/100ML; 530MG/100ML;500MG/100ML	N18252 001	
AP		30MG/100ML;37MG/100ML;370MG/100ML; 530MG/100ML;500MG/100ML	N19711 001	SEP 29, 1989
AP	MCGAW	30MG/100ML;37MG/100ML;370MG/100ML; 530MG/100ML;500MG/100ML	N18252 001	
AP		30MG/100ML;37MG/100ML;370MG/100ML; 530MG/100ML;500MG/100ML	N19711 001	SEP 29, 1989

MALATHION

LOTION; TOPICAL

	OVIDE		
	◉ GENDERM	0.5%	N18613 001 AUG 02, 1982
	◉ MEDICIS	0.5%	N18613 001 AUG 02, 1982

MANNITOL

INJECTABLE; INJECTION

	MANNITOL 10% IN PLASTIC CONTAINER		
AP	B BRAUN	10GM/100ML	N20006 002 JUL 26, 1993
AP	MCGAW	10GM/100ML	N20006 002 JUL 26, 1993
	MANNITOL 15% IN PLASTIC CONTAINER		
AP	B BRAUN	15GM/100ML	N20006 003 JUL 26, 1993
AP	MCGAW	15GM/100ML	N20006 003 JUL 26, 1993
	MANNITOL 20%		
AP	B BRAUN	20GM/100ML	N14738 001
AP	MCGAW	20GM/100ML	N14738 001
	MANNITOL 20% IN PLASTIC CONTAINER		
AP	B BRAUN	20GM/100ML	N20006 004 JUL 26, 1993
AP	MCGAW	20GM/100ML	N20006 004 JUL 26, 1993
	MANNITOL 5% IN PLASTIC CONTAINER		
AP	B BRAUN	5GM/100ML	N20006 001 JUL 26, 1993
AP	MCGAW	5GM/100ML	N20006 001 JUL 26, 1993

SOLUTION; IRRIGATION

	RESECTISOL IN PLASTIC CONTAINER		
	B BRAUN	5GM/100ML	N16772 002
	MCGAW	5GM/100ML	N16772 002

MECAMYLAMINE HYDROCHLORIDE

TABLET; ORAL

	INVERSINE		
+	LAYTON	2.5MG	N10251 001
+	MERCK SHARP DOHME	2.5MG	N10251 001

MEGESTROL ACETATE

TABLET; ORAL

	MEGESTROL ACETATE		
AB	PHARMACHEMIE	40MG	N74745 001 FEB 27, 1998

MEPERIDINE HYDROCHLORIDE

TABLET; ORAL

	MEPERIDINE HCL		
AA	ROXCE LABS	50MG	N40186 001 JUN 30, 1997
AA	WATSON LABS	50MG	N40186 001 JUN 30, 1997

MEPROBAMATE

TABLET; ORAL

	MEPROBAMATE		
AA	DANBURY PHARMA	600MG	N84274 001
	◉	600MG	N84274 001

MESALAMINE

CAPSULE, EXTENDED RELEASE; ORAL

	PENTASA		
+	HOECHST MARION RSSL	250MG	N20049 001 MAY 10, 1993
+	ROBERTS LABS	250MG	N20049 001 MAY 10, 1993

MESTRANOL; NORETHINDRONE

TABLET; ORAL-21

	NORETHIN 1/50M-21		
AB	SEARLE	0.05MG;1MG	N71539 001 APR 12, 1988
AB	WATSON LABS	0.05MG;1MG	N71539 001 APR 12, 1988

TABLET; ORAL-28

	NORETHIN 1/50M-28		
AB	SEARLE	0.05MG;1MG	N71540 001 APR 12, 1988

MESTRANOL; NORETHINDRONE

TABLET; ORAL-28
NORETHIN 1/50M-28

AB	WATSON LABS	0.05MG;1MG	N71540 001 APR 12, 1988

METFORMIN HYDROCHLORIDE

TABLET; ORAL
GLUCOPHAGE

> DLT >	BRISTOL MYERS SQUIBB	500MG	N20357 001 MAR 03, 1995	
> DLT >	+	850MG	N20357 002 MAR 03, 1995	
> DLT >				
> ADD >	+	500MG	N20357 001 MAR 03, 1995	
> ADD >				
> ADD >		625MG	N20357 003 NOV 05, 1998	
> ADD >				
> ADD >		750MG	N20357 004 NOV 05, 1998	
> ADD >				
> ADD >		850MG	N20357 002 MAR 03, 1995	
> ADD >				
> ADD >	+	1GM	N20357 005 NOV 05, 1998	
> ADD >				

METHADONE HYDROCHLORIDE

CONCENTRATE; ORAL
METHADONE HCL

AA	ROXANE	10MG/ML	N40180 001 APR 30, 1998

TABLET; ORAL
METHADONE HCL

AA	EON	5MG	N40241 001 MAY 29, 1998
AA		10MG	N40241 002 MAY 29, 1998

TABLET, DISPERSIBLE; ORAL
METHADONE HCL

AA	EON	40MG	N75082 001 MAR 25, 1998

METHOCARBAMOL

INJECTABLE; INJECTION
METHOCARBAMOL

AP	MARSAM	100MG/ML	N89849 001 DEC 27, 1991
	@	100MG/ML	N89849 001 DEC 27, 1991

TABLET; ORAL
ROBAXIN

AA	FOREST LABS	750MG	N85136 001
	@	750MG	N85136 001

METHOCARBAMOL

AA	INWOOD LABS	500MG	N85137 001
	@	500MG	N85137 001

METHYLPHENIDATE HYDROCHLORIDE

TABLET; ORAL
METHYLPHENIDATE HCL

> ADD >	AB	MALLINCKRODT	5MG	N40300 001 NOV 27, 1998
> ADD >				
> ADD >	AB		10MG	N40300 002 NOV 27, 1998
> ADD >				
> ADD >	AB		20MG	N40300 003 NOV 27, 1998
> ADD >				

METOCLOPRAMIDE HYDROCHLORIDE

TABLET; ORAL
METOCLOPRAMIDE HCL

AB	INVAMED	EQ 5MG BASE	N72436 001 JUN 22, 1989
AB		EQ 10MG BASE	N70850 001 FEB 03, 1987
	@	EQ 5MG BASE	N72436 001 JUN 22, 1989
	@	EQ 10MG BASE	N70850 001 FEB 03, 1987

METOPROLOL TARTRATE

INJECTABLE; INJECTION
METOPROLOL TARTRATE

AP	ABBOTT	1MG/ML	N75160 001 JUL 06, 1998

METRONIDAZOLE

LOTION; TOPICAL

>ADD>		METROLOTION		
>ADD>	+	GALDERMA	0.75%	N20901 001 NOV 24, 1998

MEXILETINE HYDROCHLORIDE

CAPSULE; ORAL

		MEXILETINE HCL		
AB		DANBURY PHARMA	150MG	N74865 001 APR 13, 1998
AB			200MG	N74865 002 APR 13, 1998
AB			250MG	N74865 003 APR 13, 1998

MIDAZOLAM HYDROCHLORIDE

SYRUP; ORAL

		VERSED		
	+	ROCHE	EQ 2MG BASE/ML	N20942 001 OCT 15, 1998

MITOMYCIN

INJECTABLE; INJECTION

		MITOMYCIN		
AP		SUPERGEN	5MG/VIAL	N64144 001 APR 30, 1998
AP			20MG/VIAL	N64144 002 APR 30, 1998

MONTELUKAST SODIUM

TABLET; ORAL

		SINGULAIR		
	+	MERCK	EQ 10MG BASE	N20829 002 FEB 20, 1998

TABLET, CHEWABLE; ORAL

		SINGULAIR		
	+	MERCK	EQ 5MG BASE	N20830 001 FEB 20, 1998

MORPHINE SULFATE

CAPSULE, EXTENDED RELEASE; ORAL

		KADIAN		
	+	FAULDING	20MG	N20616 001 JUL 03, 1996
	+		50MG	N20616 002 JUL 03, 1996
	+		100MG	N20616 003 JUL 03, 1996
	+	FAULDING SVCS	20MG	N20616 001 JUL 03, 1996
	+		50MG	N20616 002 JUL 03, 1996
	+		100MG	N20616 003 JUL 03, 1996

TABLET, EXTENDED RELEASE; ORAL

		MORPHINE SULFATE		
AP		AB GENERICS	15MG	N74862 001 JUL 07, 1998
AB			30MG	N74862 002 JUL 07, 1998
AB			60MG	N74862 003 JUL 07, 1998
AB			100MG	N74769 001 JUL 02, 1998
AB			200MG	N74769 002 JUL 02, 1998
AB		ENDO PHARMS	15MG	N75295 001 OCT 28, 1998
AB			30MG	N75295 002 OCT 28, 1998
AB			60MG	N75295 003 OCT 28, 1998
		MS CONTIN		
AB	+	PURDUE FREDERICK	15MG	N19516 003 SEP 12, 1989
AB	+		30MG	N19516 001 MAY 29, 1987
AB	+		60MG	N19516 002 APR 08, 1988
AB	+		100MG	N19516 004 JAN 16, 1990
AB	+		200MG	N19516 005 NOV 08, 1993
BC	+		15MG	N19516 003 SEP 12, 1989

MORPHINE SULFATE

TABLET, EXTENDED RELEASE; ORAL
MS CONTIN

RC	*	PURDUE FREDERICK	30MG	N19516 001 MAY 29, 1987
RC	*		60MG	N19516 002 APR 08, 1988
RC	*		100MG	N19516 004 JAN 16, 1990

MYCOPHENOLATE MOFETIL

SUSPENSION; ORAL
CELLCEPT

	+	ROCHE GLOBAL	200MG/ML	N50759 001 OCT 01, 1998

MYCOPHENOLATE MOFETIL HYDROCHLORIDE

INJECTABLE; INJECTION
CELLCEPT

	+	ROCHE GLOBAL	500MG/VIAL	N50758 001 AUG 12, 1998

NADOLOL

TABLET; ORAL
CORGARD

AB		BRISTOL MYERS SQUIBB	20MG	N18063 005 OCT 28, 1986
AB			40MG	N18063 001
AB			80MG	N18063 002
AB			120MG	N18063 003
AB	+		160MG	N18063 004
AB		SQUIBB	20MG	N18063 005 OCT 28, 1986
AB			40MG	N18063 001
AB			80MG	N18063 002
AB			120MG	N18063 003
AB	+		160MG	N18063 004

NALBUPHINE HYDROCHLORIDE

INJECTABLE; INJECTION
NALBUPHINE HCL

AP		KING PHARMS	10MG/ML	N74471 001 MAR 19, 1998
AP			20MG/ML	N74471 002 MAR 19, 1998

NALOXONE HYDROCHLORIDE

INJECTABLE; INJECTION
NALOXONE HCL

AP		ABBOTT	0.4MG/ML	N70172 001 SEP 24, 1986
	@		0.4MG/ML	N70172 001 SEP 24, 1986

NALOXONE HYDROCHLORIDE; PENTAZOCINE HYDROCHLORIDE

TABLET; ORAL
PENTAZOCINE AND NALOXONE HYDROCHLORIDES

AB		ROYCE LABS	EQ 0.5MG BASE; EQ 50MG BASE	N74736 001 JAN 21, 1997
AB		WATSON LABS	EQ 0.5MG BASE; EQ 50MG BASE	N74736 001 JAN 21, 1997

NALTREXONE HYDROCHLORIDE

TABLET; ORAL
NALTREXONE HCL

AB		BARR	50MG	N74918 001 MAY 08, 1998

REVIA

AB	+	DUPONT MERCK	50MG	N18932 001 NOV 20, 1984

NAPROXEN

TABLET, DELAYED RELEASE; ORAL
EC-NAPROSYN

AB	+	SYNTEX	375MG	N20067 002 OCT 14, 1994

NAPROXEN

TABLET, DELAYED RELEASE; ORAL

EC-NAPROSYN

AB	+ SYNTEX	500MG	N20067 003	OCT 14, 1994

NAPROXEN

AB	INVAMED	375MG	N75061 001	FEB 18, 1998
AB		500MG	N75061 002	FEB 18, 1998
AB	PUREPAC PHARM	375MG	N74936 001	FEB 24, 1998
AB		500MG	N74936 002	FEB 24, 1998
AB	TEVA	375MG	N75227 001	JUN 30, 1998
AB		500MG	N75227 002	JUN 30, 1998

NAPROXEN SODIUM

TABLET; ORAL

NAPROXEN SODIUM

AB	AL HIKMA	EQ 250MG BASE	N74480 002	FEB 18, 1998
AB	INVAMED	EQ 250MG BASE	N74495 001	DEC 05, 1994
AB		EQ 275MG BASE	N74495 001	DEC 05, 1994
AB		EQ 500MG BASE	N74495 002	DEC 05, 1994
AB		EQ 550MG BASE	N74495 002	DEC 05, 1994

NARATRIPTAN HYDROCHLORIDE

TABLET; ORAL

AMERGE

	GLAXO WELLCOME	EQ 1MG BASE	N20763 002	FEB 10, 1998
	+	EQ 2.5MG BASE	N20763 001	FEB 10, 1998

NEOMYCIN SULFATE

TABLET; ORAL

NEOMYCIN SULFATE

	TEVA	EQ 350MG BASE	N60304 001	
	+	EQ 350MG BASE	N60304 001	

NEOMYCIN SULFATE; POLYMYXIN B SULFATE

SOLUTION; IRRIGATION

NEOSPORIN G.U. IRRIGANT

AT	GLAXO WELLCOME	EQ 40MG BASE/ML; 200,000 UNITS/ML	N60707 003	
AT	MONARCH PHARMS	EQ 40MG BASE/ML; 200,000 UNITS/ML	N60707 001	

NEVIRAPINE

SUSPENSION; ORAL

VIRAMUNE

	+ BOEHRINGER INGELHEIM	50MG/5ML	N20933 001	SEP 11, 1998

NIACIN

TABLET; ORAL

NIACIN

AA	DANBURY PHARMA	500MG	N83305 001	
	@	500MG	N83305 001	

NICARDIPINE HYDROCHLORIDE

CAPSULE; ORAL

NICARDIPINE HCL

AB	GENPHARM	20MG	N74928 001	MAR 19, 1998
AB		30MG	N74928 002	MAR 19, 1998

NITROGLYCERIN

FILM, EXTENDED RELEASE; TRANSDERMAL

MINITRAN

AB	3M	0.1MG/HR	N19771 001	AUG 10, 1994

NITROGLYCERIN

FILM, EXTENDED RELEASE; TRANSDERMAL

	MINITRAN			
AB1	3M	0.1MG/HR	N89771 001	AUG 30, 1996
AB		0.2MG/HR	N89772 001	AUG 30, 1996
AB1		0.2MG/HR	N89772 001	AUG 30, 1996
AB		0.4MG/HR	N89773 001	AUG 30, 1996
AB1		0.4MG/HR	N89773 001	AUG 30, 1996
AB		0.6MG/HR	N89774 001	AUG 30, 1996
AB1		0.6MG/HR	N89774 001	AUG 30, 1996
	NITRO-DUR			
AB +	KEY PHARMS	0.1MG/HR	N20145 001	APR 04, 1995
AB1 +		0.1MG/HR	N20145 001	APR 04, 1995
AB +		0.2MG/HR	N20145 002	APR 04, 1995
AB1 +		0.2MG/HR	N20145 002	APR 04, 1995
AB +		0.4MG/HR	N20145 004	APR 04, 1995
AB1 +		0.4MG/HR	N20145 004	APR 04, 1995
AB +		0.6MG/HR	N20145 005	APR 04, 1995
AB1 +		0.6MG/HR	N20145 005	APR 04, 1995
	NITROGLYCERIN			
AB2	HERCON LABS	0.2MG/HR	N89884 001	OCT 30, 1998
AB2		0.4MG/HR	N89885 001	OCT 30, 1998
AB2		0.6MG/HR	N89886 001	OCT 30, 1998
AB2	MYLAN	0.1MG/HR	N75033 001	FEB 06, 1998
AB		0.2MG/HR	N74609 001	AUG 30, 1996
AB2		0.2MG/HR	N74609 001	AUG 30, 1996

NITROGLYCERIN

FILM, EXTENDED RELEASE; TRANSDERMAL

	NITROGLYCERIN			
AB	MYLAN	0.4MG/HR	N74607 001	AUG 30, 1996
AB2		0.4MG/HR	N74607 001	AUG 30, 1996
AB		0.6MG/HR	N74559 001	AUG 30, 1996
AB2		0.6MG/HR	N74559 001	AUG 30, 1996
	TRANSDERM-NITRO			
AB2 +	NOVARTIS	0.1MG/HR	N20144 001	FEB 27, 1996
AB +		0.2MG/HR	N20144 002	FEB 27, 1996
AB2 +		0.2MG/HR	N20144 002	FEB 27, 1996
AB +		0.4MG/HR	N20144 003	FEB 27, 1996
AB2 +		0.4MG/HR	N20144 003	FEB 27, 1996
AB +		0.6MG/HR	N20144 004	FEB 27, 1996
AB2 +		0.6MG/HR	N20144 004	FEB 27, 1996
BX +		0.1MG/HR	N20144 001	FEB 27, 1996

NORETHINDRONE

TABLET; ORAL

	NOR-QD			
+	SEARLE	0.35MG	N17060 001	
+	WATSON LABS	0.35MG	N17060 001	

NORETHINDRONE ACETATE

TABLET; ORAL

	AYGESTIN			
AB	WYETH AYERST	5MG	N18405 001	APR 21, 1982
AB +		5MG	N18405 001	APR 21, 1982
	NORLUTATE			
AB +	PARKE DAVIS	5MG	N12184 002	

NORETHINDRONE ACETATE

TABLET; ORAL
NORLUTATE
@ PARKE DAVIS 5MG N12184 002

NYSTATIN

SUSPENSION; ORAL
NYSTATIN
AA UDL 100,000 UNITS/ML N64142 001
JUN 25, 1998

OCTREOTIDE ACETATE

INJECTABLE; INJECTION
> ADD > SANDOSTATIN LAR
> ADD > EQ 10MG BASE/VIAL N21008 001
> ADD > NOV 25, 1998
> ADD > EQ 20MG BASE/VIAL N21008 002
> ADD > NOV 25, 1998
> ADD > + EQ 30MG BASE/VIAL N21008 003
> ADD > NOV 25, 1998

OLANZAPINE

TABLET; ORAL
ZYPREXA
@ LILLY 2.5MG N20592 001
SEP 30, 1996
+ 2.5MG N20592 001
SEP 30, 1996
@ 15MG N20592 005
SEP 09, 1997
@ 20MG N20592 006
SEP 09, 1997

OMEPRAZOLE

CAPSULE, DELAYED REL PELLETS; ORAL
PRILOSEC
+ ASTRA MERCK 40MG N19810 002
JAN 15, 1998

ORPHENADRINE CITRATE

TABLET, EXTENDED RELEASE; ORAL
NORFLEX
AB + 3M 100MG N12157 001
ORPHENADRINE CITRATE
AB INVAMED 100MG N40284 001
JUN 19, 1998

OXAZEPAM

TABLET; ORAL
OXAZEPAM
AB DANBURY PHARMA 15MG N71494 001
APR 21, 1987
@ 15MG N71494 001
APR 21, 1987
SERAX
AB + WYETH AYERST 15MG N15539 008
+ 15MG N15539 008

OXYBUTYNIN CHLORIDE

SYRUP; ORAL
DITROPAN
AA + ALZA 5MG/5ML N18211 001
AA + HOECHST MARION RSSL 5MG/5ML N18211 001

TABLET; ORAL
DITROPAN
AB + ALZA 5MG N17577 001
AB + HOECHST MARION RSSL 5MG N17577 001

OXYCODONE HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL
OXYCONTIN
BX + PURDUE PHARMA 10MG N20553 001
DEC 12, 1995
ROXICODONE
BX ROXANE 10MG N20932 001
OCT 26, 1998
+ 30MG N20932 002
OCT 26, 1998

OXYTETRACYCLINE

TABLET; ORAL
TERRAMYCIN
[redacted] PFIZER 250MG N50287 001
@ 250MG N50287 001

OXYTOCIN

INJECTABLE; INJECTION
PITOCIN
AP [redacted] KING PHARMS 10 USP UNITS/ML N18261 001
AP + PARKEDALE 10 USP UNITS/ML N18261 001

PARICALCITOL

INJECTABLE; INJECTION
ZEMPLAR
+ ABBOTT 0.005MG/ML N20819 001 APR 17, 1998

PAROMOMYCIN SULFATE

CAPSULE; ORAL
HUMATIN
AA KING PHARMS EQ 250MG BASE N62310 001
AB [redacted] PARKE DAVIS EQ 250MG BASE N60521 001
AA + PARKEDALE EQ 250MG BASE N60521 001
AB [redacted] EQ 250MG BASE N62310 001

PAROMOMYCIN SULFATE
AA CARACO EQ 250MG BASE N64171 001 JUN 30, 1997
AB [redacted] EQ 250MG BASE N64171 001 JUN 30, 1997

PAROXETINE HYDROCHLORIDE

CAPSULE; ORAL
PAXIL
SMITHKLINE BEECHAM EQ 10MG BASE N20885 001 OCT 09, 1998
EQ 20MG BASE N20885 002 OCT 09, 1998
EQ 30MG BASE N20885 003 OCT 09, 1998

PAROXETINE HYDROCHLORIDE

CAPSULE; ORAL
PAXIL
+ SMITHKLINE BEECHAM EQ 40MG BASE N20885 004 OCT 09, 1998

PENTOSAN POLYSULFATE SODIUM

CAPSULE; ORAL
ELMIRON
+ ALZA 100MG N20193 001 SEP 26, 1996
[redacted] BAKER NORTON 100MG N20193 001 SEP 26, 1996

PENTOXIFYLLINE

TABLET, EXTENDED RELEASE; ORAL
PENTOXIFYLLINE
AB BIOVAIL 400MG N75028 001 JUL 20, 1998
AB WATSON LABS 400MG N75107 001 SEP 04, 1998

PERINDOPRIL ERBUMINE

TABLET; ORAL
ACEON
@ HUESCHEN 2MG N20184 001 DEC 30, 1993
@ 4MG N20184 002 DEC 30, 1993
@ 8MG N20184 003 DEC 30, 1993
@ RHONE POULENC RORER 2MG N20184 001 DEC 30, 1993
@ 4MG N20184 002 DEC 30, 1993
@ 8MG N20184 003 DEC 30, 1993

PERMETHRIN

CREAM; TOPICAL

ELIMITE

AB	+ ALLERGAN	5%	N19855 001	AUG 25, 1989

PERMETHRIN

AB	ALPHARMA	5%	N74806 001	JAN 23, 1998

PHENAZOPYRIDINE HYDROCHLORIDE; SULFAMETHOXAZOLE

TABLET; ORAL

AZO GANTANOL

	+ ROCHE	100MG;500MG	N13294 001	> DLT >	
			SEP 10, 1987	> DLT >	
				> ADD >	
	@	100MG;500MG	N13294 001	> ADD >	
			SEP 10, 1987		

PHENAZOPYRIDINE HYDROCHLORIDE; SULFISOXAZOLE

TABLET; ORAL

AZO GANTRISIN

+ ROCHE	50MG;500MG	N19358 001	AUG 31, 1990
@	50MG;500MG	N19358 001	AUG 31, 1990

PHENTERMINE HYDROCHLORIDE

CAPSULE; ORAL

PHENTERMINE HCL

AA	EON	37.5MG	N88414 001 OCT 19, 1983
@		37.5MG	N88414 001 OCT 19, 1983

TABLET; ORAL

PHENTERMINE HCL

	+ EON	30MG	N88605 001 SEP 28, 1987
	@	30MG	N88605 001 SEP 28, 1987
> ADD > AA	PUREPAC PHARM	37.5MG	N40276 001 NOV 25, 1998
> ADD >			

PHENTOLAMINE MESYLATE

INJECTABLE; INJECTION

PHENTOLAMINE MESYLATE

AP	BEDFORD	5MG/VIAL	N40235 001 MAR 11, 1998

REGITINE

AP	+ NOVARTIS	5MG/VIAL	N08278 003

PHENYTOIN SODIUM

INJECTABLE; INJECTION

PHENYTOIN SODIUM

AP	SMITH AND NEPHEW	50MG/ML	N88519 001 DEC 19, 1984
@		50MG/ML	N88519 001 DEC 19, 1984

PHENYTOIN SODIUM, PROMPT

CAPSULE; ORAL

PROMPT PHENYTOIN SODIUM

BX	+ DANBURY PHARMA	100MG	N80905 001
	@	100MG	N80905 001
	+ ZENITH GOLDLINE	100MG	N80259 001
BX	ZENITH LABS	100MG	N80259 001

PILOCARPINE

DRUG DELIVERY SYSTEM; OPHTHALMIC

OCUSERT PILO-40

+ AKORN	11MG	N17548 001
+ ALZA	11MG	N17548 001

PINDOLOL

TABLET; ORAL

PINDOLOL

AB	PUREPAC PHARM	5MG	N74125 001 APR 28, 1993
AB		10MG	N74125 002 APR 28, 1993
@		5MG	N74125 001 APR 28, 1993

PINDOLOL

TABLET; ORAL
PINDOLOL

@	PUREPAC PHARM	10MG	N74125 002 APR 28, 1993
AB	[redacted]	[redacted]	[redacted]
AB		[redacted]	[redacted]
AB	WATSON LABS	5MG	N74437 001 FEB 27, 1995
AB		10MG	N74437 002 FEB 27, 1995

PIPERACILLIN SODIUM; TAZOBACTAM SODIUM

INJECTABLE; INJECTION
ZOSYN IN PLASTIC CONTAINER

+	LEDERLE	EQ 40MG BASE/ML; EQ 5MG BASE/ML	N50750 001 FEB 24, 1998
+		EQ 4GM BASE/100ML; EQ 500MG BASE/100ML	N50750 003 FEB 24, 1998
+		EQ 60MG BASE/ML; EQ 7.5MG BASE/ML	N50750 002 FEB 24, 1998

PIROXICAM

CAPSULE; ORAL
PIROXICAM

AB	[redacted]	[redacted]	[redacted]
AB		[redacted]	[redacted]
AB	WATSON LABS	10MG	N74460 001 SEP 29, 1995
AB		20MG	N74460 002 SEP 29, 1995

POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE; SODIUM SULFATE, ANHYDROUS

POWDER FOR RECONSTITUTION; ORAL
[redacted]

AA	[redacted]	[redacted]	[redacted]
@		236GM/BOT;2.97GM/BOT;6.74GM/BOT; 5.86GM/BOT;22.74GM/BOT	N73098 001 AUG 31, 1993

POLYMYXIN B SULFATE

INJECTABLE; INJECTION
[redacted]

AP	* GLAXO WELLCOME	[redacted]	[redacted]
@		EQ 500,000 U BASE/VIAL	N62036 001

POLYMYXIN B SULFATE

AP	+ BEDFORD	EQ 500,000 U BASE/VIAL	N60716 001
AP	PFIZER	[redacted]	[redacted]

POWDER; FOR RX COMPOUNDING
POLY-RX

AA	PHARMA TEK	[redacted]	[redacted]
+		100,000,000 UNITS/BOT	N61578 001
[redacted]			
AA	PADDOCK	[redacted]	[redacted] JUL 27, 1983
@		100,000,000 UNITS/BOT	N62455 001 JUL 27, 1983

POLYMYXIN B SULFATE; TRIMETHOPRIM SULFATE

SOLUTION/DROPS; OPHTHALMIC
TRIMETHOPRIM SULFATE AND POLYMYXIN B SULFATE

AT	ALCON	10,000 UNITS/ML; EQ 1MG BASE/ML	N64211 001 APR 13, 1998

POTASSIUM CHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL
[redacted]

AB	[redacted]	[redacted]	[redacted] JAN 28, 1992

POTASSIUM CHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

		K-DUR 10			
AB		SAVAGE LABS	10MEQ		N72427 001
					MAR 28, 1990
		●	8MEQ		N73398 001
					JAN 28, 1992
		●	10MEQ		N72427 001
					MAR 28, 1990

INJECTABLE; INJECTION

		POTASSIUM CHLORIDE			
AP		B BRAUN	2MEQ/ML		N85870 001
AP		MCGAW	2MEQ/ML		N85870 001
		POTASSIUM CHLORIDE 20MEQ IN PLASTIC CONTAINER			
AP	+	ABBOTT	29.8MG/ML		N20161 006
					AUG 11, 1998
AP	+	BAXTER HLTHCARE	29.8MG/ML		N19904 002
					DEC 26, 1989
		POTASSIUM CHLORIDE 30MEQ IN PLASTIC CONTAINER			
AP	+	ABBOTT	2.24GM/100ML		N20161 003
					AUG 11, 1998
AP	+	BAXTER HLTHCARE	2.24GM/100ML		N19904 003
					DEC 26, 1989
		POTASSIUM CHLORIDE 40MEQ IN PLASTIC CONTAINER			
AP	+	ABBOTT	2.98GM/100ML		N20161 004
					AUG 11, 1998
AP	+	BAXTER HLTHCARE	2.98GM/100ML		N19904 004
					DEC 26, 1989

TABLET, EXTENDED RELEASE; ORAL

		K-DUR 20			
>ADD>	AB	+ KEY PHARMS	20MEQ		N19439 001
>ADD>					JUN 13, 1986
>ADD>		KLOR-CON M20			
>ADD>	AB	UPSHER SMITH	20MEQ		N74726 001
>ADD>					NOV 20, 1998
		SLOW-K			
RC		NOVARTIS	10MEQ		N19381 001
					APR 16, 1986
		●	10MEQ		N19381 001
					APR 16, 1986

POTASSIUM CHLORIDE; SODIUM CHLORIDE

INJECTABLE; INJECTION

		POTASSIUM CHLORIDE 0.037% IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER			
		B BRAUN	37MG/100ML;900MG/100ML		N19708 001
					SEP 29, 1989
	●		37MG/100ML;900MG/100ML		N19708 001
					SEP 29, 1989
		POTASSIUM CHLORIDE 0.075% IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER			
		B BRAUN	75MG/100ML;900MG/100ML		N19708 002
					SEP 29, 1989
	●		75MG/100ML;900MG/100ML		N19708 002
					SEP 29, 1989
		POTASSIUM CHLORIDE 0.11% IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER			
		B BRAUN	110MG/100ML;900MG/100ML		N19708 003
					SEP 29, 1989
	●		110MG/100ML;900MG/100ML		N19708 003
					SEP 29, 1989
		POTASSIUM CHLORIDE 0.22% IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER			
		B BRAUN	220MG/100ML;900MG/100ML		N19708 005
					SEP 29, 1989
	●		220MG/100ML;900MG/100ML		N19708 005
					SEP 29, 1989
		POTASSIUM CHLORIDE 0.3% IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER			
AP		B BRAUN	300MG/100ML;900MG/100ML		N19708 006
					SEP 29, 1989
	●		300MG/100ML;900MG/100ML		N19708 006
					SEP 29, 1989
		SODIUM CHLORIDE 0.9% AND POTASSIUM CHLORIDE 0.075% IN PLASTIC CONTAINER			
	●	B BRAUN	75MG/100ML;900MG/100ML		N18722 001
					NOV 09, 1982
	#	MCGAW	75MG/100ML;900MG/100ML		N18722 001
					NOV 09, 1982
		SODIUM CHLORIDE 0.9% AND POTASSIUM CHLORIDE 0.15% IN PLASTIC CONTAINER			
	●	B BRAUN	150MG/100ML;900MG/100ML		N18722 002
					NOV 09, 1982
	#	MCGAW	150MG/100ML;900MG/100ML		N18722 002
					NOV 09, 1982
		SODIUM CHLORIDE 0.9% AND POTASSIUM CHLORIDE 0.22% IN PLASTIC CONTAINER			
	●	B BRAUN	220MG/100ML;900MG/100ML		N18722 003
					NOV 09, 1982

POTASSIUM CHLORIDE; SODIUM CHLORIDE

INJECTABLE; INJECTION
SODIUM CHLORIDE 0.9% AND POTASSIUM CHLORIDE 0.22% IN PLASTIC CONTAINER

	@	MCGAW	220MG/100ML;900MG/100ML	N18722 003 NOV 09, 1982

SODIUM CHLORIDE 0.9% AND POTASSIUM CHLORIDE 0.3% IN PLASTIC CONTAINER

	@	B BRAUN	300MG/100ML;900MG/100ML	N18722 004 NOV 09, 1982
	@	MCGAW	300MG/100ML;900MG/100ML	N18722 004 NOV 09, 1982

PRAMIPEXOLE DIHYDROCHLORIDE

TABLET; ORAL
MIRAPEX

		PHARMACIA AND UPJOHN	0.5MG	N20667 006 FEB 12, 1998

PREDNISOLONE

SYRUP; ORAL
PRE-PRED

AA		WE PHARMS	15MG/5ML	N40192 001 MAY 28, 1998

PREDNISOLONE

AA		WE PHARMS	15MG/5ML	N40192 001 MAY 28, 1998

PRELONE

AA	+	MURO	15MG/5ML	N89081 001 FEB 04, 1986

TABLET; ORAL
PREDNISOLONE

BX		DANBURY PHARMA	5MG	N80354 001
BX	+		5MG	N80354 001
RX	*	GENEVA PHARMS	5MG	N80339 001
	@		5MG	N80339 001

PREDNISOLONE SODIUM PHOSPHATE; SULFACETAMIDE SODIUM

SOLUTION/DROPS; OPHTHALMIC
SULAMYD

AT	+	AKORN	EQ 0.23% PHOSPHATE;10%	N74511 001 JUL 30, 1996

PREDNISOLONE SODIUM PHOSPHATE; SULFACETAMIDE SODIUM

SOLUTION/DROPS; OPHTHALMIC
SULAMYD

	@	AKORN	EQ 0.23% PHOSPHATE;10%	N74511 001 JUL 30, 1996

PREDNISONE

TABLET; ORAL
PREDNISONE

AB		PUREPAC PHARM	5MG	N80353 001
AB			10MG	N86062 001
AB			20MG	N86061 001
	@		5MG	N80353 001
	@		10MG	N86062 001
	@		20MG	N86061 001

PRIMIDONE

SUSPENSION; ORAL
MYSOLINE

	+	ELAN PHARMA	250MG/5ML	N10401 001
	*	WYETH AYERST	250MG/5ML	N10401 001

TABLET; ORAL
MYSOLINE

AB	+	ELAN PHARMA	250MG	N09170 002
	+		50MG	N09170 003
AB	*	WYETH AYERST	250MG	N09170 002
	*		50MG	N09170 003

PROCAINAMIDE HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL
PROCAINAMIDE HCL

AB		INVAMED	500MG	N89284 001 JUN 23, 1986
	@		500MG	N89284 001 JUN 23, 1986
AB		SIDMAK LABS NJ	250MG	N88958 001 DEC 02, 1985
	@		250MG	N88958 001 DEC 02, 1985

PROCAN SR

AB		PARKE DAVIS	500MG	N86065 001

PROCAINAMIDE HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL
PROCAN SR

AB		PARKE DAVIS	250MG	N87510 001 APR 01, 1982
AB		"	1GM	N88489 001 JAN 16, 1985
AB	+	PARKEDALE	500MG	N86065 001
AB	+		750MG	N87510 001 APR 01, 1982
AB	+		1GM	N88489 001 JAN 16, 1985

PROCARBAZINE HYDROCHLORIDE

CAPSULE; ORAL
MATULANE

>_DLT_>	*	ROCHE	EQ 50MG BASE	N16785 001
>_ADD_>	+	SIGMA TAU	EQ 50MG BASE	N16785 001

PROCHLORPERAZINE EDISYLATE

INJECTABLE; INJECTION
PROCHLORPERAZINE EDISYLATE

AP	MARSAM	EQ 5MG BASE/ML	N89675 001 DEC 05, 1988
	@	EQ 5MG BASE/ML	N89675 001 DEC 05, 1988

PROCHLORPERAZINE MALEATE

TABLET; ORAL
PROCHLORPERAZINE MALEATE

AB	TRIGEN	EQ 5MG BASE	N40268 001 FEB 27, 1998
AB		EQ 10MG BASE	N40268 002 FEB 27, 1998
AB	ZENITH GOLDLINE	EQ 5MG BASE	N40162 001 JAN 20, 1998
AB		EQ 10MG BASE	N40162 002 JAN 20, 1998

PROGESTERONE

CAPSULE; ORAL
PROMETRIUM

+	SCHERING PLOUGH	100MG	N19781 001 MAY 14, 1998

PROMETHAZINE HYDROCHLORIDE

INJECTABLE; INJECTION
PROMETHAZINE HCL

AP	MARSAM	25MG/ML	N89463 001 MAY 02, 1988
AP		50MG/ML	N89477 001 MAY 02, 1988
	@	25MG/ML	N89463 001 MAY 02, 1988
	@	50MG/ML	N89477 001 MAY 02, 1988

SYRUP; ORAL
PROMETHAZINE HCL

AA	HI TECH PHARMA	6.25MG	N40026 001 SEP 25, 1998

TABLET; ORAL
PROMETHAZINE HCL

BP	DANBURY PHARMA	12.5MG	N83712 001
	@	12.5MG	N83712 001

PROPOXYPHENE HYDROCHLORIDE

CAPSULE; ORAL
PROPOXYPHENE HCL

AA	DANBURY PHARMA	65MG	N80908 002
	@	65MG	N80908 002
AA	PUREPAC PHARM	65MG	N83278 001
	@	65MG	N83278 001

PROPRANOLOL HYDROCHLORIDE

TABLET; ORAL
PROPRANOLOL HCL

AB	DANBURY PHARMA	60MG	N71038 001 OCT 06, 1986

PROPRANOLOL HYDROCHLORIDE

TABLET; ORAL

PROPRANOLOL HCL

	● DANBURY PHARMA	60MG	N71098 001	
			OCT 06, 1986	
AB	INVAMED	10MG	N71688 001	
			JUL 05, 1988	
AB		20MG	N71687 001	
			JUL 05, 1988	
AB		40MG	N71688 001	
			JUL 05, 1988	
AB		60MG	N72197 001	
			JUL 05, 1988	
AB		80MG	N71689 001	
			JUL 05, 1988	
AB		90MG	N72198 001	
			JUL 05, 1988	
	●	10MG	N71658 001	
			JUL 05, 1988	
	●	20MG	N71687 001	
			JUL 05, 1988	
	●	40MG	N71688 001	
			JUL 05, 1988	
	●	60MG	N72197 001	
			JUL 05, 1988	
	●	80MG	N71689 001	
			JUL 05, 1988	
	●	90MG	N72198 001	
			JUL 05, 1988	

PSEUDOEPHEDRINE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

NOVAFED

> DLT >	◆ HOECHST MARION RSSL	120MG	N17603 001	
> ADD >	●	120MG	N17603 001	

QUINIDINE SULFATE

TABLET; ORAL

QUINIDINE SULFATE

AB	DANBURY PHARMA	100MG	N85584 001	
	●	100MG	N85584 001	> DLT >
AB	PUREPAC PHARM	200MG	N84003 001	> DLT >
	●	200MG	N84003 001	> ADD >
				> ADD >

QUINIDINE SULFATE

TABLET, EXTENDED RELEASE; ORAL

QUINIDEX

AB	◆ ROBINS AH	300MG	N12796 002
AB	◆ WYETH AYERST	300MG	N12796 002

RANITIDINE HYDROCHLORIDE

SYRUP; ORAL

ZANTAC

	GLAXO WELLCOME	EQ 15MG BASE/ML	N19675 001
			DEC 30, 1988
	◆	EQ 15MG BASE/ML	N19675 001
			DEC 30, 1988

TABLET; ORAL

RANITIDINE HCL

AB	MYLAN	EQ 150MG BASE	N74552 001
			JUL 30, 1998
AB		EQ 300MG BASE	N74552 002
			JUL 30, 1998
AB	RANBAXY	EQ 150MG BASE	N75000 001
			JAN 30, 1998
AB		EQ 300MG BASE	N75000 002
			JAN 30, 1998
AB	ZENITH GOLDLINE	EQ 150MG BASE	N75165 001
			SEP 30, 1998
AB		EQ 300MG BASE	N75165 002
			SEP 30, 1998

RAUNOLFIA SERPENTINA

TABLET; ORAL

RAUNOLFIA SERPENTINA

	DANBURY PHARMA	50MG	N80907 001
	●	50MG	N80907 001

RIBAVIRIN

CAPSULE; ORAL

REBETOL

	◆ SCHERING PLOUGH RES	200MG	N20903 001
			JUN 03, 1998
	◆	200MG †	N20903 001
			JUN 03, 1998

† SEE SECTION 1.5 OF INTRODUCTION

RIFAMPIN

CAPSULE; ORAL

	RIFADIN			
AB	HOECHST MARION RSSL	150MG	N62303 001	
	RIFAMPIN			
AB	EON	150MG	N64150 002	
			JAN 02, 1998	
	RIMACTANE			
AB	GENEVA PHARMS	300MG	N50429 001	
RE	NOVARTIS	300MG	N50429 001	

RIFAPENTINE

TABLET; ORAL

	PRIFTIN		
+	HOECHST MARION RSSL	150MG	N21024 001
			JUN 22, 1998

RISEDRONATE SODIUM

TABLET; ORAL

	ACTONEL		
+	PROCTER AND GAMBLE	30MG	N20835 001
			MAR 27, 1998

RITODRINE HYDROCHLORIDE

INJECTABLE; INJECTION

	RITODRINE HCL			
AP	ABBOTT	10MG/ML	N71618 001	
			FEB 28, 1991	
AP		15MG/ML	N71619 001	
			FEB 28, 1991	
+		10MG/ML	N71618 001	
			FEB 28, 1991	
+		15MG/ML	N71619 001	
			FEB 28, 1991	
	YUTOPAR			
AP	+ ASTRA	10MG/ML	N18580 001	
AP	+	15MG/ML	N18580 002	
@		10MG/ML	N18580 001	
@		15MG/ML	N18580 002	

RIZATRIPTAN BENZOATE

TABLET; ORAL

	MAXALT		
	MERCK	EQ 5MG BASE	N20864 001
			JUN 29, 1998
+		EQ 10MG BASE	N20864 002
			JUN 29, 1998

TABLET, ORALLY DISINTEGRATING; ORAL

	MAXALT		
	MERCK	EQ 5MG BASE	N20864 001
			JUN 29, 1998
+		EQ 10MG BASE	N20864 002
			JUN 29, 1998
	MAXALT-MLT		
	MERCK	EQ 5MG BASE	N20865 001
			JUN 29, 1998
+		EQ 10MG BASE	N20865 002
			JUN 29, 1998

SACROSIDASE

SOLUTION; ORAL

	SUCRAID		
+	ORPHAN MEDCL	8,500 IU/ML	N20772 001
			APR 09, 1998

SAQUINAVIR

CAPSULE; ORAL

	FORTOVASE		
+	ROCHE	EQ 200MG BASE	N20828 001
			NOV 07, 1997
+		200MG	N20828 001
			NOV 07, 1997

SELEGILINE HYDROCHLORIDE

CAPSULE; ORAL

		ELDEPRYL				
> ADD >	AB	+ SOMERSET	5MG			N20647 001
> ADD >						MAY 15, 1996
> ADD >		SELEGILINE HCL				
> ADD >	AB	ESI LEDERLE	5MG			N75352 001
> ADD >						NOV 30, 1998

SELEGILINE HYDROCHLORIDE

TABLET; ORAL
SELEGILINE HCL

AB	ESI LEDERLE	5MG	N74641 001	AUG 02, 1996
AB	[illegible]	5MG	N74643 001	AUG 02, 1996
> ADD > AB	NORTON WATERFORD	5MG	N74756 001	NOV 25, 1998
> ADD > AB	STASON	5MG	N74912 001	APR 30, 1998

SEVELAMER HYDROCHLORIDE

CAPSULE; ORAL
RENAGEL

+	GELTEX	403MG	N20926 001	OCT 30, 1998

SILDENAFIL CITRATE

TABLET; ORAL
VIAGRA

	PFIZER	25MG	N20895 001	MAR 27, 1998
		50MG	N20895 002	MAR 27, 1998
+		100MG	N20895 003	MAR 27, 1998

SIMETHICONE-CELLULOSE

SUSPENSION; ORAL
SONORX

+	BRACCO	7.5MG/ML	N20773 001	OCT 29, 1998

SIMVASTATIN

TABLET; ORAL
ZOCOR

	MERCK	5MG	N19766 001	DEC 23, 1991

SIMVASTATIN

TABLET; ORAL
ZOCOR

+	MERCK	10MG	N19766 004	DEC 23, 1991
+		5MG	N19766 001	DEC 23, 1991
		10MG	N19766 004	DEC 23, 1991
+		80MG	N19766 005	JUL 10, 1998

SODIUM CHLORIDE

INJECTABLE; INJECTION
SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER

AP	B BRAUN	450MG/100ML	N19635 001	MAR 09, 1988
@		450MG/100ML	N18184 001	
AP	MCGAW	450MG/100ML	N19635 001	MAR 09, 1988
@		450MG/100ML	N18184 001	

SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

AP	B BRAUN	900MG/100ML	N17464 001	
AP		900MG/100ML	N19635 002	MAR 09, 1988
AP	MCGAW	900MG/100ML	N17464 001	
AP		900MG/100ML	N19635 002	MAR 09, 1988

SODIUM CHLORIDE 3% IN PLASTIC CONTAINER

@	B BRAUN	3GM/100ML	N19635 003	MAR 09, 1988
@	MCGAW	3GM/100ML	N19635 003	MAR 09, 1988

SODIUM CHLORIDE 5% IN PLASTIC CONTAINER

@	B BRAUN	5GM/100ML	N19635 004	MAR 09, 1988
@	MCGAW	5GM/100ML	N19635 004	MAR 09, 1988

SODIUM LACTATE

INJECTABLE; INJECTION
SODIUM LACTATE 0.167 MOLAR IN PLASTIC CONTAINER

@	B BRAUN	1.87GM/100ML	N18186 001	
@	MCGAW	1.87GM/100ML	N18186 001	

SODIUM LACTATE

INJECTABLE; INJECTION
SODIUM LACTATE 1/6 MOLAR IN PLASTIC CONTAINER

AP		B BRAUN	1.87GM/100ML	N20004 001 APR 21, 1992
AP		MCGAW	1.87GM/100ML	N20004 001 APR 21, 1992

SODIUM POLYSTYRENE SULFONATE

POWDER; ORAL, RECTAL
KAYEXALATE

AA		SANOFI	453.6GM/BOT	N11287 001
AA	+		453.6GM/BOT	N11287 001

KIONEX

AA		PADDOCK	454GM/BOT	N40029 001 FEB 06, 1998

SOMATROPIN, BIOSYNTHETIC

INJECTABLE; INJECTION
GENOTROPIN

	+	PHARMACIA AND UPJOHN	13.8MG/VIAL	N20280 007 OCT 23, 1996

SOTALOL HYDROCHLORIDE

TABLET; ORAL
BETAPACE

	@	BERLEX LABS	120MG	N19865 005 APR 20, 1994
			160MG	N19865 002 OCT 30, 1992
	#		240MG	N19865 003 OCT 30, 1992
			120MG	N19865 005 APR 20, 1994
	+		160MG	N19865 002 OCT 30, 1992
			240MG	N19865 003 OCT 30, 1992

SOYBEAN OIL

INJECTABLE; INJECTION
INTRALIPID 30%

AP	+	PHARMACIA AND UPJOHN	30%	N19942 001 DEC 30, 1993

LIPOSYN III 30%

AP	+	ABBOTT	30%	N20181 001 JAN 13, 1998

NUTRILIPID 10%

AP	+	B BRAUN	10%	N19531 001 MAY 28, 1993
AP	#	MCGAW	10%	N19531 001 MAY 28, 1993

NUTRILIPID 20%

AP	+	B BRAUN	20%	N19531 002 MAY 28, 1993
AP	#	MCGAW	20%	N19531 002 MAY 28, 1993

SPARFLOXACIN

TABLET; ORAL
ZAGAM

	+	MYLAN	200MG	N20677 001 DEC 19, 1996
	#	RHONE POULENC RORER	200MG	N20677 001 DEC 19, 1996

STREPTOMYCIN SULFATE

INJECTABLE; INJECTION
STREPTOMYCIN SULFATE

AP	+	PFIZER	EQ 1GM BASE/VIAL	N60076 001
			EQ 1GM BASE/2.5ML	N60111 001
	+		EQ 1GM BASE/2.5ML	N60111 001
AP		PHARMA TEK	EQ 1GM BASE/VIAL	N64210 001 JUN 30, 1998

SUCCINYLCHOLINE CHLORIDE

INJECTABLE; INJECTION
SUCOSTRIN

AP	#	ARGATROBAN	20MG/ML	N08847 001
	@		20MG/ML	N08847 001

SUCRALFATE

TABLET; ORAL

SUCRALFATE

AB		RATIOPHARM	1GM	N74415 001 JUN 08, 1998

SUFENTANIL CITRATE

INJECTABLE; INJECTION

SUFENTA

AP	+	AKORN	EQ 0.05MG BASE/ML	N19050 001 MAY 04, 1984
AP	*	JANSSEN	EQ 0.05MG BASE/ML	N19050 001 MAY 04, 1984

SUFENTANIL CITRATE

AP		[redacted]	EQ 0.05MG BASE/ML	N74406 001 DEC 15, 1995
	●		EQ 0.05MG BASE/ML	N74406 001 DEC 15, 1995

SULFACETAMIDE SODIUM

SOLUTION/DROPS; OPHTHALMIC

[redacted]

AP		[redacted]	10%	N80025 001
	●		10%	N80025 001

SULFAMETHOXAZOLE; TRIMETHOPRIM

INJECTABLE; INJECTION

SEPTRA

AP	*	GLAXO WELLCOME	80MG/ML;16MG/ML	N18452 001
AP	+	MONARCH PHARMS	80MG/ML;16MG/ML	N18452 001

SUSPENSION; ORAL

[redacted]

AB		TEVA	200MG/5ML;40MG/5ML	N70028 001 JUN 02, 1987

SEPTRA

AB		GLAXO WELLCOME	200MG/5ML;40MG/5ML	N17598 001
AB		MONARCH PHARMS	200MG/5ML;40MG/5ML	N17598 001

[redacted]

AB		TEVA	200MG/5ML;40MG/5ML	N18812 001 JAN 28, 1983

SULFAMETHOXAZOLE AND TRIMETHOPRIM

AB		TEVA	200MG/5ML;40MG/5ML	N18812 001 JAN 28, 1983
AB			200MG/5ML;40MG/5ML	N18812 002 JUN 10, 1983
AB			200MG/5ML;40MG/5ML	N70028 001 JUN 02, 1987

TABLET; ORAL

SEPTRA

AB		GLAXO WELLCOME	400MG;80MG	N17376 001
AB		MONARCH PHARMS	400MG;80MG	N17376 001

SEPTRA DS

AB		GLAXO WELLCOME	800MG;160MG	N17376 002
AB		MONARCH PHARMS	800MG;160MG	N17376 002

[redacted]

AB		TEVA	400MG;80MG	N18242 001
AB			800MG;160MG	N18242 002

SULFAMETHOXAZOLE AND TRIMETHOPRIM

AB		TEVA	400MG;80MG	N18242 001
AB			800MG;160MG	N18242 002

SULFASALAZINE

TABLET; ORAL

SULFASALAZINE

AB		SUPERPHARM	500MG	N89339 001 OCT 26, 1987
	●		500MG	N89339 001 OCT 26, 1987

SULFINPYRAZONE

TABLET; ORAL

SULFINPYRAZONE

AB		DANBURY PHARMA	100MG	N87667 001 MAY 26, 1982
	●		100MG	N87667 001 MAY 26, 1982

SUTILAINS

OINTMENT; TOPICAL
  EPIVATE
  # [redacted] 82,000 UNITS/GM [redacted]
  • 82,000 UNITS/GM N12828 001

TACRINE HYDROCHLORIDE

CAPSULE; ORAL
  COGNEX
    [redacted] EQ 10MG BASE [redacted]
    EQ 20MG BASE [redacted]
    EQ 30MG BASE [redacted]
    # EQ 40MG BASE [redacted]
    PARKE DAVIS PHARMS EQ 10MG BASE SEP 09, 1993
    EQ 20MG BASE N20070 002 SEP 09, 1993
    EQ 30MG BASE N20070 003 SEP 09, 1993
    + EQ 40MG BASE N20070 004 SEP 09, 1993

TACROLIMUS

CAPSULE; ORAL
  PROGRAF
  # [redacted] EQ 1MG BASE [redacted] APR 08, 1994
  # EQ 5MG BASE [redacted] APR 08, 1994
  + FUJISAWA HLTHCARE EQ 1MG BASE N50708 001 APR 08, 1994
  + EQ 5MG BASE N50708 002 APR 08, 1994

INJECTABLE; INJECTION
  PROGRAF
  # [redacted] EQ 5MG BASE/ML [redacted] APR 08, 1994
  + FUJISAWA HLTHCARE EQ 5MG BASE/ML N50709 001 APR 08, 1994

TECHNETIUM TC-99M ALBUMIN AGGREGATED KIT

INJECTABLE; INJECTION
  TECHNETIUM TC 99M ALBUMIN AGGREGATED KIT
  BS DRAXIMAGE N/A N17881 001 DEC 30, 1987
  BS [redacted] N/A [redacted] DEC 30, 1987

TECHNETIUM TC-99M APCITIDE

INJECTABLE; INJECTION
  ACUTECT
    DIATIDE N/A N20887 001 SEP 14, 1998

TECHNETIUM TC-99M DISOFENIN KIT

INJECTABLE; INJECTION
  HEPATOLITE
    [redacted] N/A [redacted] MAR 16, 1982
    DUPONT PHARMS N/A N18467 001 MAR 16, 1982

TECHNETIUM TC-99M GLUCEPTATE KIT

INJECTABLE; INJECTION
  [redacted]
  AP [redacted] N/A [redacted] JAN 27, 1982
  • N/A N17907 001
  TECHNESCAN GLUCEPTATE
  AP [redacted] N/A [redacted] JAN 27, 1982
  N/A N18272 001 JAN 27, 1982

TECHNETIUM TC-99M LIDOFENIN KIT

INJECTABLE; INJECTION
  TECHNESCAN HIDA
    DRAXIMAGE N/A N18489 001 OCT 31, 1986
    [redacted] N/A [redacted] OCT 31, 1986

TECHNETIUM TC-99M MEDRONATE KIT

INJECTABLE; INJECTION
TECHNESCAN MDP KIT

AP	DRAXIMAGE	N/A	N18035 001	
[redacted]				

TECHNETIUM TC-99M PENTETATE KIT

INJECTABLE; INJECTION
DTPA

AP	DRAXIMAGE	N/A	N18511 001	DEC 29, 1989
[redacted]				

TECHNETIUM TC-99M SULFUR COLLOID KIT

SOLUTION; INJECTION, ORAL
AN-SULFUR COLLOID

AP	CIS	N/A	N17858 001	
	[redacted]			
	TECHLOID			
[redacted]				
	[redacted]	N/A	N16923 001	

> ADD > **TELMISARTAN**

TABLET; ORAL
MICARDIS

	BOEHRINGER INGELHEIM	40MG	N20850 001	NOV 10, 1998
	+	80MG	N20850 002	NOV 10, 1998

TERAZOSIN HYDROCHLORIDE

CAPSULE; ORAL
HYTRIN

AB	ABBOTT	EQ 1MG BASE	N20347 001	DEC 14, 1994
AB	+	EQ 2MG BASE	N20347 002	DEC 14, 1994
AB		EQ 5MG BASE	N20347 003	DEC 14, 1994

TERAZOSIN HYDROCHLORIDE

CAPSULE; ORAL
HYTRIN

AB	ABBOTT	EQ 10MG BASE	N20347 004	DEC 14, 1994

TERAZOSIN HCL

AB	GENEVA PHARMS	EQ 1MG BASE	N74823 001	MAR 30, 1998
AB		EQ 2MG BASE	N74823 002	MAR 30, 1998
AB		EQ 5MG BASE	N74823 003	MAR 30, 1998
AB		EQ 10MG BASE	N74823 004	MAR 30, 1998

TERBINAFINE

GEL; TOPICAL
LAMISIL

	+ NOVARTIS	1%	N20846 001	APR 29, 1998

> DLT > **TERFENADINE**

> DLT > TABLET; ORAL
> DLT > SELDANE
> DLT > AB + [redacted] 60MG N18949 001 MAY 08, 1985
> DLT >
> DLT > [redacted]
> DLT > AB [redacted] 60MG N74475 001 JAN 03, 1997
> DLT >

TESTOSTERONE

FILM, EXTENDED RELEASE; TRANSDERMAL
ANDRODERM

RX	+ [redacted]	2.5MG/24HR	N20489 001	SEP 29, 1995
	+	2.5MG/24HR	N20489 001	SEP 29, 1995

TETRACYCLINE HYDROCHLORIDE

CAPSULE; ORAL
ACHROMYCIN V

AB	RSI LEDERLE	250MG	N50278 003	
AB	+	500MG	N50278 001	
AB	[illegible]	[illegible]	[illegible]	
AB	#	[illegible]	[illegible]	

TABLET; ORAL
SUMYCIN

	APOTHECON	50MG	N61147 003	
		100MG	N61147 002	
	●	50MG	N61147 003	
	●	100MG	N61147 002	

THALIDOMIDE

CAPSULE; ORAL
THALOMID

	+ CELGENE	50MG	N20785 001 JUL 16, 1998	

THEOPHYLLINE

CAPSULE; ORAL
ELIXOPHYLLIN

RX	FOREST LABS	100MG	N85545 001 JUL 31, 1984	
RX	#	200MG	N83921 001 JUL 31, 1984	
	●	100MG	N85545 001 JUL 31, 1984	
	●	200MG	N83921 001 JUL 31, 1984	

CAPSULE, EXTENDED RELEASE; ORAL
[illegible]

RC	FOREST LABS	125MG	N86826 001 JAN 29, 1985	
RC		250MG	N86826 002 JAN 29, 1985	
	●	125MG	N86826 001 JAN 29, 1985	>ADD>
	●	250MG	N86826 002 JAN 29, 1985	>ADD>
				>ADD>
				>ADD>
				>ADD>

THEOPHYLLINE

TABLET; ORAL
QUIBRON-T

+	MONARCH PHARMS	300MG	N88656 001 AUG 22, 1985
#	[illegible]	300MG	[illegible] AUG 22, 1985

TABLET, EXTENDED RELEASE; ORAL
QUIBRON-T/SR

BC	KING PHARMS	300MG	N87563 001 JUN 21, 1983
BC	MONARCH PHARMS	300MG	N87563 001 JUN 21, 1983

THIAMYLAL SODIUM

[illegible]
SURITAL

*	PARKE DAVIS	1GM/VIAL	N07600 003
*		5GM/VIAL	N07600 005
*		10GM/VIAL	N07600 009
●	PARKEDALE	1GM/VIAL	N07600 003
●		5GM/VIAL	N07600 005
●		10GM/VIAL	N07600 009

THIORIDAZINE HYDROCHLORIDE

CONCENTRATE; ORAL
THIORIDAZINE HCL

AA	PHARM ASSOC	100MG/ML	N40213 001 MAY 29, 1998

TABLET; ORAL
THIORIDAZINE HCL

AB	[illegible]	[illegible]	[illegible] JUL 24, 1984
	●	25MG	N88755 001 JUL 24, 1984

THYROTROPIN ALFA

INJECTABLE; INJECTION
THYROGEN

	+ GENZYME	1.1MG/VIAL	N20898 001 NOV 30, 1998

TICLOPIDINE HYDROCHLORIDE

TABLET; ORAL
TICLID

	● ROCHE	125MG	N19979 001	MAR 24, 1993
	+	250MG	N19979 002	OCT 31, 1991
	● [illegible]	[illegible]	[illegible]	[illegible]
	●	[illegible]	[illegible]	[illegible]

TIMOLOL MALEATE

SOLUTION, GEL FORMING/DROPS; OPHTHALMIC
TIMOLOL MALEATE

AB	ALCON	EQ 0.25% BASE	N20963 001	OCT 21, 1998
AB		EQ 0.5% BASE	N20963 002	OCT 21, 1998

TIMOPTIC-XE

AB	+ MERCK	EQ 0.25% BASE	N20330 001	NOV 04, 1993
AB	+	EQ 0.5% BASE	N20330 002	NOV 04, 1993

SOLUTION/DROPS; OPHTHALMIC
TIMOLOL MALEATE

>DLT>	[illegible]	[illegible]	[illegible]	[illegible]
>DLT>	[illegible]	[illegible]	[illegible]	[illegible]
>DLT>	[illegible]	[illegible]	[illegible]	[illegible]
>DLT>				
>ADD>	AT	EQ 0.5% BASE	N74466 001	MAR 25, 1997
>ADD>				
>ADD>	AT AKORN	EQ 0.25% BASE	N74465 001	MAR 25, 1997
>ADD>				

TABLET; ORAL
BLOCADREN

AB	MERCK	5MG	N18017 001	
AB		10MG	N18017 002	
AB	+	20MG	N18017 004	
[illegible]	[illegible]	[illegible]	[illegible]	[illegible]
[illegible]		[illegible]	[illegible]	[illegible]
[illegible]	●	[illegible]	[illegible]	[illegible]

TIROFIBAN HYDROCHLORIDE

INJECTABLE; INJECTION
AGGRASTAT

	+ MERCK	EQ 0.05MG BASE/ML	N20913 001	MAY 14, 1998
	+	EQ 0.25MG BASE/ML	N20912 001	MAY 14, 1998

TOLBUTAMIDE

TABLET; ORAL
TOLBUTAMIDE

AB	ZENITH GOLDLINE	500MG	N87093 001	
[illegible]	[illegible]	[illegible]	[illegible]	[illegible]

TOLCAPONE

TABLET; ORAL
TASMAR

	ROCHE	100MG	N20697 001	JAN 29, 1998
	+	200MG	N20697 002	JAN 29, 1998

TOLTERODINE TARTRATE

TABLET; ORAL
DETROL

	PHARMACIA AND UPJOHN	1MG	N20771 001	MAR 25, 1998
	+	2MG	N20771 002	MAR 25, 1998

TOPIRAMATE

CAPSULE; ORAL
TOPAMAX SPRINKLE

	JOHNSON RW	15MG	N20844 001	OCT 26, 1998
		25MG	N20844 002	OCT 26, 1998
	+	50MG	N20844 003	OCT 26, 1998

TORSEMIDE

INJECTABLE; INJECTION

DEMADEX

	‡	[redacted]	[redacted]	[redacted]
	+	ROCHE	10MG/ML	N20137 002 AUG 23, 1993

TABLET; ORAL

DEMADEX

		[redacted]	5MG	[redacted]
			10MG	[redacted]
			20MG	[redacted]
	‡		100MG	[redacted]
		ROCHE	5MG	N20136 001 AUG 23, 1993
			10MG	N20136 002 AUG 23, 1993
			20MG	N20136 003 AUG 23, 1993
	+		100MG	N20136 004 AUG 23, 1993

TRETINOIN

CREAM; TOPICAL

AVITA

AB	‡	[redacted]	[redacted]	[redacted]
AB			0.025%	N20404 003 JAN 14, 1997

GEL; TOPICAL

AVITA

>ADD>	BT	PENEDERM	0.025%	N20400 001 JAN 29, 1998
>ADD>				
>DLT>	RX		[redacted]	[redacted]
>DLT>				

RETIN-A

>ADD>	BT	+ JOHNSON AND JOHNSON	0.025%	N17579 002
>DLT>	RX	‡	[redacted]	[redacted]

SOLUTION; TOPICAL

RETIN-A

	‡	[redacted]	[redacted]	[redacted]

TRETINOIN

SOLUTION; TOPICAL

RETIN-A

AT	+	JOHNSON AND JOHNSON	0.05%	N16921 001

TRETINOIN

AT		COPLEY PHARM	0.05%	N74873 001 JUN 19, 1998

TRIAMCINOLONE ACETONIDE

CREAM; TOPICAL

TRIAMCINOLONE ACETONIDE

	@	ALPHARMA	0.025%	N87797 001 JUN 07, 1982
AT		[redacted]	[redacted]	[redacted]

TRIAMCINOLONE DIACETATE

SYRUP; ORAL

[redacted]

		[redacted]	[redacted]	[redacted]
	@		EQ 4MG BASE/5ML	N12515 001

TRICHLORMETHIAZIDE

TABLET; ORAL

TRICHLORMETHIAZIDE

RB		DANBURY PHARMA	[redacted]	[redacted]
RB			[redacted]	[redacted]
	@		2MG	N83847 001
	@		4MG	N83855 001

TRIFLUOPERAZINE HYDROCHLORIDE

TABLET; ORAL

TRIFLUOPERAZINE HCL

AB		ZENITH GOLDLINE	EQ 1MG BASE	N87612 001 NOV 19, 1982
AB			EQ 2MG BASE	N87613 001 NOV 19, 1982
AB		[redacted]	[redacted]	[redacted]

TRIFLUOPERAZINE HYDROCHLORIDE

TABLET; ORAL
TRIFLUOPERAZINE HCL

[redacted]	[redacted]	[redacted]	[redacted]

TRIFLURIDINE

SOLUTION/DROPS; OPHTHALMIC
VIROPTIC

[redacted]	[redacted]	[redacted]	[redacted]
AT +	MONARCH PHARMS	1%	N18299 001

TRIHEXYPHENIDYL HYDROCHLORIDE

TABLET; ORAL
TRIHEXYPHENIDYL HCL

AA	CIRCA	2MG	N40184 001 FEB 06, 1998
AA		5MG	N40184 002 FEB 06, 1998

TRIMEPRAZINE TARTRATE

[redacted]
TABLET

[redacted]	[redacted]	[redacted]	[redacted]
●		EQ 5MG BASE	N11316 004

[redacted]
SYRUP

[redacted]	[redacted]	[redacted]	[redacted]
●		EQ 2.5MG BASE/5ML	N11316 003

[redacted]
TABLET

[redacted]	[redacted]	[redacted]	[redacted]
●		EQ 2.5MG BASE	N11316 001

TRIMETHAPHAN CAMSYLATE

[redacted]
INJECTABLE; INJECTION
ARFONAD

[redacted]	[redacted]	[redacted]	[redacted]

TRIMETHAPHAN CAMSYLATE

[redacted]
INJECTABLE; INJECTION
ARFONAD

●	ROCHE	50MG/ML	N08983 001

TRIMETHOBENZAMIDE HYDROCHLORIDE

INJECTABLE; INJECTION
TIGAN

AP	+	ROBERTS LABS	100MG/ML	N17530 001
[redacted]	[redacted]	[redacted]	[redacted]	[redacted]

TRIMETHOPRIM

TABLET; ORAL
PROLOPRIM

[redacted]		[redacted]	[redacted]	[redacted]
[redacted]	[redacted]	[redacted]	[redacted]	[redacted]
AB		MONARCH PHARMS	100MG	N17943 001
AB	+		200MG	N17943 003 JUL 14, 1982

TRIMETREXATE GLUCURONATE

INJECTABLE; INJECTION
NEUTREXIN

+	US BIOSCIENCE	EQ 200MG BASE/VIAL	N20326 002 JUL 31, 1998

TROGLITAZONE

TABLET; ORAL
REZULIN

[redacted]	[redacted]	[redacted]	[redacted]
[redacted]		[redacted]	[redacted]
[redacted]		[redacted]	[redacted]
AB		PARKE DAVIS PHARMS	200MG	N20720 001 JAN 29, 1997
AB			300MG	N20720 003 AUG 04, 1997

TROGLITAZONE

TABLET; ORAL
REZULIN
AB PARKE DAVIS PHARMS 400MG N20720 002
JAN 29, 1997

TROPICAMIDE

SOLUTION/DROPS; OPHTHALMIC
TROPICAMIDE
[redacted] [redacted] [redacted] [redacted]
● 1% N88447 001
AUG 28, 1985

UREA, C-14

CAPSULE; ORAL
PYTEST
+ BALLARD MEDCL 1 uCi N20617 001
MAY 09, 1997
[redacted] [redacted] [redacted] [redacted]
PYTEST KIT
+ BALLARD MEDCL 1 uCi N20617 002
MAY 09, 1997
[redacted] [redacted] [redacted] [redacted]

UROFOLLITROPIN

INJECTABLE; INTRAMUSCULAR
FERTINEX
+ SERONO 75 IU/AMP N19415 002
SEP 18, 1986
+ 150 IU/AMP N19415 003
SEP 18, 1986
METROFIN
[redacted] [redacted] [redacted] [redacted]
[redacted] [redacted] [redacted] [redacted]

VALRUBICIN

SOLUTION; INTRAVESICAL
VALSTAR PRESERVATIVE FREE
+ ANTHRA 40MG/ML N20892 001
SEP 25, 1998

VERAPAMIL HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL
VERELAN
+ ELAN 120MG N19614 001
MAY 29, 1990
+ 180MG N19614 003
JAN 09, 1992
+ 240MG N19614 002
MAY 29, 1990
+ 360MG N19614 004
[redacted] [redacted]
VERELAN PM
+ ELAN PHARM 100MG N20943 001
NOV 25, 1998
+ 200MG N20943 002
NOV 25, 1998
+ 300MG N20943 003
NOV 25, 1998

INJECTABLE; INJECTION
VERAPAMIL HCL
AP ABBOTT 2.5MG/ML N75136 001
OCT 20, 1998
[redacted] [redacted] [redacted] [redacted]
[redacted] [redacted] [redacted] [redacted]
● 2.5MG/ML N72233 001
FEB 26, 1993
● 2.5MG/ML N73485 001
SEP 27, 1993

VIDARABINE

INJECTABLE; INJECTION

VIRA-A

[redacted]	[redacted]	[redacted]	[redacted]
●	PARKEDALE	EQ 187.4MG BASE/ML	N50523 001

OINTMENT; OPHTHALMIC

VIRA-A

[redacted]	[redacted]	[redacted]	[redacted]
+	PARKEDALE	3%	N50486 001

VINCRISTINE SULFATE

INJECTABLE; INJECTION

[redacted]

[redacted]	[redacted]	[redacted]	[redacted]
[redacted]	[redacted]	[redacted]	[redacted]
[redacted]	[redacted]	[redacted]	[redacted]
●		1MG/VIAL	N71559 001 APR 11, 1988
●		2MG/VIAL	N71560 001 APR 11, 1988
●		5MG/VIAL	N71561 001 APR 11, 1988

WARFARIN SODIUM

TABLET; ORAL

COUMADIN

>ADD>	AB	DUPONT MERCK	3MG	N09218 025
>ADD>				NOV 18, 1996
>ADD>	AB		6MG	N09218 026
>ADD>				NOV 18, 1996

WARFARIN SODIUM

>ADD>	AB	BARR	3MG	N40145 008
>ADD>				NOV 05, 1998
>ADD>	AB		6MG	N40145 009
>ADD>				NOV 05, 1998

WATER FOR INJECTION, STERILE

LIQUID; N/A

STERILE WATER FOR INJECTION IN PLASTIC CONTAINER

AP	B BRAUN	100%	N19633 001	FEB 29, 1988
[redacted]	[redacted]	[redacted]	[redacted]	[redacted]

ACETAMINOPHEN; ASPIRIN; CAFFEINE

TABLET; ORAL
EXCEDRIN (MIGRAINE)

+	BRISTOL MYERS	250MG;250MG;65MG	N20802 001 JAN 14, 1998	

ALUMINUM HYDROXIDE; MAGNESIUM TRISILICATE

TABLET, CHEWABLE; ORAL
GAVISCON

§	[redacted]	[redacted]	[redacted]	
		80MG;20MG	N18685 001 DEC 09, 1983	
+		160MG;40MG	N18685 002 DEC 09, 1983	> DLT >

GAVISCON-2

§	[redacted]	[redacted]	[redacted]	> DLT >

CHLORHEXIDINE GLUCONATE

SOLUTION; TOPICAL
CHG SCRUB

	ECOLAB	4%	N19258 002 JUL 22, 1986	> ADD >
	[redacted]	[redacted]	[redacted]	> ADD >

CIDA-STAT

	ECOLAB	2%	N19258 001 JUL 22, 1986	> ADD >
	[redacted]	[redacted]	[redacted]	> ADD >

CIMETIDINE

TABLET; ORAL
CIMETIDINE

	LEK PHARM	100MG	N75122 001 JUN 19, 1998	
		200MG	N75122 002 JUN 19, 1998	
	NOVOPHARM	200MG	N74961 001 JUN 19, 1998	

CIMETIDINE

TABLET; ORAL
CIMETIDINE

	PERRIGO	100MG	N74972 001 JUN 19, 1998	
		200MG	N75285 001 OCT 29, 1998	
	PHARM FORM	200MG	N74963 001 JUN 19, 1998	
	TORPHARM	100MG	N74948 001 JUN 19, 1998	

CLEMASTINE FUMARATE

TABLET; ORAL
[redacted]

§	[redacted]	[redacted]	[redacted]	
	●	1.34MG	N17661 003 AUG 21, 1992	
	+	1.34MG	N20925 001 AUG 21, 1992	

CLOTRIMAZOLE

CREAM; VAGINAL
GYNE-LOTRIMIN 3

+	SCHERING PLOUGH	2%	N20574 001 NOV 24, 1998	

TABLET; VAGINAL
GYNIX

	COPLEY PHARM	100MG	N73249 001 FEB 13, 1998	

FAMOTIDINE

TABLET, CHEWABLE; ORAL
PEPCID AC

+	MERCK	10MG	N20801 001 SEP 24, 1998	

IBUPROFEN

CAPSULE; ORAL
IBUPROFEN

>ADD<	PHARM FORM	200MG	N74782 001	JUL 06, 1998
>ADD<				

SUSPENSION; ORAL
CHILDREN'S ADVIL-FLAVORED

§	WHITEHALL ROBINS	100MG/5ML	N20589 002	NOV 07, 1997
		100MG/5ML	N20589 002	NOV 07, 1997

SUSPENSION/DROPS; ORAL
PEDIATRIC ADVIL

+	WHITEHALL ROBINS	100MG/2.5ML	N20812 001	JAN 30, 1998

TABLET; ORAL
IBUPRIN

	ZENITH LABS NJ	200MG	N71773 001	JUL 16, 1987
@		200MG	N71773 001	JUL 16, 1987

IBUPROFEN

	EMERGENT PHARMA	200MG	N71905 001	MAR 08, 1988
		200MG	N71905 001	MAR 08, 1988
§	MCNEIL	200MG	N73019 001	MAR 30, 1994
		200MG	N73019 001	MAR 30, 1994
	NOVOPHARM	200MG	N74931 001	JUL 20, 1998
>DLT<	PHARM FORM	200MG	N74782 001	JUL 06, 1998
>DLT<				

NUPRIN

	BRISTOL MYERS	200MG	N72035 001	FEB 16, 1988
		200MG	N72036 001	FEB 16, 1988
@		200MG	N72035 001	FEB 16, 1988
@		200MG	N72036 001	FEB 16, 1988
	MCNEIL	200MG	N19012 001	MAY 18, 1984

IBUPROFEN

TABLET; ORAL
NUPRIN

@	MCNEIL	200MG	N19012 003	JUL 29, 1987
+		200MG	N19012 001	MAY 18, 1984
		200MG	N19012 003	JUL 29, 1987

TABLET, CHEWABLE; ORAL
JUNIOR STRENGTH MOTRIN

	MCNEIL	100MG	N20601 003	NOV 15, 1996
+		100MG	N20601 003	NOV 15, 1996

INSULIN BIOSYNTHETIC HUMAN

INJECTABLE; INJECTION
HUMULIN R PEN

+	LILLY	100 UNITS/ML	N18780 005	AUG 06, 1998

INSULIN BIOSYNTHETIC HUMAN; INSULIN SUSP ISOPHANE BIOSYNTHETIC HUMAN

INJECTABLE; INJECTION
HUMULIN 70/30 PEN

+	LILLY	30 UNITS/ML;70 UNITS/ML	N19717 002	AUG 06, 1998

MICONAZOLE NITRATE

CREAM; VAGINAL
MONISTAT 3

+	ADVANCED CARE PRODS	4%	N20827 001	MAR 30, 1998

MINOXIDIL

SOLUTION; TOPICAL
MINOXIDIL (FOR MEN)

	NOVEX	2%	N74924 001	APR 29, 1998

MINOXIDIL

SOLUTION; TOPICAL
MINOXIDIL (FOR MEN)
[redacted] 2% [redacted]
MINOXIDIL (FOR WOMEN)
MOVEX 2% N74924 002 APR 29, 1998
[redacted] 5% [redacted]

NAPHAZOLINE HYDROCHLORIDE; PHENIRAMINE MALEATE

SOLUTION/DROPS; OPHTHALMIC
> DLT > [redacted]
> DLT > [redacted] [redacted] [redacted]
> DLT >
> ADD > VISINE-A
> ADD > AKORN 0.025%;0.3% N20485 001 JAN 31, 1996
> ADD >

NAPROXEN SODIUM

TABLET; ORAL
NAPROXEN SODIUM
PAR PHARM EQ 200MG BASE N75168 001 JUL 28, 1998

NICOTINE

FILM, EXTENDED RELEASE; TRANSDERMAL
NICOTROL
[redacted] [redacted] [redacted]
+ PHARMACIA AND UPJOHN 15MG/16HR N20536 001 JUL 03, 1996

RANITIDINE HYDROCHLORIDE

TABLET, EFFERVESCENT; ORAL
ZANTAC 75
+ GLAXO WELLCOME EQ 75MG BASE N20745 001 FEB 26, 1998

DRUG PRODUCTS WITH APPROVAL UNDER SECTION 505 OF THE ACT ADMINISTERED BY THE CENTER FOR BIOLOGICS EVALUATION AND RESEARCH LIST

CUMULATIVE SUPPLEMENT NUMBER 11 NOV '98

NO NOVEMBER 1998 APPROVALS

This data is provided to the Division of Data Management and Services from the Office of Orphan Products Development and it is not edited prior to publication.

Orphan Product Designations and Approvals List
January 1998 through November 1998

Name Generic Name TN=Trade Name	Indication Designated	Sponsor & Address DD= Date Designated MA=Marketing Approval
1,5-(Butylimino) -1,5 dideoxy,D-glucitol TN=	Treatment of Fabry's disease.	Oxford GlycoSciences 10, The Quadrant Abington Science Park, Abington Oxfordshire OX14 3YS UK DD=05/12/1998
1,5-(Butylimino) -1,5 dideoxy,D-glucitol TN=	Treatment of Gaucher disease.	Oxford GlycoSciences 10, The Quadrant Abington Science Park, Abington Oxfordshire OX14 3YS UK DD=05/29/1998
3-(3,5-dimethyl-1H-2ylmethylene) -1,3-dihydro-indol-2-one TN=	Treatment of Kaposi's sarcoma.	Sugen, Inc. 230 East Grand Ave. South San Francisco, CA 94080 DD=09/11/1998
Aldesleukin TN= Proleukin	Treatment of metastatic melanoma.	Chiron Corporation 4560 Horton Street Emeryville, CA 94608 DD=09/10/1996 MA=01/09/1998
Aldesleukin TN= Proleukin	Treatment of acute myelogenous leukemia.	Chiron Corporation 4560 Horton St. Emeryville, CA 94608 DD=07/31/1998
Aldesleukin TN= Proleukin	For the treatment non-Hodgkin's lymphoma.	Chiron Corporation 4560 Horton St. Emeryville, CA 94608 DD=11/24/1998

Orphan Product Designations and Approvals List
January 1998 through November 1998

Name Generic Name TN=Trade Name	Indication Designated	Sponsor & Address DD= Date Designated MA=Marketing Approval
Aliperetinate TN= Panretin	For the topical treatment of cutaneous lesions in patients with AIDS-related Kaposi's sarcoma.	Ligand Pharmaceuticals Inc. 10275 Science Center Drive San Diego, CA 92121 DD=03/24/1998
Alpha-galactosidase A TN=	Long-term enzyme replacement therapy for the treatment of Fabry disease.	Transkaryotic Therapies Inc. 195 Albany St. Cambridge, MA 02139 DD=06/22/1998
Amifostine TN= Ethyol	Reduction of the incidence and severity of radiation-induced xerostomia.	U.S. Bioscience, Inc. One Tower Bridge 100 Front Street, Suite 400 Conshohocken, PA 19428 DD=05/12/1998
Amifostine TN= Ethyol	For the reduction of the incidence and severity of toxicities associated with cisplatin administration.	U.S. Bioscience, Inc. One Tower Bridge 100 Front St., Suite #400 West Conshohocken, PA 19428 DD=11/24/1998
Arsenic trioxide TN=	Treatment of acute promyelocytic leukemia.	PolaRx, Inc. 787 7th Ave., 48th Floor New York, NY 10019 DD=03/03/1998

Orphan Product Designations and Approvals List
January 1998 through November 1998

Name Generic Name TN=Trade Name	Indication Designated	Sponsor & Address DD= Date Designated MA=Marketing Approval
Basiliximab TN= Simulect	Prophylaxis of solid organ rejection.	Novartis Pharmaceuticals Corporation 59 Route 10 East Hanover, NJ 07936 DD=12/12/1997 MA=05/12/1998
Beclomethasone dipropionate TN=	For oral administration in the treatment of intestinal graft-versus-host disease.	George B. McDonald, M.D. Fred Hutchinson Cancer Research Center 1100 Fairview Avenue North (SC-113); PO Box 19024 Seattle, WA 98109 DD=03/27/1998
Benzydamine hydrochloride TN= Tantum	Prophylactic treatment of oral mucositis resulting from radiation therapy for head and neck cancer.	Angelini Pharmaceuticals, Inc. 70 Grand Avenue River Edge, NJ 07661 DD=05/18/1998
Bindarit TN=	Treatment of lupus nephritis.	Angelini Pharmaceuticals, Inc. 70 Grand Avenue River Edge, NJ 07661 DD=02/03/1998
Botulinum toxin type A TN= Dysport	Treatment of spasmodic torticollis (cervical dystonia).	Ipsen Limited 1 Bath Road Maidenhead, Berkshire U.K. SL6 4UH DD=08/12/1998

Orphan Product Designations and Approvals List
January 1998 through November 1998

Name Generic Name TN=Trade Name	Indication Designated	Sponsor & Address DD= Date Designated MA=Marketing Approval
Carbamylglutamic acid TN=	Treatment of N-acetylglutamate synthetase deficiency.	Orphan Europe Immeuble "Le Guillaumet" 60 avenue du President Wilson 92046 Paris France DD=01/20/1998
Corticotropin-releasing factor, human TN= Xerecept	Treatment of peritumoral brain edema.	Neurobiological Technologies, Inc. 1387 Marina Way South Richmond, CA 94804 DD=04/06/1998
Dexamethasone TN=	For use in posterior segment drug delivery system in the treatment of idiopathic intermediate uveitis.	Oculex Pharmaceuticals 639 N. Pastoria Avenue Sunnyvale, CA 94086 DD=09/11/1998
Dimethylsulfoxide TN=	Treatment of palmar-plantar erythrodysesthesia syndrome.	Cancer Technologies, Inc. 7301 East 22nd Street Suite 10E Tucson, AZ 85710 DD=04/06/1998
Doxorubicin liposome TN= Doxil	Treatment of ovarian cancer.	Sequus Pharmaceuticals, Inc. 960 Hamilton Ct. Menlo Park, CA 94025 DD=11/04/1998
Filgrastim TN= Neupogen	Reduction in the duration of neutropenia, fever, antibiotic use, and hospitalization, following induction and consolidation treatment for acute myeloid leukemia.	Amgen, Inc. 1840 DeHavilland Drive Thousand Oaks, CA 91320 DD=11/07/1996 MA=04/02/1998

Orphan Product Designations and Approvals List
January 1998 through November 1998

Name Generic Name TN=Trade Name	Indication Designated	Sponsor & Address DD= Date Designated MA=Marketing Approval
Fructose-1,6-diphosphate TN=	Treatment of painful vaso-occlusive episodes associated with sickle cell disease.	Cypros Pharmaceutical Corporation 2714 Loker Avenue West Carlsbad, CA 92008 DD=05/29/1998
Humanized anti-CD2 monoclonal antibody TN=	Treatment of graft-versus-host disease.	MedImmune, Inc. 35 West Watkins Mill Rd. Gaithersburg, MD 20878 DD=11/13/1998
Humanized anti-human CD2 MAb TN= MEDI-507	For the induction of donor-specific immunologic unresponsiveness resulting in prophylaxis of organ rejection without the need for chronic immunosuppressive therapy, in patients receiving allogeneic renal transplants.	Biotransplant, Inc. Building 75, 3rd. Ave. Charlestown Navy Yard Charlestown, MA 02129 DD=09/17/1998
Hydroxyurea TN= Droxia	Treatment of patients with sickle cell anemia as shown by the presence of hemoglobin S.	Bristol-Myers Squibb Pharmaceutical Research Institute P.O. Box 4000 Princeton, NJ 08543 DD=10/01/1990 MA=02/25/1998
Infliximab TN= Remicade	Treatment of moderately to severely active Crohn's disease for the reduction of the signs and symptoms, in patients who have an inadequate response to conventional therapy; and treatment of patients with fistulizing Crohn's disease for the reduction in the number of draining enterocutaneous fistula(s).	Centocor, Inc. 200 Great Valley Parkway Malvern, PA 19355 DD=11/14/1995 MA=08/24/1998

Orphan Product Designations and Approvals List
January 1998 through November 1998

Name Generic Name TN=Trade Name	Indication Designated	Sponsor & Address DD= Date Designated MA=Marketing Approval
Interferon Beta-1a TN= Avonex	Treatment of juvenile rheumatoid arthritis.	Biogen, Inc. 14 Cambridge Center Cambridge, MA 02142 DD=10/14/1998
L-baclofen TN=	Treatment of trigeminal neuralgia.	Pharmascience, Inc. 8400 Darnley Road Montreal, Quebec Canada H4T 1M4 DD=01/06/1998
Lamotrigine TN= Lamictal	Treatment of Lennox-Gastaut syndrome.	Glaxo Wellcome Research and Development 5 Moore Drive P.O. Box 13398 Research Triangle Park, NC 27709 DD=08/23/1995 MA=08/24/1998
Lepirudin TN= Refluden	Treatment of heparin-associated thrombocytopenia type II.	Hoechst Marion Roussel Frankfurt am Main Germany DD=02/13/1997 MA=03/06/1998
Liposomal Cyclosporin A TN= Cyclospire	For aerosolized administration in the prevention and treatment of lung allograft rejection and pulmonary rejection events associated with bone marrow transplantation.	Vernon Knight, M.D. Baylor College of Medicine, Dept. of Molecular Physiology One Baylor Plaza Houston, TX 77030 DD=04/30/1998
Liposomal N-Acetylglucosminyl-N-Acetylmuramly-L-Ala-D-isoGln-L-Ala -gylcerolidpalmitoyl TN= ImmTher	Treatment of osteosarcoma.	Endorex Corp. 900 North Shore Drive Lake Bluff, IL 60044 DD=06/10/1998

Orphan Product Designations and Approvals List
January 1998 through November 1998

Name Generic Name TN=Trade Name	Indication Designated	Sponsor & Address DD= Date Designated MA=Marketing Approval
Liposomal N-Acetylglucosminyl-N-Acetylmuramly-L-Ala-D-isoGln-L-Ala -gylcerolidpalmitoyl TN= ImmTher	Treatment of Ewing's sarcoma.	Endorex Corp. 900 North Shore Drive Lake Bluff, IL 60044 DD=06/10/1998
MN14 monoclonal antibody to carcinoembryonic antigen TN= CEA-CIDE	For the treatment of small cell lung cancer.	Immunomedics, Inc. 300 American Rd. Morris Plains, NJ 07950 DD=09/18/1998
MN14 monoclonal antibody to carcinoembryonic antigen TN= Cea-cide	Treatment of pancreatic cancer.	Immunomedics, Inc. 300 American Road Morris Plains, NJ 07950 DD=11/24/1998
Mafenide acetate solution TN= Sulfamylon solution	For use as an adjunctive topical antimicrobial agent to control bacterial infection when used under moist dressings over meshed autografts on excised burn wounds.	Mylan Laboratories, Inc. 781 Chestnut Ridge Road P.O. Box 4310 Morgantown, WV 26504 DD=07/18/1990 MA=06/05/1998
Mecamylamine TN= Inversine	Treatment of Tourette's syndrome.	Layton Bioscience, Inc. 105 Reservoir Rd. Atherton, CA 94027 DD=10/14/1998
Methoxsalen TN= Uvadex	For use in conjunction with the UVAR photopheresis system to treat graft versus host disease.	Therakos, Inc. 437 Creamery Way Exton, PA 19431 DD=10/14/1998

Orphan Product Designations and Approvals List
January 1998 through November 1998

Name Generic Name TN=Trade Name	Indication Designated	Sponsor & Address DD= Date Designated MA=Marketing Approval
Murine MAb (Lym-1) and Iodine 131-I radiolabeled murine MAb (Lym-1) to human B-cell lymphoma TN= Oncolym	Treatment of B-cell non-Hodgkin's lymphoma.	Techniclone Corporation 14282 Franklin Ave. Tustin, CA 92780 DD=11/27/1998
Octreotide TN= Sandostatin LAR	Treatment of acromegaly.	Novartis Pharmaceuticals Corporation 59 Route 10 East Hanover, NJ 07936 DD=08/24/1998 MA=11/25/98
Octreotide TN= Sandostatin LAR	Treatment of severe diarrhea and flushing associated with malignant carcinoid tumors.	Novartis Pharmaceuticals Corporation 59 Route 10 East Hanover, NJ 07936 DD=08/24/1998 MA=11/25/98
Octreotide TN= Sandostatin LAR	Treatment of diarrhea associated with vasoactive intestinal peptide tumors (VIPoma).	Novartis Pharmaceuticals Corporation 59 Route 10 East Hanover, NJ 07936 DD=08/24/1998 MA=11/25/98
Oxypurinol TN=	Treatment of hyperuricemia in patients intolerant to allopurinol.	ILEX Oncology, Inc. 11550 IH-10 West, Suite 300 San Antonio, TX 78230 DD=11/09/1998

Orphan Product Designations and Approvals List
January 1998 through November 1998

Name Generic Name TN=Trade Name	Indication Designated	Sponsor & Address DD= Date Designated MA=Marketing Approval
P1, P4-Di(uridine 5'-tetraphosphate), tetrasodium salt TN=	Treatment of cystic fibrosis.	Inspire Pharmaceuticals, Inc. 4222 Emperor Blvd., Suite 470 Durham, NC 27703 DD=10/27/1998
PEGASYS TN=	Treatment of renal cell carcinoma.	Hoffman-La Roche Inc. 340 Kingsland St. Nutley, NJ 07110 DD=07/13/1998
Pentostatin TN=	Treatment of cutaneous T-cell lymphoma.	SuperGen, Inc. Two Annbel Lane, Suite 220 San Ramon, CA 94583 DD=03/27/1998
Phenylacetate TN=	For use as an adjunct to surgery, radiation therapy and chemotherapy for the treatment of patients with primary or recurrent malignant glioma.	Targon Corporation 307 College Road East Princeton, NJ 08540 DD=03/06/1998
Pilocarpine HCl TN= Salagen	Treatment of xerostomia and keratoconjunctivitis sicca in Sjogren's syndrome patients.	MGI Pharma, Inc. 9900 Bren Road East Suite 300E Minneapolis, MN 55343 DD=02/28/1992 MA=02/11/1998
Prostaglandin E1 enol ester (AS-013) TN=	Treatment of Fontaine Stage IV chronic critical limb ischemia.	Alpha Therapeutic Corp. 5555 Valley Blvd. Los Angeles, CA 90032 DD=06/12/1998
Radiolabeled monoclonal antibody to CD22 antigen on B-cells TN= LymphoCIDE	Treatment of non-Hodgkin's lymphoma.	Immunomedics, Inc. 300 American Rd. Morris Plains, NJ 07950 DD=07/13/1998

Orphan Product Designations and Approvals List
January 1998 through November 1998

Name Generic Name TN=Trade Name	Indication Designated	Sponsor & Address DD= Date Designated MA=Marketing Approval
Recombinant bactericidal/permeability-increasing protein TN= Neuprex	Treatment of severe meningococcal disease.	Xoma Corporation 2910 Seventh Street Berkeley, CA 94710 DD=06/22/1998
Recombinant human Clara Cell 10kDa protein TN=	Prevention of neonatal bronchopulmonary dysplasia in premature neonates with respiratory distress syndrome.	Claragen, Inc. 335 Paint Branch Drive College Park, MD 20742 DD=07/13/1998
Recombinant human tumor necrosis factor receptor fusion protein TN= Enbrel	Treatment of juvenile rheumatoid arthritis.	Immunex Corporation 51 University St. Seattle, WA 98101 DD=10/27/1998
Recombinant humanized MAb 5c8 TN=	Prevention and treatment of Factor VIII/Factor IX inhibitors in patients with hemophilia A or B.	Biogen, Inc. 14 Cambridge Center Cambridge, MA 02142 DD=10/14/1998
Recombinant humanized monclonal antibody 5c8 TN=	Treatment of immune thrombocytopenic purpura.	Biogen, Inc. 14 Cambridge Center Cambridge, MA 02142 DD=02/03/1998
Recombinant humanized monoclonal antibody 5c8 TN=	Treatment of systemic lupus erythematosus.	Biogen, Inc. 14 Cambridge Center Cambridge, MA 02142 DD=02/18/1998
Rifapentine TN= Priftin	Treatment of pulmonary tuberculosis.	Hoechst Marion Roussel P.O. Box 9627 Mail Station: H3-M2516 Kansas City, MO 64134 DD=06/09/1995 MA=06/22/1998

Orphan Product Designations and Approvals List
January 1998 through November 1998

Name Generic Name TN=Trade Name	Indication Designated	Sponsor & Address DD= Date Designated MA=Marketing Approval
Rifaximin TN= Normix	Treatment of hepatic encephalopathy.	Salix Pharmaceuticals, Inc. 3600 W. Bayshore Road Palo Alto, CA 94303 DD=02/10/1998
S-adenosylmethionine TN=	Treatment of AIDS-myelopathy.	Di Rocco, Alessandro M.D. Beth Israel Medical Center, Phillips Ambulatory Care Center Philips Building, Suite 2Q; 10 Union Square East New York, NY 10003 DD=04/30/1998
Sacrosidase TN= Sucraid	Treatment of congenital sucrase-isomaltase deficiency.	Orphan Medical, Inc. 13911 Ridgedale Drive Suite 475 Minnetonka, MN 55305 DD=12/10/1993 MA=04/09/1998
Sodium phenylbutyrate TN=	For use as an adjuct to surgery, radiation therapy and chemotherapy for the treatment of patients with primary or recurrent malignant glioma.	Targon Corporation 307 College Road East Princeton, NJ 08540 DD=04/24/1998
TAK-603 TN=	Treatment of Crohn's disease.	TAP Holdings Inc. 2355 Waukegan Road Deerfield, IL 60015 DD=05/13/1998
Tacrolimus TN= Prograf	Prophylaxis of graft-versus-host-disease.	Fujisawa USA, Inc. 3 Parkway North Center Deerfield, IL 60015 DD=04/06/1998

Orphan Product Designations and Approvals List
January 1998 through November 1998

Name Generic Name TN=Trade Name	Indication Designated	Sponsor & Address DD= Date Designated MA=Marketing Approval
Temozolomide TN= Temodal	Treatment of recurrent malignant glioma.	Shering-Plough Research Institute 2000 Galloping Hill Rd. Kenilworth, NJ 07033 DD=10/05/1998
Temozolomide TN= Temodal	Treatment of advanced metastatic melanoma.	Schering-Plough Research Institute 2000 Galloping Hill Rd. Kenilworth, NJ 07033 DD=10/14/1998
Tetrabenazine TN=	Treatment for moderate/severe tardive dyskinesia.	Lifehealth Limited Richmond House, Old Brewery Court, Sandyford Road Newcastle upon Tyne NE2 1XG England DD=05/12/1998
Thalidomide TN= Thalomid	Treatment of erythema nodosum leprosum.	Celgene Corporation P.O. Box 4914 7 Powder Horn Drive Warren, NJ 07059 DD=07/26/1995 MA=07/16/1998
Thalidomide TN=	Treatment of primary brain malignancies.	EntreMed, Inc. 9610 Medical Center Drive, Suite 200 Rockville, MD 20850 DD=02/27/1998
Thalidomide TN=	Treatment of Kaposi's sarcoma.	EntreMed, Inc. 9610 Medical Center Dr., Suite 200 Rockville, MD 20850 DD=07/29/1998
Thalidomide TN= Thalomid	Treatment of multiple myeloma.	Celgene Corporation 7 Powder Horn Dr. Warren, NJ 07059 DD=10/14/1998

Orphan Product Designations and Approvals List
January 1998 through November 1998

Name Generic Name TN=Trade Name	Indication Designated	Sponsor & Address DD= Date Designated MA=Marketing Approval
Thymalfasin TN= Zadaxin	Treatment of DiGeorge anomaly with immune defects.	SciClone Pharmaceuticals, Inc. 901 Mariner's Island Blvd. San Mateo, CA 94404 DD=01/08/1998
Tiapride TN=	Treatment of Tourette's syndrome.	Synthelabo Research, Inc. 400 Plaza Drive Secaucus, NJ 07094 DD=04/21/1998
Transgenic human alpha 1 antitrypsin TN=	Treatment of cystic fibrosis.	PPL Therapeutics (Scotland) Limited Roslin, Edinburgh EH25 9PP Scotland U.K., DD=03/06/1998
Valrubicin TN= Valstar	Treatment of carcinoma in situ of the urinary bladder.	Anthra Pharmaceuticals, Inc. 103 Carnegie Center, Suite 102 Princeton, NJ 08540 DD=05/23/1994 MA=09/25/1998
Xenogeneic hepatocytes TN= HepatAssist Liver Assist System	Treatment of severe liver failure.	Circe Biomedical, Inc. 99 Hayden Ave. Lexington, MA 02421 DD=11/27/1998

DRUG PRODUCTS WHICH MUST DEMONSTRATE *IN VIVO* BIOAVAILABILITY ONLY IF PRODUCT FAILS TO ACHIEVE ADEQUATE DISSOLUTION

NO NOVEMBER 1998 ADDITIONS

PATENT AND EXCLUSIVITY TERMS PATENT AND EXCLUSIVITY TERMS

DUE TO SPACE LIMITATIONS IN THE PATENT AND EXCLUSIVITY COLUMNS, ABBREVIATIONS AND REFERENCES HAVE BEEN DEVELOPED. PLEASE REFER BACK TO THE APPROVED DRUG PRODUCTS WITH THERAPEUTIC EQUIVALENCE EVALUATIONS, 18TH EDITION FOR A FULL LISTING OF PATENT AND EXCLUSIVITY TERMS (ABBREVIATIONS, NEW DOSING SCHEDULE, NEW INDICATIONS AND PATENT USE CODES). ONLY NEW CODES WILL BE ADDED TO THE CUMULATIVE SUPPLEMENT.

ABBREVIATIONS

PED	PEDIATRIC EXCLUSIVITY

REFERENCES

NEW DOSING *SCHEDULE*

D-38	CONTINUOUS INFUSION AS AN ALTERNATE METHOD OF ADMINISTRATION
D-39	CHANGE IN TIME TO TAKE THE DRUG PRIOR TO A MEAL TO PREVENT MEAL-INDUCED HEARTBURN SYMPTOMS FROM " ...1/2-1 HOUR BEFORE EATING..." TO "...RIGHT BEFORE EATING OR UP TO 60 MIN BEFORE CONSUMING..."
D-40	ONCE-A-DAY DOSING REGIMEN
D-41	DRUG MAY BE DOSED RIGHT BEFORE A MEAL OR ANY TIME UP TO 30 MIN BEFORE EATING OR DRINKING FOOD AND BEVERAGES THAT WOULD BE EXPECTED TO CAUSE SYMPTOMS
D-42	TEN DAY DOSING REGIMEN FOR TRIPLE THERAPY, PREVACID IN COMBINATION WITH CLARITHROMYCIN AND AMOXICCLIN, FOR THE ERADICATION OF H. PYLORI IN PATIENTS WITH DUODENAL ULCER DISEASE
D-43	INITIATION OF TREATMENT WITH 900MG/DAY BY DELETION OF THE REQUIREMENT TO TITRATE TO 900MG/DAY OVER A 3-DAY PERIOD
D-44	IN A CLINICAL TRIAL, FEWER DISCONTINUATIONS DUE TO ADVERSE EVENTS, ESPECIALLY DIZZINESS AND VERTIGO, WERE OBSERVED WHEN TITRATING THE DOSE IN INCREMENTS OF 50MG/DAY EVERY THREE DAYS UNTIL AN EFFECTIVE DOSE (NOT EXCEEDING 400MG/DAY) WAS REACHED
D-45	ONCE DAILY DOSING FOR MAINTENANCE ONLY
D-46	NEW DOSING REGIMEN OF 80MG DAILY
D-47	TAKE DRUG "15 MINUTES TO 1 HOUR" PRIOR TO A MEAL TO PREVENT MEAL-INDUCED HEARTBURN
D-48	ADMINISTRATION OF CISATRICURIUM, A NEUROMUSCULAR BLOCKING AGENT AT DOSES OF 3 AND 4X THE ED95 OF CISATRICUNIUM FOLLOWING INDUCTION WITH THIOPENTAL
D-49	PEDIATRIC DOSING GUIDELINES

NEW INDICATION

I-212	TREATMENT OF SYMPTOMS OF DRY MOUTH IN PATIENTS WITH SJOGREN'S SYNDROME
I-213	TEMPORARY RELIEF OF PAIN AND PHOTOPHOBIA IN PATIENTS UNDERGOING CORNEAL REFRACTIVE SURGERY
I-214	TREATMENT OF OSTEOPOROSIS
I-215	PRE-PROCEDURAL APPLICATION TO ADULT MALE GENITAL SKIN PRIOR TO SITE-SPECIFIC SUBCUTANEOUS INFILTRATION WITH LIDOCAINE FOR THE REMOVAL OF GENITAL WARTS
I-216	FOR THE LONG-TERM TWICE-DAILY (MORNING AND EVENING) ADMINISTRATION IN THE MAINTENANCE TREATMENT OF BRONCHOSPASM ASSOCIATED WITH COPD, INCLUDING CHRONIC BRONCHITIS AND EMPHYSEMA
I-217	PREVENTION (DURING AND FOLLOWING HOSPITALIZATION) OF DEEP VEIN THROMBOSIS, WHICH MAY LEAD TO PULMONARY EMBOLISM, IN PATIENTS UNDERGOING HIP REPLACEMENT SURGERY
I-218	USE OF LIPITOR AS AN ADJUNCTIVE THERAPY TO DIET FOR THE TREATMENT OF PATIENTS WITH ELEVATED SERUM TRIGLYCERIDE LEVELS (FREDERICKSON TYPE IV)

PATENT AND EXCLUSIVITY TERMS

NEW INDICATION

I-219	USE OF LIPITOR BY PATIENTS WITH PRIMARY DYSBETALIPOPROTEINEMIA (FREDERICKSON TYPE III) WHO DO NOT RESPOND ADEQUATELY TO DIET
I-220	TREATMENT OF EPISODIC HEARTBURN, ACID INDIGESTION AND SOUR STOMACH
I-221	TREATMENT OF BENIGN PROSTATIC HYPERPLASIA (BPH) IN MEN WITH AN ENLARGED PROSTATE TO IMPROVE SYMPTOMS, REDUCE THE RISK OF ACUTE URINARY RETENTION AND REDUCE THE RISK OF THE NEED OF SURGERY
I-222	PREVENTION OF ISCHEMIC COMPLICATIONS OF UNSTABLE ANGINA AND NON-Q-WAVE MYOCARDIAL INFARCTION, WHEN CONCURRENTLY ADMINISTERED WITH ASPIRIN
I-223	USE IN THE SYMPTOMATIC RELIEF OF RHINORRHEA ASSOICATED WITH ALLERGIC AND NONALLERGIC PERENNIAL RHINITIS IN CHILDREN AGE 6-11 YEARS
I-224	FOR THE USE IN PEDIATRIC PATIENTS 4 TO 11 YEARS OF AGE FOR THE MANAGEMENT OF THE NASAL SYMPTOMS OF SEASONAL AND PERENNIAL ALLERGIC RHINITIS
I-225	USE IN PATIENTS WITH PREVIOUS MI AND NORMAL CHOLESTEROL LEVELS, TO REDUCE RISK OF RECURRENT MI, MYOCARDIAL REVASCULARIZATION, AND CEREBROVASCULAR DISEASE EVENTS
I-226	FIRST-LINE THERAPY FOR THE TREATMENT OF ADVANCED CARCINOMA OF THE OVARY IN COMBINATION WITH CISPLATIN
I-227	SHORT-TERM TREATMENT OF SYMPTOMATIC GASTROESOPHAGEAL REFLUX DISEASE (GERD)
I-228	PREVENTION OF MEAL INDUCED HEARTBURN AT A DOSE OF 75MG TAKEN 30-60 MIN PRIOR TO A MEAL
I-229	PRILOSEC (OMEPRAZOLE), AMOXICILLIN AND CLARITHROMYCIN FOR THE ERADICATION OF H. PYLORI IN PATIENTS WITH DUODENAL ULCER DISEASE
I-230	IN COMBINATION WITH CISPLATIN, FOR THE FIRST-LINE TREATMENT OF NON-SMALL CELL LUNG CANCER IN PATIENTS WHO ARE NOT CANDIDATES FOR POTENTIALLY CURATIVE SURGERY AND/OR RADIATION
I-231	TREATMENT OF PATIENTS WITH LOCALLY ADVANCED OR METASTATIC BREAST CANCER AFTER FAILURE OF PRIOR CHEMOTHERAPY
I-232	TREATMENT OF RECURRENT MUCOCUTANEOUS HERPES SIMPLEX INFECTIONS IN HIV-AFFECTED PATIENTS AT A DOSE OF 500MG TWICE DAILY
I-233	PROPHYLACTIC USE TO REDUCE PERIOPERATIVE BLOOD LOSS AND THE NEED FOR BLOOD TRANSFUSION IN PATIENTS UNDERGOING CARDIOPULMONARY BYPASS IN THE COURSE OF CORONARY ARTERY BYPASS GRAFT SURGERY
I-234	FOR USE IN COMBINATION WITH CISPLATIN FOR THE FIRST-LINE TREATMENT OF PATIENTS WITH INOPERABLE LOCALLY ADVANCED (STAGE IIIA OR IIIB) OR METASTATIC (STAGE IV) NON-SMALL CELL LUNG CANCER
I-235	PREVENTION OF EXERCISE-INDUCED BRONCHOSPASM IN PATIENTS 12 YEARS OF AGE AND OLDER
I-236	PREVENTION OF EXERCISE-INDUCED BRONCHOSPASM IN PATIENTS 4 YEARS OF AGE AND OLDER
I-237	MAINTENANCE TREATMENT OF ASTHMA AND PREVENTION OF BRONCHOSPASM IN PATIENTS 4 YEARS OF AGE AND OLDER
I-238	ADJUNCTIVE TREATMENT OF LENNOX-GASTAUT SYNDROME IN PEDIATRIC AND ADULT PATIENTS
I-239	TREATMENT OF PATIENTS WITH HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA
I-240	MANAGEMENT OF SECONDARY HYPERPARATHYROIDISM AND RESULTANT METABOLIC BONE DISEASE IN PATIENTS WITH MODERATE TO SEVERE CHRONIC RENAL FAILURE (Ccr 15 TO 55ML MIN) NOT YET ON DIALYSIS
I-241	USE IN PHOTODYNAMIC THERAPY (PDT) FOR REDUCTION OF OBSTRUCTION AND PALLIATION OF SYMPTOMS IN PATIENTS WITH COMPLETELY OR PARTIALLY OBSTRUCTING ENDOBRONCHIAL NONSMALL CELL LUNG CANCER
I-242	TREATMENT OF MODERATE TO SEVERE VASOMOTOR SYMPTOMS ASSOCIATED WITH THE MENOPAUSE AND IN THE TREATMENT OF VULVAR AND VAGINAL ATROPHY IN WOMEN WITH AN INTACT UTERUS
I-243	USE IN THE SYMPTOMATIC RELIEF OF RHINORRHEA ASSOCIATED WITH THE COMMON COLD IN CHILDREN AGE 5 TO 11 YEARS
I-244	REDUCE THE INCIDENCE OF BREAST CANCER IN WOMEN AT HIGH RISK FOR BREAST CANCER
I-245	TREATMENT OF ACUTE SINUSITIS
I-246	TREATMENT OF UNCOMPLICATED URINARY TRACT INFECTIONS
I-247	USE IN CONVERSION TO MONOTHERAPY IN ADULTS WITH PARTIAL SEIZURES WHO ARE RECEIVING TREATMENT WITH A SINGLE ENZYME-INDUCING ANTIEPILEPTIC DRUG

PATENT AND EXCLUSIVITY TERMS

NEW INDICATION

I-248	INPATIENT TREATMENT OF ACUTE DEEP VEIN THROMBOSIS WITH/WITHOUT PULMONARY EMBOLISM WHEN ADMIN IN CONJUNCTION WITH WARFARIN SODIUM AND OUTPATIENT TREATMENT OF ACUTE DEEP VEIN THROMBOSIS WITHOUT PULMONARY EMBOLISM WHEN ADMINISTERED IN CONJUNCITON WITH WARFARIN SODIUM
I-249	TREATMENT OF CHRONIC HEPATITIS C IN PATIENTS WITH COMPENSATED LIVER DISEASE PREVIOUSLY UNTREATED WITH ALPHA INTERFERON THERAPY

PATENT USE CODE

U-215	TREATMENT OF EPILEPSY TWICE DAILY, TREATING A PATIENT BY ADMINISTERING CARBAMAZEPINE IN A DOSAGE FORM CAPABLE OF MAINTAINING BLOOD CONCENTRATION FROM 4-12MCG/ML OVER 12 HOURS
U-216	TREATMENT OF ADENOCARCINOMA, INCLUDING STAGE B2-C, BY ADMINISTERING AN AGONIST OF LR-RH AND FLUTAMIDE
U-217	METHOD OF PRODUCING ANESTHESIA
U-218	METHOD FOR LIMITING THE POTENTIAL FOR MICROBIAL GROWTH IN THE DRUG PRODUCT
U-219	TREATMENT OF PARKISON'S DISEASE
U-220	METHOD OF DIAGNOSIS
U-221	SELECTIVE VASODILATION BY CONTINUOUS ADENOSINE INFUSION
U-222	METHOD OF TREATING PAGETS DISEASE USING ACTONEL
U-223	TREATMENT OF BACTERIAL CONJUNCTIVITIS CAUSED BY SUSCEPTIBLE STRAINS OF MICROORGANISMS
U-224	CONTROLLING INTRAOCULAR PRESSURE
U-225	METHOD FOR DELIVERY
U-226	METHOD OF ENHANCING THE DISSOLUTION PROFILE OF A PHARMACEUTICAL FROM A SOLID DOSAGE FORM CONTAINING THE PHARMACEUTICAL AND SIMETHICONE
U-227	NASAL ADMINISTRATION
U-228	ASTHMA
U-229	CARDIAC INSUFFICIENCY (CONGESTIVE HEART FAILURE)
U-230	PREVENTION OF ACUTE CARDIAC ISCHEMIC EVENTS
U-231	USE IN PARKINSON'S DISEASE
U-232	METHOD OF TREATING MIGRAINE
U-233	DECREASING MORTALITY CAUSED BY CONGESTIVE HEART FAILURE
U-234	METHOD OF USING RIBAVIRIN TO TREAT VIRAL INFECTIONS IN MAMMALS
U-235	METHOD OF MODULATING TH1 AND TH2 RESPONSE IN ACTIVATED T CELLS OF A HUMAN COMPRISING ADMINISTERING RIBAVIRIN TO THE T CELLS IN A DOSAGE WHICH PROMOTES THE TH1 RESPONSE AND SUPPRESSES THE TH2 RESPONSE
U-236	TREATING MALE PATTERN BALDNESS WITH 0.05 TO 3 MG/DAY
U-237	METHOD OF PERFORMING NMR IMAGING WITH A PATIENT COMPRISING ADMINISTERING TO THE PATIENT AN EFFECTIVE AMOUNT OF CONTRAST AGENT DISCLOSED IN THE CLAIMS
U-238	IMAGING A BODY TISSUE AND SUBJECTING TO NMR TOMOGRAPHY, ADMINISTERING AN AMOUNT OF PHARMACEUTICAL AGENT FOR AFFECTING THE RELAXATION TIMES OF ATOMS IN BODY TISSUES UNDERGOING NMR DIAGNOSIS, WHEREBY THE IMAGE CONTRAST IN ENHANCED....
U-239	TREATING OR CONTROLLING OCULAR INFLAMMATION WHICH COMPRISES TOPICALLY ADMINISTERING TO THE AFFECTED EYE A COMPOSITION COMPRISING A NSAID, A POLYMERIC QUATERNARY AMMONIUM COMPOUND AND BORIC ACID
U-240	TREATMENT OF ACUTE MIGRAINE ATTACKS

PATENT AND EXCLUSIVITY TERMS

PATENT USE CODE

U-241	FOR SHORT-TERM TREATMENT ACTIVE DUODENAL ULCER, MAINTENANCE THERAPY FOR DUODENAL ULCER PATIENTS AT REDUCED DOSAGE AFTER HEALING OF ACTIVE ULCER, SHORT-TERM TREATMENT ACTIVE BENIGN GASTRIC ULCER & GERD, PATHOLOGICAL HYPERSECRETORY CONDITIONS
U-242	USE OF FOLLITROPIN ALPHA ALONE IN IN-VITRO FERTILIZATION
U-243	TOPICAL ADMINISTRATION
U-244	PLATELET AGGREGATION INHIBITORS
U-245	TREATMENT OF SEBORRHEA DERMATITIS IN HUMANS
U-246	PHOSPHATE BINDING
U-247	TREATMENT OF RHEUMATOID ARTHRITIS
U-248	TREATMENT OF HIV
U-249	METHOD OF TREATING ALLERGIC OR NON-ALLERGIC RHINITIS IN PATIENTS BY ADMINISTERING AEROSOLIZED PARTICLES OF MOMETASONE FUROATE

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
*PED and PED represent Pediatric Exclusivity

	APPL/PROD NUMBER		INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
>ADD>	020977	001	ABACAVIR SUCCINATE;ZIAGEN	5089500	JUN 26, 2009	U-248	PED	JUN 17, 2004
>ADD>				5089500*PED	DEC 26, 2009	U-248	NCE	DEC 17, 2003
>ADD>				5034394	JUN 26, 2009			
>ADD>				5034394*PED	DEC 26, 2009			
>ADD>	020978	001	ABACAVIR SULFATE;ZIAGEN	5089500	JUN 26, 2009	U-248	PED	JUN 17, 2004
>ADD>				5089500*PED	DEC 26, 2009	U-248	NCE	DEC 17, 2003
>ADD>				5034394	JUN 26, 2009			
>ADD>				5034394*PED	DEC 26, 2009			
	020482	004	ACARBOSE;PRECOSE	4904769	FEB 27, 2007		NCE	SEP 06, 2000
	020802	001	ACETAMINOPHEN;EXCEDRIN (MIGRAINE)				NP	JAN 14, 2001
	020059	001	ADENOSINE;ADENOSCAN	5070877	DEC 10, 2008	U-116		
				5731296	MAR 24, 2015	U-221		
	020503	001	ALBUTEROL SULFATE;PROVENTIL-HFA	5766573	JUN 16, 2015		I-235	SEP 23, 2001
	020560	001	ALENDRONATE SODIUM;FOSAMAX	5804570	FEB 17, 2015			
	020560	002	ALENDRONATE SODIUM;FOSAMAX	5804570	FEB 17, 2015			
	020560	003	ALENDRONATE SODIUM;FOSAMAX	5804570	FEB 17, 2015			
	020511	001	ALEXANOX;APHTHASOL	5362737	NOV 08, 2011	U-243		
	019787	001	AMLODIPINE BESYLATE;NORVASC	4572909	JUL 31, 2006			
	019787	002	AMLODIPINE BESYLATE;NORVASC	4572909	JUL 31, 2006			
	019787	003	AMLODIPINE BESYLATE;NORVASC	4572909	JUL 31, 2006			
>ADD>	050740	001	AMPHOTERICIN B;AMBISOME				ODE	AUG 11, 2004
	020304	001	APROTININ BOVINE;TRASYLOL				I-233	AUG 28, 2001
	020420	001	ARBUTAMINE HYDROCHLORIDE;GENESA	5108363	APR 28, 2009	U-220		
				5234404	AUG 10, 2010	U-220		
				5395970	MAR 07, 2012			
	020702	001	ATORVASTATIN CALCIUM;LIPITOR	4681893	SEP 24, 2009	U-161	I-218	JUL 10, 2001
							I-219	JUL 10, 2001
	020702	002	ATORVASTATIN CALCIUM;LIPITOR	4681893	SEP 24, 2009	U-161	I-218	JUL 10, 2001
							I-219	JUL 10, 2001
	020702	003	ATORVASTATIN CALCIUM;LIPITOR	4681893	SEP 24, 2009	U-161	I-218	JUL 10, 2001
							I-219	JUL 10, 2001
	020114	001	AZELASTINE HYDROCHLORIDE;ASTELIN	5164194	OCT 16, 2011	U-207		
	018521	001	BECLOMETHASONE DIPROPIONATE;VANCENASE	4364923	DEC 21, 1999			
	017573	001	BECLOMETHASONE DIPROPIONATE;VANCERIL	4364923	DEC 21, 1999			
	020486	001	BECLOMETHASONE DIPROPIONATE;VANCERIL DOUBLE STRENGTH	4364923	DEC 21, 1999			
	019408	001	BETAMETHASONE DIPROPIONATE;DIPROLENE	4489070	MAY 13, 2003			
	020816	001	BRINZOLAMIDE;AZOPT	5240923	AUG 31, 2010	U-224	NCE	APR 01, 2003
				5378703	AUG 31, 2010	U-224		
				5461081	OCT 24, 2012	U-225		
	020441	002	BUDESONIDE;PULMICORT				D-45	OCT 08, 2001
	020358	001	BUPROPION HYDROCHLORIDE;WELLBUTRIN	5763493	AUG 12, 2013			
				5731000	AUG 12, 2013			
	020358	002	BUPROPION HYDROCHLORIDE;WELLBUTRIN	5763493	AUG 12, 2013			
				5731000	AUG 12, 2013			
	020358	003	BUPROPION HYDROCHLORIDE;WELLBUTRIN	5731000	AUG 12, 2013			
				5763493	AUG 12, 2013			
	020711	002	BUPROPION HYDROCHLORIDE;ZYBAN	5731000	AUG 12, 2013			
	020711	003	BUPROPION HYDROCHLORIDE;ZYBAN	5731000	AUG 12, 2013			

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
*PED and PED represent Pediatric Exclusivity

	APPL/PROD NUMBER		INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
	020524	001	BUTENAFINE HYDROCHLORIDE;MENTAX	5021458	OCT 18, 2010	U-177		
	020554	001	CALCIPOTRIENE;DOVONEX	4866048	DEC 29, 2007			
	020611	001	CALCIPOTRIENE;DOVONEX	4866048	DEC 29, 2007			
	020313	002	CALCITONIN, SALMON;MIACALCIN	5733569	MAR 31, 2015	U-227		
	018044	001	CALCITRIOL;ROCALTROL				I-240	NOV 20, 2001
	021068	001	CALCITRIOL;ROCALTROL				NDF	NOV 20, 2001
							I-240	NOV 20, 2001
	020521	001	CALFACTANT;INFASURF PRESERVATIVE FREE				NCE	JUL 01, 2003
	020838	001	CANDESARTAN CILEXETIL;ATACAND	5196444	APR 18, 2011	U-3	NCE	JUN 04, 2003
				5534534	JUL 09, 2013			
				5703110	APR 18, 2011			
				5705517	APR 18, 2011			
	020838	002	CANDESARTAN CILEXETIL;ATACAND	5196444	APR 18, 2011	U-3	NCE	JUN 04, 2003
				5534534	JUL 09, 2013			
				5703110	APR 18, 2011			
				5705517	APR 18, 2011			
	020838	003	CANDESARTAN CILEXETIL;ATACAND	5196444	APR 18, 2011	U-3	NCE	JUN 04, 2003
				5534534	JUL 09, 2013			
				5703110	APR 18, 2011			
				5705517	APR 18, 2011			
	020838	004	CANDESARTAN CILEXETIL;ATACAND	5196444	APR 18, 2011	U-3	NCE	JUN 04, 2003
				5534534	JUL 09, 2013			
				5703110	APR 18, 2011			
				5705517	APR 18, 2011			
	020896	001	CAPECITABINE;XELODA				NCE	APR 30, 2003
	020896	002	CAPECITABINE;XELODA				NCE	APR 30, 2003
	020712	001	CARBAMAZEPINE;CARBATROL	5326570	JUL 05, 2011	U-215		
	020712	002	CARBAMAZEPINE;CARBATROL	5326570	JUL 05, 2011	U-215		
	019972	001	CARTEOLOL HYDROCHLORIDE;OCUPRESS	4309432	JAN 02, 2000			
	020297	001	CARVEDILOL;COREG	4503067	MAR 05, 2007	U-3		
				5760069	JUN 07, 2015	U-233		
	020297	002	CARVEDILOL;COREG	4503067	MAR 05, 2007	U-3		
				5760069	JUN 07, 2015	U-233		
	020297	003	CARVEDILOL;COREG	4503067	MAR 05, 2007	U-3		
				5760069	JUN 07, 2015	U-233		
	020297	004	CARVEDILOL;COREG	4503067	MAR 05, 2007	U-3		
				5760069	JUN 07, 2015	U-233		
>ADD>	020998	001	CELECOXIB;CELEBREX				NCE	DEC 31, 2003
>ADD>	020998	002	CELECOXIB;CELEBREX				NCE	DEC 31, 2003
	020774	001	CHLORHEXIDINE GLUCONATE;PERIOCHIP				NP	MAY 15, 2001
	020238	002	CIMETIDINE;TAGAMET HB				D-41	JUN 05, 2001
	020369	001	CIPROFLOXACIN HYDROCHLORIDE;CILOXAN	4670444	JUN 02, 2004	U-223	NDF	MAR 30, 2001
	020805	001	CIPROFLOXACIN HYDROCHLORIDE;CIPRO HC	4670444	DEC 09, 2003		NC	FEB 10, 2001
				4844902	FEB 11, 2008			
	019847	001	CIPROFLOXACIN;CIPRO				I-164	SEP 11, 1999
							I-245	JUN 03, 2000
	020780	001	CIPROFLOXACIN;CIPRO	4670444	DEC 09, 2003			
	020780	002	CIPROFLOXACIN;CIPRO	4670444	DEC 09, 2003			
	019857	001	CIPROFLOXACIN;CIPRO IN DEXTROSE 5%				I-164	SEP 11, 1999
							I-245	JUN 03, 2000

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
*PED and PED represent Pediatric Exclusivity

	APPL/PROD NUMBER		INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
	019858	001	CIPROFLOXACIN;CIPRO IN SODIUM CHLORIDE 0.9%				I-164	SEP 11, 1999
							I-245	JUN 03, 2000
	020551	001	CISATRACURI				D-48	OCT 15, 2001
	020551	002	CISATRACURI [redacted] PRESERVATIVE FREE				D-48	OCT 15, 2001
	020551	003	CISATRACURI [redacted] PRESERVATIVE FREE				D-48	OCT 15, 2001
	020822	002	CITALOPRAM [redacted]				NCE	JUL 17, 2003
	020822	003	CITALOPRAM [redacted]				NCE	JUL 17, 2003
	020822	004	CITALOPRAM [redacted]				NCE	JUL 17, 2003
	020839	001	CLOPIDOGREL [redacted]	4529596	JUL 05, 2003			
				4847265	FEB 12, 2008			
				5576328	JAN 31, 2014			
>ADD>	020574	001	CLOTRIMAZOLE;GYNE-LOTRIMIN 3				NP	NOV 24, 2001
	017922	001	DESMOPRESSIN ACETATE;DDAVP	5763407	DEC 23, 2013			
	017922	002	DESMOPRESSIN ACETATE;DDAVP	5763407	DEC 23, 2013			
	017922	003	DESMOPRESSIN ACETATE;DDAVP	5763407	DEC 23, 2013			
	018938	001	DESMOPRESSIN ACETATE;DDAVP	5763407	DEC 23, 2013			
	018938	002	DESMOPRESSIN ACETATE;DDAVP	5763407	DEC 23, 2013			
	019955	001	DESMOPRESSIN ACETATE;DDAVP	5763407	DEC 23, 2013		I-40	MAR 25, 2001
	019955	002	DESMOPRESSIN ACETATE;DDAVP	5763407	DEC 23, 2013		I-40	MAR 25, 2001
	020713	001	DESOGESTREL;MIRCETTE				NP	APR 22, 2001
	020344	001	DEXFENFLURAMINE HYDROCHLORIDE;REDUX	4309445	FEB 19, 2004	U-133		
	020809	001	DICLOFENAC SODIUM;DICLOFENAC SODIUM	5603929	NOV 16, 2014	U-239		
				5653972	NOV 16, 2014	U-239		
	020037	001	DICLOFENAC SODIUM;VOLTAREN				I-213	FEB 25, 2001
	020148	001	DIHYDROERGOTAMINE MESYLATE;MIGRANAL	4758423	JUL 31, 2001			
				4462983	JUL 31, 2001	U-227		
				5169849	DEC 08, 2009			
						U-227		
	020401	001	DILTIAZEM HYDROCHLORIDE;TIAZAC				I-133	JAN 30, 2001
	020401	002	DILTIAZEM HYDROCHLORIDE;TIAZAC				I-133	JAN 30, 2001
	020401	003	DILTIAZEM HYDROCHLORIDE;TIAZAC				I-133	JAN 30, 2001
	020401	004	DILTIAZEM HYDROCHLORIDE;TIAZAC				I-133	JAN 30, 2001
	020401	005	DILTIAZEM HYDROCHLORIDE;TIAZAC				I-133	JAN 30, 2001
	020449	001	DOCETAXEL;TAXOTERE				I-231	JUN 22, 2001
	020690	001	DONEPEZIL HYDROCHLORIDE;ARICEPT	4895841	NOV 25, 2010			
	020690	002	DONEPEZIL HYDROCHLORIDE;ARICEPT	4895841	NOV 25, 2010			
	020869	001	DORZOLAMIDE HYDROCHLORIDE;COSOPT				NC	APR 07, 2001
	020972	001	EFAVIRENZ;SUSTIVA				NCE	SEP 17, 2003
	020972	002	EFAVIRENZ;SUSTIVA				NCE	SEP 17, 2003
	020972	003	EFAVIRENZ;SUSTIVA				NCE	SEP 17, 2003
>ADD>	020164	001	ENOXAPARIN SODIUM;LOVENOX				I-248	DEC 31, 2001
							I-217	JAN 30, 2001
							I-222	MAR 27, 2001
>ADD>	020164	002	ENOXAPARIN SODIUM;LOVENOX				I-248	DEC 31, 2001
							I-222	MAR 27, 2001
							I-217	JAN 30, 2001
>ADD>	020164	003	ENOXAPARIN SODIUM;LOVENOX				I-248	DEC 31, 2001
>ADD>	020164	004	ENOXAPARIN SODIUM;LOVENOX				I-248	DEC 31, 2001
>ADD>	020164	005	ENOXAPARIN SODIUM;LOVENOX				I-248	DEC 31, 2001

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
*PED and PED represent Pediatric Exclusivity

	APPL/PROD NUMBER		INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
	020738	004	EPROSARTAN MESYLATE;TEVETEN	5185351	FEB 09, 2010	U-3	D-40	OCT 28, 2001
	020738	005	EPROSARTAN MESYLATE;TEVETEN	5185351	FEB 09, 2010	U-3	D-40	OCT 28, 2001
	020718	001	EPTIFIBATIDE;INTEGRILIN	5756451	NOV 11, 2014		NCE	MAY 18, 2003
				5686570	NOV 11, 2014			
				5807825	SEP 15, 2015	U-244		
	020718	002	EPTIFIBATIDE;INTEGRILIN	5756451	NOV 11, 2014		NCE	MAY 18, 2003
				5686570	NOV 11, 2014			
				5807825	SEP 15, 2015	U-244		
	020907	001	ESTRADIOL;ACTIVELLE				NC	NOV 18, 2001
							I-242	NOV 18, 2001
	020375	003	ESTRADIOL;CLIMARA	5223261	JUN 29, 2010			
	020870	001	ESTRADIOL;COMBIPATCH				NP	AUG 07, 2001
	020870	002	ESTRADIOL;COMBIPATCH				NP	AUG 07, 2001
>ADD>	020847	001	ESTRADIOL;ESCLIM	4842864	MAR 25, 2008			
>ADD>	020847	002	ESTRADIOL;ESCLIM	4842864	MAR 25, 2008			
>ADD>	020847	003	ESTRADIOL;ESCLIM	4842864	MAR 25, 2008			
>ADD>	020847	004	ESTRADIOL;ESCLIM	4842864	MAR 25, 2008			
>ADD>	020847	005	ESTRADIOL;ESCLIM	4842864	MAR 25, 2008			
	020527	002	ESTROGENS, CONJUGATED;PREMPHASE 14/14	5547948	JAN 17, 2015			
	020527	001	ESTROGENS, CONJUGATED;PREMPRO 14/14	5547948	JAN 17, 2015			
	083209	001	ESTROGENS, ESTERIFIED;ESTRATAB				I-214	MAR 10, 2001
	086715	001	ESTROGENS, ESTERIFIED;ESTRATAB				I-214	MAR 10, 2001
	020363	001	FAMCICLOVIR;FAMVIR				NCE	JUN 29, 1999
							I-232	JUN 12, 2001
	020363	002	FAMCICLOVIR;FAMVIR				I-232	JUN 12, 2001
	020363	003	FAMCICLOVIR;FAMVIR				I-232	JUN 12, 2001
	020325	001	FAMOTIDINE;PEPCID AC				D-47	NOV 09, 2001
	019510	004	FAMOTIDINE;PEPCID PRESERVATIVE FREE	4283408	OCT 15, 2000			
	020752	001	FAMOTIDINE;PEPCID RPD	4283408	OCT 15, 2000			
				4305502	DEC 15, 1998			
				4371516	JAN 31, 2000	U-241		
	020752	002	FAMOTIDINE;PEPCID RPD	4283408	OCT 15, 2000			
				4305502	DEC 15, 1998			
				4371516	JAN 31, 2000	U-241		
	020625	001	FEXOFENADINE HYDROCHLORIDE;ALLEGRA	4254129	FEB 18, 2001	U-139		
	020786	001	FEXOFENADINE HYDROCHLORIDE;ALLEGRA-D	4254129	FEB 18, 2001		NCE	JUL 25, 2001
				5375693	AUG 03, 2012			
				5578610	NOV 26, 2013			
	020788	001	FINASTERIDE;PROPECIA	5547957	OCT 15, 2013	U-236		
	020180	001	FINASTERIDE;PROSCAR				I-221	MAR 20, 2001
	018830	001	FLECAINIDE ACETATE;TAMBOCOR	4642384	FEB 10, 2004			
	018830	002	FLECAINIDE ACETATE;TAMBOCOR	4642384	FEB 10, 2004			
	018830	003	FLECAINIDE ACETATE;TAMBOCOR	4642384	FEB 10, 2004			
	018830	004	FLECAINIDE ACETATE;TAMBOCOR	4642384	FEB 10, 2004			
	018554	001	FLUTAMIDE;EULEXIN	4472382	SEP 18, 2001	U-24		
				5712251	SEP 18, 2001	U-216		
	020121	001	FLUTICASONE PROPIONATE;FLONASE				I-224	OCT 31, 2000
	020378	001	FOLLITROPIN ALFA/BETA;GONAL-F	4589402	JUL 26, 2004	U-242		
				5767251	JUN 16, 2015			

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
*PED and PED represent Pediatric Exclusivity

	APPL/PROD NUMBER		INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
	020378	002	FOLLITROPIN ALFA/BETA;GONAL-F	4589402	JUL 26, 2004	U-242		
				5767251	JUN 16, 2015			
	020961	001	FOMIVIRSEN SODIUM;VITRAVENE PRESERVATIVE FREE				NCE	AUG 26, 2003
	020450	001	FOSPHENYTOIN SODIUM;CEREBYX	4260769	APR 07, 2003			
	020235	001	GABAPENTIN;NEURONTIN				D-43	SEP 29, 2001
	020235	002	GABAPENTIN;NEURONTIN				D-43	SEP 29, 2001
	020235	003	GABAPENTIN;NEURONTIN				D-43	SEP 29, 2001
	020882	001	GABAPENTIN;NEURONTIN	4087544	JAN 16, 2000			
				4894476	MAY 02, 2008			
				5084479	JAN 02, 2010			
	020882	002	GABAPENTIN;NEURONTIN	4087544	JAN 16, 2000			
				4894476	MAY 02, 2008			
				5084479	JAN 02, 2010			
	019596	001	GADOPENTETATE DIMEGLUMINE;MAGNEVIST	5560903	OCT 01, 2013			
	020460	001	GANCICLOVIR;CYTOVENE	4423050	MAY 21, 2001	U-64		
				4642346	JUN 24, 2005			
				4507305	MAY 12, 2001	U-64		
	020509	001	GEMCITABINE HYDROCHLORIDE;GEMZAR				I-234	AUG 26, 2001
	020509	002	GEMCITABINE HYDROCHLORIDE;GEMZAR				I-234	AUG 26, 2001
	020695	001	GREPAFLOXACIN HYDROCHLORIDE;RAXAR	5563138	OCT 08, 2013			
	020818	001	HYDROCHLOROTHIAZIDE;DIOVAN HCT	5399578	MAR 21, 2012	U-3	NCE	DEC 23, 2001
							NC	MAR 06, 2001
	020818	002	HYDROCHLOROTHIAZIDE;DIOVAN HCT	5399578	MAR 21, 2012	U-3	NCE	DEC 23, 2001
							NC	MAR 06, 2001
	020716	001	HYDROCODONE BITARTRATE;VICOPROFEN	4587252	DEC 18, 2004	U-55		
	016295	002	HYDROXYUREA;DROXIA				ODE	FEB 25, 2005
	016295	003	HYDROXYUREA;DROXIA				ODE	FEB 25, 2005
	016295	004	HYDROXYUREA;DROXIA				ODE	FEB 25, 2005
	019771	001	IBUPROFEN;ADVIL COLD AND SINUS	4552899	NOV 12, 2002			
				4552899*PED	MAY 12, 2003			
	019833	002	IBUPROFEN;CHILDREN'S ADVIL	4788220	NOV 29, 2005			
				4788220*PED	MAY 29, 2006			
	020589	001	IBUPROFEN;CHILDREN'S ADVIL	4788220	JUL 08, 2007		NP	JUN 16, 1998
				4788220*PED	JAN 08, 2008		PED	DEC 16, 1998
>ADD>	020944	001	IBUPROFEN;CHILDREN'S ADVIL				NP	NOV 15, 1999
	020516	001	IBUPROFEN;CHILDREN'S MOTRIN	5374659	DEC 20, 2011		NP	JUN 16, 1998
				5374659*PED	JUN 20, 2012		PED	DEC 16, 1998
	020601	001	IBUPROFEN;CHILDREN'S MOTRIN	5215755	JUN 01, 2010		NP	NOV 15, 1999
				5215755*PED	DEC 01, 2010		PED	MAY 15, 2000
	020603	001	IBUPROFEN;CHILDREN'S MOTRIN	5374659	DEC 20, 2011		NP	JUN 16, 1998
				5374659*PED	JUN 20, 2012		PED	DEC 16, 1998
	020267	002	IBUPROFEN;JUNIOR STRENGTH ADVIL				NP	JUN 16, 1998
							PED	DEC 16, 1998
>ADD>	020944	002	IBUPROFEN;JUNIOR STRENGTH ADVIL				NP	NOV 15, 1999
	020601	003	IBUPROFEN;JUNIOR STRENGTH MOTRIN	5215755	JUN 01, 2010		NP	NOV 15, 1999
				5215755*PED	DEC 01, 2010		PED	MAY 15, 2000
	020602	001	IBUPROFEN;JUNIOR STRENGTH MOTRIN				NP	JUN 16, 1998
							PED	DEC 16, 1998
	019842	001	IBUPROFEN;MOTRIN	5374659	DEC 20, 2011			
				5374659*PED	JUN 20, 2012			

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
*PED and PED represent Pediatric Exclusivity

	APPL/PROD NUMBER		INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
	020135	001	IBUPROFEN;MOTRIN	5215755	JUN 01, 2010			
				5320855	JUN 14, 2011			
				5215755*PED	DEC 01, 2010			
				5320855*PED	DEC 14, 2011			
	020135	002	IBUPROFEN;MOTRIN	5215755	JUN 01, 2010			
				5320855	JUN 14, 2011			
				5215755*PED	DEC 01, 2010			
				5320855*PED	DEC 14, 2011			
	020812	001	IBUPROFEN;PEDIATRIC ADVIL				NP	JUN 16, 1998
							PED	DEC 16, 1998
	020923	001	IOVERSOL;OPTIRAY 240	4396598	DEC 30, 2002			
	020923	002	IOVERSOL;OPTIRAY 320	4396598	DEC 30, 2002			
	020923	003	IOVERSOL;OPTIRAY 350	4396598	DEC 30, 2002			
	020393	001	IPRATROPIUM BROMIDE;ATROVENT				I-223	APR 01, 2001
	020394	001	IPRATROPIUM BROMIDE;ATROVENT				I-243	NOV 09, 2001
	020571	001	IRINOTECAN HYDROCHLORIDE;CAMPTOSAR	4604463	AUG 20, 2007			
	020083	001	ITRACONAZOLE;SPORANOX	5633015	MAY 27, 2014			
	020657	001	ITRACONAZOLE;SPORANOX	4267179	JUN 23, 2000			
				5707975	JAN 13, 2015			
				4727064	FEB 23, 2005			
	019927	001	KETOCONAZOLE;NIZORAL	4942162	FEB 11, 2003			
	020310	001	KETOCONAZOLE;NIZORAL A-D	4942162	FEB 11, 2003	U-245		
				4335125	JUN 15, 1999			
				5456851	APR 07, 2014			
>ADD>	020241	001	LAMOTRIGINE;LAMICTAL				I-247	DEC 14, 2001
							ODE	AUG 24, 2005
							I-238	AUG 24, 2001
>ADD>	020241	002	LAMOTRIGINE;LAMICTAL				I-247	DEC 14, 2001
							ODE	AUG 24, 2005
							I-238	AUG 24, 2001
>ADD>	020241	003	LAMOTRIGINE;LAMICTAL				I-247	DEC 14, 2001
							ODE	AUG 24, 2005
							I-238	AUG 24, 2001
>ADD>	020241	004	LAMOTRIGINE;LAMICTAL				I-247	DEC 14, 2001
							ODE	AUG 24, 2005
							I-238	AUG 24, 2001
>ADD>	020241	005	LAMOTRIGINE;LAMICTAL				I-247	DEC 14, 2001
							ODE	AUG 24, 2005
							I-238	AUG 24, 2001
>ADD>	020241	006	LAMOTRIGINE;LAMICTAL				I-247	DEC 14, 2001
							ODE	AUG 24, 2005
							I-238	AUG 24, 2001
	020764	001	LAMOTRIGINE;LAMICTAL CD	5698226	JAN 29, 2012		ODE	AUG 24, 2005
				4602017	JUL 22, 2008	U-106	I-238	AUG 24, 2001
	020764	002	LAMOTRIGINE;LAMICTAL CD	5698226	JAN 29, 2012		ODE	AUG 24, 2005
				4602017	JUL 22, 2008	U-106	I-238	AUG 24, 2001
	020764	003	LAMOTRIGINE;LAMICTAL CD	5698226	JAN 29, 2012		ODE	AUG 24, 2005
				4602017	JUL 22, 2008	U-106	I-238	AUG 24, 2001
	020406	001	LANSOPRAZOLE;PREVACID				I-227	MAR 12, 2001
							D-42	JUL 20, 2001

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
*PED and PED represent Pediatric Exclusivity

	APPL/PROD NUMBER		INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
	020406	002	LANSOPRAZOLE;PREVACID				I-227	MAR 12, 2001
							D-42	JUL 20, 2001
	020905	001	LEFLUNOMIDE;ARAVA	4284786	DEC 13, 1999	U-247	NCE	SEP 10, 2003
				4351841	DEC 13, 1999	U-247		
				5679709	OCT 21, 2014	U-247		
	020905	002	LEFLUNOMIDE;ARAVA	4284786	DEC 13, 1999	U-247	NCE	SEP 10, 2003
				4351841	DEC 13, 1999	U-247		
				5679709	OCT 21, 2014	U-247		
	020905	003	LEFLUNOMIDE;ARAVA	4284786	DEC 13, 1999	U-247	NCE	SEP 10, 2003
				4351841	DEC 13, 1999	U-247		
				5679709	OCT 21, 2014	U-247		
	020807	001	LEPIRUDIN;REFLUDAN	5180668	JAN 19, 2010		ODE	MAR 06, 2005
							NCE	MAR 06, 2003
	019732	001	LEUPROLIDE ACETATE;LUPRON DEPOT	5716640	SEP 02, 2013			
	020011	001	LEUPROLIDE ACETATE;LUPRON DEPOT	5716640	SEP 02, 2013			
	020517	001	LEUPROLIDE ACETATE;LUPRON DEPOT	5716640	SEP 02, 2013			
	020263	002	LEUPROLIDE ACETATE;LUPRON DEPOT-PED	5716640	SEP 02, 2013			
	020263	003	LEUPROLIDE ACETATE;LUPRON DEPOT-PED	5716640	SEP 02, 2013			
	020263	004	LEUPROLIDE ACETATE;LUPRON DEPOT-PED	5716640	SEP 02, 2013			
	020263	005	LEUPROLIDE ACETATE;LUPRON DEPOT-PED	5716640	SEP 02, 2013			
	020263	006	LEUPROLIDE ACETATE;LUPRON DEPOT-PED	5716640	SEP 02, 2013			
	020708	001	LEUPROLIDE ACETATE;LUPRON DEPOT-3	5716640	SEP 02, 2013			
	020517	002	LEUPROLIDE ACETATE;LUPRON DEPOT-4	5716640	SEP 02, 2013			
>ADD>	020634	001	LEVOFLOXACIN;LEVAQUIN				I-246	DEC 17, 2001
>ADD>	020634	002	LEVOFLOXACIN;LEVAQUIN				I-246	DEC 17, 2001
>ADD>	020635	001	LEVOFLOXACIN;LEVAQUIN				I-246	DEC 17, 2001
>ADD>	020635	002	LEVOFLOXACIN;LEVAQUIN IN DEXTROSE 5%				I-246	DEC 17, 2001
>ADD>	020635	003	LEVOFLOXACIN;LEVAQUIN IN DEXTROSE 5%				I-246	DEC 17, 2001
	019941	001	LIDOCAINE;EMLA				I-215	FEB 04, 2001
	020962	001	LIDOCAINE;EMLA				NP	FEB 04, 2001
	020606	001	LOPERAMIDE HYDROCHLORIDE;INODIUM ADVANCED	5716641	MAY 21, 2012	U-226		
	020803	001	LOTEPREDNOL ETABONATE;ALREX	4996335	FEB 26, 2008		NCE	MAR 09, 2003
				5540930	OCT 25, 2013			
	020583	001	LOTEPREDNOL ETABONATE;LOTEMAX	4996335	FEB 26, 2008		NCE	MAR 09, 2003
				5540930	OCT 25, 2013			
	020841	001	LOTEPREDNOL ETABONATE;LOTEMAX	4996335	FEB 26, 2008		NCE	MAR 09, 2003
				5540930	OCT 25, 2013			
	019832	003	MAFENIDE ACETATE;SULFAMYLON				NDF	JUN 05, 2001
							CDE	JUN 05, 2005
	020652	001	MANGAFODIPIR TRISODIUM;TESLASCAN	4933456	JUN 12, 2007			
				4992554	FEB 12, 2008			
				5091169	FEB 25, 2009			
				5223243	JUN 29, 2010	U-237		
				4647447	MAR 03, 2004	U-238		
	019618	001	MESALAMINE;ROWASA	4657900	APR 14, 2004			
				RE33239	MAY 12, 2004			
	020208	001	METRONIDAZOLE;METROGEL-VAGINAL				D-40	MAY 16, 2000
	020901	001	METRONIDAZOLE;METROLOTION				NDF	NOV 24, 2001
	020827	001	MICONAZOLE NITRATE;MONISTAT 3				NP	MAR 30, 2001

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
*PED and PED represent Pediatric Exclusivity

	APPL/PROD NUMBER		INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
	018654	001	MIDAZOLAM HYDROCHLORIDE;VERSED	4280957	DEC 20, 1999			
				4280957*PED	JUN 20, 2000			
	018654	002	MIDAZOLAM HYDROCHLORIDE;VERSED	4280957	DEC 20, 1999			
				4280957*PED	JUN 20, 2000			
	020942	001	MIDAZOLAM HYDROCHLORIDE;VERSED	4280957	DEC 20, 1999		PED	APR 15, 2002
				4280957*PED	JUN 20, 2000		NDF	OCT 15, 2001
	020415	003	MIRTAZAPINE;REMERON				NCE	JUN 14, 2001
>ADD>	020717	001	MODAFINIL;PROVIGIL				ODE	DEC 24, 2005
>ADD>							NCE	DEC 24, 2003
>ADD>	020717	002	MODAFINIL;PROVIGIL				ODE	DEC 24, 2005
>ADD>							NCE	DEC 24, 2003
>ADD>	020762	001	MOMETASONE FUROATE MONOHYDRATE;NASONEX	5837699	JAN 27, 2014	U-249		
				4472393	SEP 18, 2001			
	020829	002	MONTELUKAST SODIUM;SINGULAIR	5565473	NOV 30, 2010	U-228	NCE	FEB 20, 2003
	020830	001	MONTELUKAST SODIUM;SINGULAIR	5565473	NOV 30, 2010	U-228	NCE	FEB 20, 2003
	020763	001	NARATRIPTAN HYDROCHLORIDE;AMERGE				NCE	FEB 10, 2003
	020763	002	NARATRIPTAN HYDROCHLORIDE;AMERGE				NCE	FEB 10, 2003
	020636	001	NEVIRAPINE;VIRAMUNE				D-49	SEP 11, 2001
	020933	001	NEVIRAPINE;VIRAMUNE				NDF	SEP 11, 2001
							NCE	JUN 21, 2001
	020536	001	NICOTINE;NICOTROL	4915950	FEB 12, 2008			
	020555	001	NIZATIDINE;AXID AR				I-220	APR 01, 2001
							D-39	APR 01, 2001
	020799	001	OFLOXACIN;FLOXIN				NDF	DEC 16, 2000
	020688	001	OLOPATADINE HYDROCHLORIDE;PATANOL	5116863	DEC 18, 2010			
	019810	001	OMEPRAZOLE;PRILOSEC				I-229	JUN 29, 2001
	019810	002	OMEPRAZOLE;PRILOSEC				I-229	JUN 29, 2001
	020932	002	OXYCODONE HYDROCHLORIDE;ROXICODONE				NS	OCT 26, 2001
>ADD>							NP	OCT 26, 2001
	020262	001	PACLITAXEL;TAXOL				I-226	APR 09, 2001
							I-230	JUN 30, 2001
	020819	001	PARICALCITOL;ZEMPLAR				NCE	APR 17, 2003
	020710	001	PAROXETINE HYDROCHLORIDE;PAXIL	5811436	SEP 22, 2015			
	020237	001	PILOCARPINE HYDROCHLORIDE;SALAGEN				ODE	FEB 11, 2005
							I-212	FEB 11, 2001
>ADD>	020451	001	PORFIMER SODIUM;PHOTOFRIN	5145863	DEC 15, 2009	U-129	I-241	DEC 22, 2001
	020667	001	PRAMIPEXOLE DIHYDROCHLORIDE;MIRAPEX	4886812	DEC 12, 2006			
				4843086	JUN 27, 2006	U-231		
	020667	002	PRAMIPEXOLE DIHYDROCHLORIDE;MIRAPEX	4886812	DEC 12, 2006			
				4843086	JUN 27, 2006	U-231		
	020667	003	PRAMIPEXOLE DIHYDROCHLORIDE;MIRAPEX	4886812	DEC 12, 2006			
				4843086	JUN 27, 2006	U-231		
	020667	004	PRAMIPEXOLE DIHYDROCHLORIDE;MIRAPEX	4886812	DEC 12, 2006			
				4843086	JUN 27, 2006	U-231		
	020667	005	PRAMIPEXOLE DIHYDROCHLORIDE;MIRAPEX	4886812	DEC 12, 2006			
				4843086	JUN 27, 2006	U-231		
	019898	002	PRAVASTATIN SODIUM;PRAVACHOL				I-225	MAR 27, 2001
	019898	003	PRAVASTATIN SODIUM;PRAVACHOL				I-225	MAR 27, 2001
	019898	004	PRAVASTATIN SODIUM;PRAVACHOL				I-225	MAR 27, 2001

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
*PED and PED represent Pediatric Exclusivity

	APPL/PROD NUMBER		INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
	019781	001	PROGESTERONE;PROMETRIUM				NP	MAY 14, 2001
	019627	002	PROPOFOL;DIPRIVAN	5731355	MAR 22, 2015	U-217		
				5731356	MAR 22, 2015	U-218		
	020815	001	RALOXIFENE HYDROCHLORIDE;EVISTA	4418068	APR 03, 2001			
				5393763	JUL 28, 2012	U-114		
				5457117	JUL 28, 2012	U-114		
				5478847	MAR 02, 2014	U-114		
>ADD>	019090	001	RANITIDINE HYDROCHLORIDE;ZANTAC	4585790	MAY 11, 2004			
>ADD>				4521431	JUN 04, 2002			
>ADD>				4521431*PED	DEC 04, 2002			
>ADD>				4585790*PED	NOV 11, 2004			
>ADD>	019593	001	RANITIDINE HYDROCHLORIDE;ZANTAC	4585790	MAY 11, 2004			
>ADD>				4521431	JUN 04, 2002	U-121		
>ADD>				4585790*PED	NOV 11, 2001			
>ADD>				4521431*PED	DEC 04, 2002			
>ADD>	019593	002	RANITIDINE HYDROCHLORIDE;ZANTAC	4585790	MAY 11, 2004			
>ADD>				4521431	JUN 04, 2002	U-121		
>ADD>				4585790*PED	NOV 11, 2004			
>ADD>				4521431*PED	DEC 04, 2002			
>ADD>	019675	001	RANITIDINE HYDROCHLORIDE;ZANTAC	4585790	MAY 11, 2004			
>ADD>				4521431	JUN 04, 2002			
>ADD>				5068249	NOV 26, 2008			
>ADD>				5068249*PED	MAY 26, 2009			
>ADD>				4521431*PED	DEC 04, 2002			
>ADD>				4585790*PED	NOV 11, 2004			
>ADD>	018703	001	RANITIDINE HYDROCHLORIDE;ZANTAC 150	4880636	MAY 13, 2008			
>ADD>				4521431*PED	DEC 04, 2002			
>ADD>				4880636*PED	NOV 13, 2008			
>ADD>				4521431	JUN 04, 2002			
>ADD>	020095	001	RANITIDINE HYDROCHLORIDE;ZANTAC 150	5028432	FEB 22, 2010			
>ADD>				4521431	JUN 04, 2002			
>ADD>				4521431*PED	DEC 04, 2002			
>ADD>				5028432*PED	AUG 22, 2010			
>ADD>	020251	001	RANITIDINE HYDROCHLORIDE;ZANTAC 150	5102665	JUN 23, 2009			
>ADD>				4521431	JUN 04, 2002			
>ADD>				4521431*PED	DEC 04, 2002			
>ADD>				5102665*PED	DEC 23, 2009			
>ADD>	020251	002	RANITIDINE HYDROCHLORIDE;ZANTAC 150	5102665	JUN 23, 2009			
>ADD>				4521431	JUN 04, 2002			
>ADD>				4521431*PED	DEC 04, 2002			
>ADD>				5102665*PED	DEC 23, 2009			
>ADD>	018703	002	RANITIDINE HYDROCHLORIDE;ZANTAC 300	4880636	MAY 13, 2008			
>ADD>				4521431	JUN 04, 2002			
>ADD>				4521431*PED	DEC 04, 2002			
>ADD>				4880636*PED	NOV 13, 2008			
>ADD>	020095	002	RANITIDINE HYDROCHLORIDE;ZANTAC 300	4521431*PED	DEC 04, 2002			
>ADD>				5028432*PED	AUG 22, 2010			
				5028432	FEB 22, 2010			
				4521431	JUN 04, 2002			

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
*PED and PED represent Pediatric Exclusivity

	APPL/PROD NUMBER		INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
>ADD>	020520	001	RANITIDINE HYDROCHLORIDE;ZANTAC 75	4521431	JUN 04, 2002		I-228	JUN 08, 2001
>ADD>				4880636	MAY 13, 2008		PED	JUN 19, 1999
>ADD>				4880636*PED	NOV 13, 2008		PED	DEC 08, 2001
>ADD>				4521431*PED	DEC 04, 2002			
>ADD>	020903	001	RIBAVIRIN;REBETOL	4530901	JUL 23, 2002		I-249	DEC 09, 2001
				4211771	JUL 08, 1999	U-234	NP	JUN 03, 2001
				5767097	JAN 23, 2016	U-235		
	021024	001	RIFAPENTINE;PRIFTIN				NCE	JUN 22, 2003
							ODE	JUN 22, 2005
	020835	001	RISEDRONATE SODIUM;ACTONEL	5583122	DEC 10, 2013	U-222	NCE	MAR 27, 2003
	020272	005	RISPERIDONE;RISPERDAL	5158952	OCT 27, 2009		D-37	OCT 17, 2000
>ADD>	020659	001	RITONAVIR;NORVIR	5846987	DEC 29, 2012	U-190		
>ADD>	020680	001	RITONAVIR;NORVIR	5846987	DEC 29, 2012	U-190		
	020864	001	RIZATRIPTAN BENZOATE;MAXALT	5298520	JAN 28, 2012	U-240	NCE	JUN 29, 2003
				5602162	MAY 10, 2015	U-240		
	020864	002	RIZATRIPTAN BENZOATE;MAXALT	5298520	JAN 28, 2012	U-240	NCE	JUN 29, 2003
				5602162	MAY 10, 2015	U-240		
	020865	001	RIZATRIPTAN BENZOATE;MAXALT-MLT	4305502	DEC 15, 1998		NCE	JUN 29, 2003
				5298520	JAN 28, 2012	U-240		
				4758598	DEC 15, 1998			
				4371516	FEB 01, 2000			
				5602162	MAY 10, 2015	U-240		
	020865	002	RIZATRIPTAN BENZOATE;MAXALT-MLT	4305502	DEC 15, 1998		NCE	JUN 29, 2003
				5298520	JAN 28, 2012	U-240		
				4758598	DEC 15, 1998			
				4371516	FEB 01, 2000			
				5602162	MAY 10, 2015	U-240		
	020533	001	ROPIVACAINE HYDROCHLORIDE MONOHYDRATE;NAROPIN	4870086	JUL 28, 2010			
	020533	003	ROPIVACAINE HYDROCHLORIDE MONOHYDRATE;NAROPIN	4870086	JUL 28, 2010			
	020533	004	ROPIVACAINE HYDROCHLORIDE MONOHYDRATE;NAROPIN	4870086	JUL 28, 2010			
	020533	005	ROPIVACAINE HYDROCHLORIDE MONOHYDRATE;NAROPIN	4870086	JUL 28, 2010			
	020772	001	SACROSIDASE;SUCRAID				ODE	APR 09, 2005
							NCE	APR 09, 2003
	020236	001	SALMETEROL XINAFOATE;SEREVENT	5126375	FEB 12, 2008		I-216	FEB 05, 2001
	020692	001	SALMETEROL XINAFOATE;SEREVENT	5225445	FEB 12, 2008	U-211	I-237	SEP 25, 2001
				5380922	JAN 10, 2012		I-236	SEP 25, 2001
				5590645	MAR 01, 2011			
				5126375	FEB 12, 2008			
				D342994	JAN 04, 2008			
	020828	001	SAQUINAVIR;FORTOVASE	5196438	NOV 19, 2012			
	020443	001	SERMORELIN ACETATE;GEREF	4517181	MAY 14, 2002			
				4703035	DEC 28, 2004			
	020443	002	SERMORELIN ACETATE;GEREF	4517181	MAY 14, 2002			
				4703035	DEC 28, 2004			
	020926	001	SEVELAMER HYDROCHLORIDE;RENAGEL	5496545	AUG 11, 2013	U-246	NCE	OCT 30, 2003
				5667775	SEP 16, 2014	U-246		
	020895	001	SILDENAFIL CITRATE;VIAGRA	5250534	JUN 18, 2011		NCE	MAR 27, 2003
	020895	002	SILDENAFIL CITRATE;VIAGRA	5250534	JUN 18, 2011		NCE	MAR 27, 2003
	020895	003	SILDENAFIL CITRATE;VIAGRA	5250534	JUN 18, 2011		NCE	MAR 27, 2003

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
*PED and PED represent Pediatric Exclusivity

	APPL/PROD NUMBER		INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
	020773	001	SIMETHICONE-CELLULOSE;SONORX				NP	OCT 29, 2001
	019766	001	SIMVASTATIN;ZOCOR	4444784	DEC 23, 2005	U-59	D-46	JUL 10, 2001
							I-239	JUL 10, 2001
	019766	002	SIMVASTATIN;ZOCOR	4444784	DEC 23, 2005	U-59	D-46	JUL 10, 2001
							I-239	JUL 10, 2001
	019766	003	SIMVASTATIN;ZOCOR	4444784	DEC 23, 2005	U-59	D-46	JUL 10, 2001
							I-239	JUL 10, 2001
	019766	004	SIMVASTATIN;ZOCOR	4444784	DEC 23, 2005	U-59	D-46	JUL 10, 2001
							I-239	JUL 10, 2001
	019766	005	SIMVASTATIN;ZOCOR	4444784	DEC 23, 2005		NS	JUL 10, 2001
							I-239	JUL 10, 2001
							D-46	JUL 10, 2001
	019676	001	SOMATROPIN, BIOSYNTHETIC;NUTROPIN				ODE	OCT 29, 2004
	019676	002	SOMATROPIN, BIOSYNTHETIC;NUTROPIN				ODE	OCT 29, 2004
	020181	001	SOYBEAN OIL;LIPOSYN III 30%				NP	JAN 13, 2001
	020626	001	SUMATRIPTAN;IMITREX	5037845	AUG 06, 2008			
				5307953	DEC 02, 2012			
				5554639	SEP 10, 2013	U-232		
				5705520	DEC 10, 2011	U-232		
	020626	002	SUMATRIPTAN;IMITREX	5037845	AUG 06, 2008			
				5307953	DEC 02, 2012			
				5554639	SEP 10, 2013	U-232		
				5705520	DEC 10, 2011	U-232		
	020626	003	SUMATRIPTAN;IMITREX	5037845	AUG 06, 2008			
				5307953	DEC 02, 2012			
				5554639	SEP 10, 2013	U-232		
				5705520	DEC 10, 2011	U-232		
	017970	001	TAMOXIFEN CITRATE;NOLVADEX				I-244	OCT 29, 2001
	017970	002	TAMOXIFEN CITRATE;NOLVADEX				I-244	OCT 29, 2001
	020887	001	TECHNETIUM TC-99M APCITIDE;ACUTECT	5508020	APR 16, 2013		NCE	SEP 14, 2003
				5645815	JUL 08, 2014			
				5443815	AUG 22, 2012			
	020850	001	TELMISARTAN;MICARDIS				NCE	NOV 10, 2003
	020850	002	TELMISARTAN;MICARDIS				NCE	NOV 10, 2003
	020791	001	TESTOSTERONE;TESTODERM	4379454	FEB 17, 2001			
	020785	001	THALIDOMIDE;THALOMID				NCE	JUL 16, 2003
							ODE	JUL 16, 2005
>ADD>	020898	001	THYROTROPIN ALFA;THYROGEN				ODE	NOV 30, 2005
>ADD>							NCE	NOV 30, 2003
	020912	001	TIROFIBAN HYDROCHLORIDE;AGGRASTAT	5292756	MAR 08, 2011	U-230	NCE	MAY 14, 2003
				5658929	MAR 08, 2011			
				5733919	OCT 23, 2016			
	020913	001	TIROFIBAN HYDROCHLORIDE;AGGRASTAT	5292756	MAR 08, 2011	U-230	NCE	MAY 14, 2003
				5658929	MAR 08, 2011			
				5733919	OCT 23, 2016			
	020697	001	TOLCAPONE;TASMAR	5236952	AUG 17, 2010		NCE	JAN 29, 2003
				5476875	DEC 19, 2012	U-219		
	020697	002	TOLCAPONE;TASMAR	5236952	AUG 17, 2010		NCE	JAN 29, 2003
				5476875	DEC 19, 2012	U-219		

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
*PED and PED represent Pediatric Exclusivity

	APPL/PROD NUMBER		INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
	020771	001	TOLTERODINE TARTRATE;DETROL	5382600	JAN 17, 2012		NCE	MAR 25, 2003
	020771	002	TOLTERODINE TARTRATE;DETROL	5382600	JAN 17, 2012		NCE	MAR 25, 2003
	020844	001	TOPIRAMATE;TOPAMAX SPRINKLE				NCE	DEC 24, 2001
	020844	002	TOPIRAMATE;TOPAMAX SPRINKLE				NCE	DEC 24, 2001
	020844	003	TOPIRAMATE;TOPAMAX SPRINKLE				NCE	DEC 24, 2001
	020671	001	TOPOTECAN HYDROCHLORIDE;HYCAMTIN	5004758	MAY 28, 2010			
	020137	002	TORSEMIDE;DEMADEX				D-38	FEB 13, 2001
	020281	001	TRAMADOL HYDROCHLORIDE;ULTRAM				D-44	AUG 21, 2001
	020281	002	TRAMADOL HYDROCHLORIDE;ULTRAM				D-44	AUG 21, 2001
	020528	001	TRANDOLAPRIL;MAVIK	5744496	APR 28, 2015	U-229		
	020528	002	TRANDOLAPRIL;MAVIK	5744496	APR 28, 2015	U-229		
	020528	003	TRANDOLAPRIL;MAVIK	5744496	APR 28, 2015	U-229		
	020719	001	TROGLITAZONE;PRELAY	4572912	NOV 09, 2008			
	020719	002	TROGLITAZONE;PRELAY	4572912	NOV 09, 2008			
	020719	003	TROGLITAZONE;PRELAY	4572912	NOV 09, 2008			
	020720	001	TROGLITAZONE;REZULIN	4572912	NOV 09, 2008			
	020720	002	TROGLITAZONE;REZULIN	4572912	NOV 09, 2008			
	020720	003	TROGLITAZONE;REZULIN	4572912	NOV 09, 2008			
	020586	001	UREA, C-13;MERETEK UBT KIT (W/ PRANACTIN)	4830010	OCT 27, 2009	U-147		
	020675	001	URSODIOL;URSO	4859660	AUG 22, 2006			
	020892	001	VALRUBICIN;VALSTAR PRESERVATIVE FREE				NCE	SEP 25, 2003
							ODE	SEP 25, 2005
	020699	001	VENLAFAXINE HYDROCHLORIDE;EFFEXOR XR	4535186	DEC 13, 2007			
	020699	002	VENLAFAXINE HYDROCHLORIDE;EFFEXOR XR	4535186	DEC 13, 2007			
	020699	003	VENLAFAXINE HYDROCHLORIDE;EFFEXOR XR	4535186	DEC 13, 2007			
	020699	004	VENLAFAXINE HYDROCHLORIDE;EFFEXOR XR	4535186	DEC 13, 2007			
>ADD>	020943	001	VERAPAMIL HYDROCHLORIDE;VERELAN PM				NP	NOV 25, 2001
>ADD>	020943	002	VERAPAMIL HYDROCHLORIDE;VERELAN PM				NP	NOV 25, 2001
>ADD>	020943	003	VERAPAMIL HYDROCHLORIDE;VERELAN PM				NP	NOV 25, 2001
	020388	001	VINORELBINE TARTRATE;NAVELBINE	4307100	JUL 08, 2002			
	020547	001	ZAFIRLUKAST;ACCOLATE	4859692	SEP 27, 2010			
	020471	001	ZILEUTON;ZYFLO	4873259	DEC 10, 2010	U-168		
	020471	003	ZILEUTON;ZYFLO	4873259	DEC 10, 2010	U-168		

*U.S. Government Printing Office: 1999 — 454-723/00005

New 19th Edition



APPROVED DRUG PRODUCTS

WITH
THERAPEUTIC EQUIVALENCE EVALUATIONS

19TH EDITION

Superintendent of Documents Subscription Order Form

Order Processing Code
*** 8240**

Charge your order. It's easy!

☐ **Yes,** enter my subscription as follows:

__ subscriptions of **APPROVED DRUG PRODUCTS WITH THERAPEUTIC EQUIVALENCE EVALUATIONS**, ADP, and the monthly Cumulative Supplements, for $78.00 per year.

The total cost of my order is $_____. Price includes regular shipping and handling and is subject to change. International customers please add 25%.

For privacy protection, check the box below:

☐ Do not make my name available to other mailers.

Please choose method of payment:

☐ Check payable to Superintendent of Documents

☐ GPO Deposit Account _____ – ___

☐ VISA or MasterCard

_____

_____
(Credit card expiration date)

Thank you for your order!

_____
Company or personal name

_____
Additional address/attention line

_____
Street address

_____
City, State, ZIP Code

(_____)
Daytime phone including area code

_____
Purchase Order No. (optional)

_____
(Authorizing Signature) (10/98)

Mail To: Superintendent of Documents, Government Printing Office, P.O. Box 371954 Pittsburgh, PA 15250-7954
To **FAX** your charge order, call (202) 512-2250.
To charge your subscription call (202) 512-1800.


UNITED STATES OF AMERICA
GOVERNMENT PRINTING OFFICE
1.0
1.1
1.25
1.4
1.6
2.0
1.8
2.2
2.5
2.8
3.2
3.6
4.0
4.5
5.0
6"